

CITATION REPORT

List of articles citing

Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer

DOI: 10.1056/nejmoa1606774

New England Journal of Medicine, 2016, 375, 1823-1833.

Source: <https://exaly.com/paper-pdf/64344770/citation-report.pdf>

Version: 2024-04-10

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
2204	Current state of immunotherapy for non-small cell lung cancer. 2017 , 6, 196-211		107
2203	Immunotherapy and radiation therapy for operable early stage and locally advanced non-small cell lung cancer. 2017 , 6, 178-185		16
2202	Clinical experiences of combining immunotherapy and radiation therapy in non-small cell lung cancer: lessons from melanoma. 2017 , 6, 169-177		2
2201	Integrating immunotherapy into chemoradiation regimens for medically inoperable locally advanced non-small cell lung cancer. 2017 , 6, 113-118		11
2200	Special topics in immunotherapy and radiation therapy: reirradiation and palliation. 2017 , 6, 119-130		10
2199	Companion diagnostics-a tool to improve pharmacotherapy. 2016 , 4, 482		45
2198	Biomarkers come of age: PD1 in the frontline and cell cycle therapy swells the ranks of personalised therapy in the European Society of Medical Oncology (ESMO) congress, Copenhagen, 7-10 October 2016. 2016 , 10, 703		
2197	PD-L1 expression in lung cancer. 2016 , 8, 3053-3055		1
2196	Pembrolizumab as first-line treatment for non-small cell lung cancer-a game changer?. 2016 , 5, 538-542		4
2195	A Case of Non-Small Cell Lung Cancer with Possible "Disease Flare" on Nivolumab Treatment. 2016 , 2016, 1075641		20
2194	Advances in Cancer Immunotherapy in Solid Tumors. 2016 , 8,		109
2193	What does PD-L1 positive or negative mean?. 2016 , 213, 2835-2840		186
2192	Recommendations of the Austrian Working Group on Pulmonary Pathology and Oncology for predictive molecular and immunohistochemical testing in non-small cell lung cancer. 2016 , 9, 191-200		5
2191	Annual Congress of the European Society for Medical Oncology (ESMO): Copenhagen, Denmark; 7-11 October 2016. 2016 , 11, 705-709		
2190	Emerging therapeutic agents for lung cancer. 2016 , 9, 138		65
2189	Companion and Complementary Diagnostics: Clinical and Regulatory Perspectives. 2016 , 2, 706-712		31
2188	Divide and Conquer to Treat Lung Cancer. <i>New England Journal of Medicine</i> , 2016 , 375, 1892-1893	59.2	12

2187	Lung cancer in 2016: immunotherapy comes of age. 2016 , 4, 947-949	9
2186	Lung cancer: Anti-PD-1 therapy in the frontline. 2016 , 13, 715	9
2185	Diminished but not dead: chemotherapy for the treatment of NSCLC. 2016 , 17, 1464-1465	14
2184	Immune checkpoint inhibition in malignant mesothelioma: Does it have a future?. 2017 , 105, 49-51	7
2183	Targeting the PD-1 pathway: a new hope for gastrointestinal cancers. 2017 , 33, 749-759	50
2182	[Which recent results in Oncology and Hematology will have an impact on our practices? The point of view of Bulletin du Cancer editorial board]. 2017 , 104, 6-19	0
2181	Unclassified Renal Cell Carcinoma With Significant Response to Nivolumab. 2017 , 15, e517-e519	4
2180	Tumor infiltrating lymphocytes in gastrointestinal tumors: Controversies and future clinical implications. 2017 , 110, 106-116	29
2179	The immune infiltrate in prostate, bladder and testicular tumors: An old friend for new challenges. 2017 , 53, 138-145	15
2178	Beyond platinum treatment for NSCLC: what does the future hold?. 2017 , 17, 293-295	7
2177	Noncoding RNAs and immune checkpoints-clinical implications as cancer therapeutics. 2017 , 284, 1952-1966	82
2176	Immunotherapy improves the prognosis of lung cancer: do we have to change intensive care unit admission and triage guidelines?. 2017 , 21, 18	6
2175	NEAT1: A novel cancer-related long non-coding RNA. 2017 , 50,	169
2174	Pharmacological management of relapsed/refractory NSCLC with chemical drugs. 2017 , 18, 295-304	10
2173	Treatments for EGFR-mutant non-small cell lung cancer (NSCLC): The road to a success, paved with failures. 2017 , 174, 1-21	87
2172	PD-1 Axis Inhibition in EGFR Positives: A Blunt Sword?. 2017 , 12, 171-172	4
2171	Temporally Distinct PD-L1 Expression by Tumor and Host Cells Contributes to Immune Escape. 2017 , 5, 106-117	162
2170	ROS1 Fusions Rarely Overlap with Other Oncogenic Drivers in Non-Small Cell Lung Cancer. 2017 , 12, 872-877	63

2169	Correlation between Classic Driver Oncogene Mutations in EGFR, ALK, or ROS1 and 22C3-PD-L1 â50% Expression in Lung Adenocarcinoma. 2017 , 12, 878-883	94
2168	Antiangiogenic Therapy in Advanced Non-small-cell Lung Cancer: A Meta-analysis of Phase III Randomized Trials. 2017 , 18, 345-353.e5	14
2167	Targeting ALK: Precision Medicine Takes on Drug Resistance. 2017 , 7, 137-155	269
2166	A new frontier for targeted therapy in NSCLC: clinical efficacy of pembrolizumab in the inhibition of programmed cell death 1 (PD-1). 2017 , 17, 199-201	9
2165	[The "immune checkpoints", how does it work]. 2017 , 37, 18-28	2
2164	Immune Checkpoint Inhibitors for Patients With Advanced Non-Small-Cell Lung Cancer: A Systematic Review. 2017 , 18, 444-459.e1	56
2163	Cardiovascular Toxicities Associated with Cancer Immunotherapies. 2017 , 19, 21	99
2162	[Strategies around PD-L1 testing in France]. 2017 , 37, 3-4	
2161	[Predictive biomarkers of efficacy of checkpoint blockade inhibitors in cancer treatment]. 2017 , 37, 46-54	1
2160	Comparative analysis of PD-L1 expression between primary and metastatic pulmonary adenocarcinomas. 2017 , 75, 141-149	66
2159	Immunotherapy comes of age: Immune aging & checkpoint inhibitors. 2017 , 8, 229-235	71
2158	[Efficacy of PD-1/PD-L1 immune checkpoint inhibitors and PD-L1 testing in thoracic cancers]. 2017 , 37, 61-78	10
2157	Consolidative local therapy in oligometastatic patients. 2017 , 18, e61	1
2156	[PD1/PD-L1 immunohistochemistry in thoracic oncology: Where are we?]. 2017 , 37, 39-45	3
2155	Approvals in 2016: the march of the checkpoint inhibitors. 2017 , 14, 131-132	13
2154	Pembrolizumab in Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017 , 376, 997	59.2 14
2153	Standard of care in immunotherapy trials: Challenges and considerations. 2017 , 13, 2164-2178	4
2152	Assays for PD-L1 Expression: Do All Roads Lead to Rome?. 2017 , 3, 1058-1059	4

2151	Towards a better cancer precision medicine: systems biology meets immunotherapy. 2017 , 2, 67-73	5
2150	Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials. 2017 , 26, 415-426	4
2149	The role of checkpoint inhibitors immunotherapy in advanced non-small cell lung cancer in the elderly. 2017 , 17, 565-571	22
2148	Clinical safety and activity of pembrolizumab in patients with malignant pleural mesothelioma (KEYNOTE-028): preliminary results from a non-randomised, open-label, phase 1b trial. 2017 , 18, 623-630	320
2147	Dapivirine Vaginal Ring for HIV-1 Prevention. <i>New England Journal of Medicine</i> , 2017 , 376, 995-6	59.2 14
2146	Anti-PD-1/PD-L1-induced psoriasis from an oncological perspective. 2017 , 31, e407-e408	6
2145	Risk of endocrine adverse events in cancer patients treated with PD-1 inhibitors: a systematic review and meta-analysis. 2017 , 9, 261-272	24
2144	Looking back and to the future: 'Are we improving 'cure' in non-small cell lung cancer?. 2017 , 75, 192-194	10
2143	Comprehensive Meta-analysis of Key Immune-Related Adverse Events from CTLA-4 and PD-1/PD-L1 Inhibitors in Cancer Patients. 2017 , 5, 312-318	259
2142	The squamous situation: Ancillary testing in pulmonary squamous cell carcinoma and implications for cytology laboratories. 2017 , 125, 153-154	
2141	iRECIST: guidelines for response criteria for use in trials testing immunotherapeutics. 2017 , 18, e143-e152	1010
2140	Immune-checkpoint inhibition in first-line treatment of advanced non-small cell lung cancer patients: Current status and future approaches. 2017 , 106, 70-75	26
2139	Immune checkpoint blockade for glioma. 2017 ,	78
2138	Eribulin in non-small cell lung cancer: challenges and potential strategies. 2017 , 26, 495-508	7
2137	PARP Inhibitor Upregulates PD-L1 Expression and Enhances Cancer-Associated Immunosuppression. 2017 , 23, 3711-3720	460
2136	Strategies for Translating Evidence-Based Medicine in Lung Cancer into Community Practice. 2017 , 19, 5	
2135	Severe nivolumab-induced pneumonitis preceding durable clinical remission in a patient with refractory, metastatic lung squamous cell cancer: a case report. 2017 , 10, 64	20
2134	Checkpoint Blockade in Lung Cancer and Mesothelioma. 2017 , 196, 274-282	42

2133	Emerging challenges of advanced squamous cell lung cancer. 2016 , 1, e000129	4
2132	Clinical Impact of Tumor DNA Repair Expression and T-cell Infiltration in Breast Cancers. 2017 , 5, 292-299	40
2131	Biological therapies in nonsmall cell lung cancer. 2017 , 49,	29
2130	Stage IV advanced diffuse large B-cell lymphoma in human immunodeficiency virus infection with achieving cure by using highly active antiretroviral therapy alone: a case report. 2017 , 28, 932-936	4
2129	A Comprehensive Analysis of Programmed Cell Death Ligand-1 Expression With the Clone SP142 Antibody in Non-Small-Cell Lung Cancer Patients. 2017 , 18, 572-582.e1	39
2128	Response to anti-programmed cell death protein-1 antibodies in men treated for platinum refractory germ cell cancer relapsed after high-dose chemotherapy and stem cell transplantation. 2017 , 76, 1-7	38
2127	Getting real about NCI-designated Cancer Center advertising. 2017 , 14, 195-196	3
2126	Adjuvant treatment following radical cystectomy for muscle-invasive urothelial carcinoma and variant histologies: Is there a role for radiotherapy?. 2016 , 1, e000123	3
2125	Surrogate endpoints for overall survival in lung cancer trials: a review. 2017 , 17, 447-454	10
2124	Immunotherapy revolutionises non-small-cell lung cancer therapy: Results, perspectives and new challenges. 2017 , 78, 16-23	75
2123	Development of psoriatic arthritis during nivolumab therapy for metastatic non-small cell lung cancer, clinical outcome analysis and review of the literature. 2017 , 108, 217-221	25
2122	Intra- and Interobserver Reproducibility Assessment of PD-L1 Biomarker in Non-Small Cell Lung Cancer. 2017 , 23, 4569-4577	65
2121	Response to the treatment immediately before nivolumab monotherapy may predict clinical response to nivolumab in patients with non-small cell lung cancer. 2017 , 22, 690-697	17
2120	Prolactin as a Potential Early Predictive Factor in Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab. 2017 , 93, 62-66	10
2119	The potential role of comprehensive genomic profiling to guide targeted therapy for patients with biliary cancer. 2017 , 10, 507-520	37
2118	Indoleamine 2,3-dioxygenase (IDO): Only an enzyme or a checkpoint controller?. 2017 , 3, 52-56	69
2117	Pembrolizumab as first-line therapy for patients with PD-L1-positive advanced non-small cell lung cancer: a phase 1 trial. 2017 , 28, 874-881	144
2116	Malignant pheochromocytoma-paraganglioma: pathogenesis, TNM staging, and current clinical trials. 2017 , 24, 174-183	50

2115	Immune checkpoint inhibitors in lung cancer: an update. 2017 , 13, 955-959	4
2114	Drug development and registration: Challenges and opportunities in ovarian cancer. 2017 , 123, 2597-2599	
2113	Incidence of Pneumonitis With Use of Programmed Death 1 and Programmed Death-Ligand 1 Inhibitors in Non-Small Cell Lung Cancer: A Systematic Review and Meta-Analysis of Trials. 2017 , 152, 271-281	249
2112	Radical treatment of oligometastatic non-small cell lung cancer: Ready for prime time?. 2017 , 79, 149-151	8
2111	Combined Radiotherapy and Anti-PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non-Small Cell Lung Cancer. 2017 , 12, 1085-1097	128
2110	Immunotherapeutic strategies in non-small-cell lung cancer: the present and the future. 2017 , 9, 507-520	8
2109	Exploiting Synthetic Lethality and Network Biology to Overcome EGFR Inhibitor Resistance in Lung Cancer. 2017 , 429, 1767-1786	12
2108	Safety and tolerability of pembrolizumab in patients with relapsed/refractory primary mediastinal large B-cell lymphoma. 2017 , 130, 267-270	201
2107	Current status of chimeric antigen receptor engineered T cell-based and immune checkpoint blockade-based cancer immunotherapies. 2017 , 66, 1113-1121	22
2106	Expanding Immunotherapy Options for Bladder Cancer: Commentary on: Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma. 2017 , 106, 1-2	6
2105	AJRCCM: 100-Year Anniversary. The Shifting Landscape for Lung Cancer: Past, Present, and Future. 2017 , 195, 1150-1160	57
2104	CAR T-cell therapy for lung cancer and malignant pleural mesothelioma. 2017 , 187, 1-10	57
2103	Second-line therapy of squamous non-small cell lung cancer: an evolving landscape. 2017 , 11, 469-479	9
2102	Programmed cell death ligand 1 as a biomarker in head and neck cancer. 2017 , 125, 529-533	1
2101	Immune Biomarkers on the Radar-Comprehensive "Immunograms" for Multimodal Treatment Prediction. 2017 , 12, 770-772	1
2100	Risk of Pneumonitis Associated with Programmed Cell Death 1 Inhibitors in Cancer Patients: A Meta-analysis. 2017 , 16, 1588-1595	16
2099	The next generation of immunotherapy: keeping lung cancer in check. 2017 , 10, 87	63
2098	Immunotherapy in Lung Cancer. 2017 , 31, 131-141	26

2097	Co-Signaling Molecules in Maternal-Fetal Immunity. 2017 , 23, 46-58	32
2096	Raising the bar on first-line immunotherapy in lung cancer. 2017 , 18, 2-3	3
2095	Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. 2017 , 18, 31-41	605
2094	The Evolving Role of Biomarkers in Personalized Lung Cancer Therapy. 2017 , 93, 1-14	6
2093	The Era of Checkpoint Blockade in Lung Cancer: Taking the Brakes Off the Immune System. 2017 , 14, 1248-1260	10
2092	Milestone Analyses of Immune Checkpoint Inhibitors, Targeted Therapy, and Conventional Therapy in Metastatic Non-Small Cell Lung Cancer Trials: A Meta-analysis. 2017 , 3, e171029	46
2091	More valuable than platinum: first-line pembrolizumab in advanced stage non-small-cell lung cancer. 2017 , 28, 685-687	1
2090	Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape. 2017 , 81, 116-129	314
2089	Programmed death-ligand 1 testing in patients with non-small cell lung cancer: Ready for prime time?. 2017 , 125, 591-593	3
2088	Cost Effectiveness of Pembrolizumab vs. Standard-of-Care Chemotherapy as First-Line Treatment for Metastatic NSCLC that Expresses High Levels of PD-L1 in the United States. 2017 , 35, 831-844	78
2087	PD-L1 Expression in Pancreatic Cancer. 2017 , 109,	26
2086	The Promise and the Hype of 'Personalised Medicine'. 2017 , 23, 13-20	24
2085	Immune Signatures of Non-Small Cell Lung Cancer. 2017 , 12, 913-915	4
2084	Evaluation of dosing strategy for pembrolizumab for oncology indications. 2017 , 5, 43	127
2083	Immunogenomics: using genomics to personalize cancer immunotherapy. 2017 , 471, 209-219	5
2082	Stereotactic ablative radiotherapy in treatment of early-stage non-small cell lung cancer: Unsolved questions and frontiers ahead. 2017 , 401, 46-52	1
2081	Cancer Immunotherapy Trials Not Immune from Imprecise Selection of Patients. <i>New England Journal of Medicine</i> , 2017 , 376, 2483-2485	59.2 22
2080	First-Line Nivolumab in Stage IV or Recurrent Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017 , 376, 2415-2426	59.2 1474

2079	Response to first line chemotherapy regimen is associated with efficacy of nivolumab in non-small-cell lung cancer. 2017 , 6, e1339856	6
2078	DNA Damage and Repair Biomarkers of Immunotherapy Response. 2017 , 7, 675-693	331
2077	Oesophageal cancer. 2017 , 390, 2383-2396	489
2076	PD-L1 protein expression assessed by immunohistochemistry is neither prognostic nor predictive of benefit from adjuvant chemotherapy in resected non-small cell lung cancer. 2017 , 28, 882-889	77
2075	Immunotherapy for Breast Cancer: What Are We Missing?. 2017 , 23, 2640-2646	112
2074	Re-biopsy after relapse of targeted therapy. T790M after epidermal growth factor mutation, where and why based on a case series. 2017 , 21, 171-175	8
2073	[The role of immunooncology in the treatment of urothelial cancer]. 2017 , 48, 329-335	
2072	Pembrolizumab for Advanced Urothelial Carcinoma. <i>New England Journal of Medicine</i> , 2017 , 376, 2302	59.2 8
2071	Combined immune checkpoint blockade as a therapeutic strategy for -mutated breast cancer. 2017 , 9,	167
2070	Immunological effect of local ablation combined with immunotherapy on solid malignancies. 2017 , 36, 49	16
2069	Immune Checkpoint Inhibitor Therapy: What Line of Therapy and How to Choose?. 2017 , 18, 33	9
2068	Sequencing of ALK Inhibitors in ALK+ Non-Small Cell Lung Cancer. 2017 , 18, 36	14
2067	Previous radiotherapy and the clinical activity and toxicity of pembrolizumab in the treatment of non-small-cell lung cancer: a secondary analysis of the KEYNOTE-001 phase 1 trial. 2017 , 18, 895-903	577
2066	Programmed cell death-1/Programmed cell death ligand-1(PD-1/PD-L1) inhibitors, heralding a new era of immunotherapy in the management of advanced Non-Small Cell Lung Cancer (NSCLC). 2017 , 12, 6-13	8
2065	Checkpoint inhibitors for the treatment of non-small-cell lung cancer: news from the 2016 European Society for Medical Oncology Annual Congress. 2017 , 33, 126-132	1
2064	Combining radiotherapy with immunotherapy: the past, the present and the future. 2017 , 90, 20170157	60
2063	What, When, and How of Biomarker Testing in Non-Small Cell Lung Cancer. 2017 , 15, 686-688	17
2062	Towards a Molecular Classification of Pulmonary Sarcomatoid Carcinomas. 2017 , 12, 910-912	2

2061	Quantitative Mass Spectrometry Analysis of PD-L1 Protein Expression, -glycosylation and Expression Stoichiometry with PD-1 and PD-L2 in Human Melanoma. 2017 , 16, 1705-1717	36
2060	Reprogramming the oncogenic response: SET protein as a potential therapeutic target in cancer. 2017 , 21, 685-694	19
2059	Paired Comparison of PD-L1 Expression on Cytologic and Histologic Specimens From Malignancies in the Lung Assessed With PD-L1 IHC 28-8pharmDx and PD-L1 IHC 22C3pharmDx. 2017 , 25, 453-459	109
2058	Non-Small Cell Lung Cancer, Version 5.2017, NCCN Clinical Practice Guidelines in Oncology. 2017 , 15, 504-535	729
2057	Indirect comparison between pembrolizumab and nivolumab for the treatment of non-small cell lung cancer: A meta-analysis of randomized clinical trials. 2017 , 49, 85-94	21
2056	High PD-1 expression on regulatory and effector T-cells in lung cancer draining lymph nodes. 2017 , 3,	16
2055	Paradigm shift of therapeutic management of brain metastases in EGFR-mutant non-small cell lung cancer in the era of targeted therapy. 2017 , 34, 121	11
2054	Scientific Advances in Thoracic Oncology 2016. 2017 , 12, 1183-1209	29
2053	The incidence and relative risk of pulmonary toxicity in patients treated with anti-PD1/PD-L1 therapy for solid tumors: a meta-analysis of current studies. 2017 , 9, 579-587	10
2052	Checkpoint inhibitors in advanced melanoma: effect on the field of immunotherapy. 2017 , 17, 647-655	10
2051	A Pharmacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer. 2017 , 109,	48
2050	New insights into the role of EMT in tumor immune escape. 2017 , 11, 824-846	180
2049	Avelumab, an anti-PD-L1 monoclonal antibody, shows activity in various tumour types. 2017 , 18, 556-557	18
2048	PACE4 is an important driver of ZR-75-1 estrogen receptor-positive breast cancer proliferation and tumor progression. 2017 , 96, 469-475	9
2047	Delayed pseudoprogression of lung adenocarcinoma accompanied with interstitial lung disease during chemotherapy after nivolumab treatment. 2017 , 8, 275-277	12
2046	Milestones in the systemic treatment of lung cancer. 2017 , 10, 22-26	6
2045	Clinical Determinants of Durable Clinical Benefit of Pembrolizumab in Veterans With Advanced Non-Small-Cell Lung Cancer. 2017 , 18, 559-564	8
2044	Primary and acquired resistance to PD-1/PD-L1 blockade in cancer treatment. 2017 , 46, 210-219	71

2043	Mechanistic and pharmacologic insights on immune checkpoint inhibitors. 2017 , 120, 1-9	29
2042	Successes and failures: what did we learn from recent first-line treatment immunotherapy trials in non-small cell lung cancer?. 2017 , 15, 55	43
2041	Prospects for combining targeted and conventional cancer therapy with immunotherapy. 2017 , 17, 286-301	510
2040	Prospects and progress of atezolizumab in non-small cell lung cancer. 2017 , 17, 781-789	11
2039	Pembrolizumab for the treatment of non-small cell lung cancer. 2017 , 17, 399-409	24
2038	How many tumor indications should be initially screened in development of next generation immunotherapies?. 2017 , 59, 113-117	12
2037	Strategies for Increasing Pancreatic Tumor Immunogenicity. 2017 , 23, 1656-1669	92
2036	Anti-PD-1-related cryoglobulinemia during treatment with nivolumab in NSCLC patient. 2017 , 28, 1405-1406	8
2035	PD-L1 expression in lung adenosquamous carcinomas compared with the more common variants of non-small cell lung cancer. 2017 , 7, 46209	25
2034	Emerging treatment using tubulin inhibitors in advanced non-small cell lung cancer. 2017 , 18, 701-716	24
2033	Harnessing the Immunotherapy Revolution for the Treatment of Childhood Cancers. 2017 , 31, 476-485	86
2032	Releasing the brake: safety profile of immune check-point inhibitors in non-small cell lung cancer. 2017 , 16, 573-585	16
2031	Immunotherapy for gastric cancers: emerging role and future perspectives. 2017 , 10, 609-619	26
2030	Comorbidities in the management of patients with lung cancer. 2017 , 49,	42
2029	[Immunotherapy of cancer with checkpoint inhibitors : Not only in malignant melanoma]. 2017 , 58, 409-423	1
2028	The PD-L1/PD-1 pathway promotes dysfunction, but not "exhaustion", in tumor-responding T cells from pleural effusions in lung cancer patients. 2017 , 66, 765-776	24
2027	Ablative Therapy for Oligometastatic Non-Small Cell Lung Cancer. 2017 , 18, 595-606	34
2026	Pulmonary Sarcomatoid Carcinomas Commonly Harbor Either Potentially Targetable Genomic Alterations or High Tumor Mutational Burden as Observed by Comprehensive Genomic Profiling. 2017 , 12, 932-942	85

2025	Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. 2017 , 5, 12	121
2024	Immuno-Oncology: The Third Paradigm in Early Drug Development. 2017 , 12, 125-138	16
2023	Evolution and Increasing Complexity of the Therapeutic Landscape in Advanced Non-Small-cell Lung Cancer. 2017 , 18, 1-4	6
2022	Pulmonary Sarcomatoid Carcinoma: An Analysis of the National Cancer Data Base. 2017 , 18, 286-292	34
2021	Targeting KRAS mutated non-small cell lung cancer: A history of failures and a future of hope for a diverse entity. 2017 , 110, 1-12	50
2020	Targeting the PD-1/PD-L1 axis in non-small cell lung cancer. 2017 , 41, 111-124	30
2019	Challenges in molecular targeted therapy for gastric cancer: considerations for efficacy and safety. 2017 , 16, 319-327	7
2018	Programmed death of chemotherapy in non-small-cell lung cancer?. 2017 , 389, 227-228	4
2017	Chemotherapy enhances programmed cell death 1/ligand 1 expression via TGF- β -induced epithelial mesenchymal transition in non-small cell lung cancer. 2017 , 38, 2277-2284	22
2016	[Personalized therapy of lung cancer - current standard and future challenges]. 2017 , 142, 1660-1668	0
2015	The clinical development of vaccines for HER2 breast cancer: Current landscape and future perspectives. 2017 , 61, 107-115	21
2014	Immune-related musculoskeletal toxicities among cancer patients treated with immune checkpoint inhibitors: a systematic review. 2017 , 9, 1175-1183	26
2013	Early Immune-Related Adverse Events and Association with Outcome in Advanced Non-Small Cell Lung Cancer Patients Treated with Nivolumab: A Prospective Cohort Study. 2017 , 12, 1798-1805	241
2012	Sorafenib and continued erlotinib or sorafenib alone in patients with advanced non-small cell lung cancer progressing on erlotinib: A randomized phase II study of the Sarah Cannon Research Institute (SCRI). 2017 , 113, 79-84	8
2011	Inter-relationship between PD-L1 expression and clinic-pathological features and driver gene mutations in pulmonary sarcomatoid carcinomas. 2017 , 113, 93-101	21
2010	Evaluation of peripheral blood T lymphocyte surface activation markers and transcription factors in patients with early stage non-small cell lung cancer. 2017 , 322, 26-33	8
2009	PD-L1 Expression in Squamous-cell Carcinoma and Adenocarcinoma of the Lung. 2017 , 51, 357-362	28
2008	Efficacy and safety of retreatment with nivolumab in metastatic melanoma patients previously treated with nivolumab. 2017 , 80, 999-1004	35

2007	Gamma Secretase Inhibition by BMS-906024 Enhances Efficacy of Paclitaxel in Lung Adenocarcinoma. 2017 , 16, 2759-2769	33
2006	PD-L1 IHC in NSCLC with a global and methodological perspective. 2017 , 113, 102-105	25
2005	Interleukin-10-regulated tumour tolerance in non-small cell lung cancer. 2017 , 117, 1644-1655	47
2004	Immunvermittelte Nebenwirkungen unter Checkpointinhibitoren. 2017 , 12, 490-495	0
2003	Immune Activation in Early-Stage Non-Small Cell Lung Cancer Patients Receiving Neoadjuvant Chemotherapy Plus Ipilimumab. 2017 , 23, 7474-7482	40
2002	Combination immunotherapy strategies in advanced non-small cell lung cancer (NSCLC): Does biological rationale meet clinical needs?. 2017 , 119, 30-39	29
2001	Not all immune-checkpoint inhibitors are created equal: Meta-analysis and systematic review of immune-related adverse events in cancer trials. 2017 , 119, 1-12	105
2000	Impaired HLA Class I Antigen Processing and Presentation as a Mechanism of Acquired Resistance to Immune Checkpoint Inhibitors in Lung Cancer. 2017 , 7, 1420-1435	302
1999	PD-L1 expression in non-small cell lung carcinoma: Comparison among cytology, small biopsy, and surgical resection specimens. 2017 , 125, 896-907	119
1998	Perspectives in immunotherapy: meeting report from the "Immunotherapy Bridge", Napoli, November 30th 2016. 2017 , 15, 205	13
1997	FEATURES. 2017 , 21, 14-27	
1996	Ginsenoside Rg3 attenuates cisplatin resistance in lung cancer by downregulating PD-L1 and resuming immune. 2017 , 96, 378-383	55
1995	[Not Available]. 2017 , 142, 1531-1534	
1994	Putative predictors of efficacy for immune checkpoint inhibitors in non-small-cell lung cancer: facing the complexity of the immune system. 2017 , 17, 1055-1069	19
1993	Genome-Editing Technologies in Adoptive T Cell Immunotherapy for Cancer. 2017 , 12, 522-529	48
1992	[Lung cancer : What has been confirmed in therapy?]. 2017 , 58, 1258-1263	1
1991	Tumor microenvironment and systemic disease: a dual target in medical oncology (also in the case of biomarkers). 2017 , 55, 1813-1816	
1990	The evolutionary nature of the cancer immunotherapy revolution. 2017 , 13, 1565-1567	3

1989	Investigational PD-1 inhibitors for advanced non-small lung cancer: new players in a shifting paradigm. 2017 , 26, 1317-1319	6
1988	Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: A meta-regression of randomised prospective studies. 2017 , 86, 257-265	21
1987	Globo H expression is associated with driver mutations and PD-L1 expressions in stage I non-small cell lung cancer. 2017 , 21, 211-220	2
1986	SELECT-3: a phase I study of selumetinib in combination with platinum-doublet chemotherapy for advanced NSCLC in the first-line setting. 2017 , 117, 938-946	11
1985	FDA Approval Summary: Pembrolizumab for Treatment of Metastatic Non-Small Cell Lung Cancer: First-Line Therapy and Beyond. 2017 , 22, 1392-1399	150
1984	Targeting VEGFR and FGFR in head and neck squamous cell carcinoma in vitro. 2017 , 38, 1877-1885	18
1983	Initial Experience With Lung Cancer Resection After Treatment With T-Cell Checkpoint Inhibitors. 2017 , 104, e217-e218	40
1982	Immunotherapy for Non-Small Cell Lung Cancer: A Therapy for All Stages?. 2017 , 29, 416-417	
1981	Novel combination strategies for enhancing efficacy of immune checkpoint inhibitors in the treatment of metastatic solid malignancies. 2017 , 18, 1477-1490	16
1980	Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence. 2017 , 11, 353-373	19
1979	Radiotherapy in combination with immune checkpoint inhibitors. 2017 , 29, 105-111	12
1978	Baseline lymphopenia should not be used as exclusion criteria in early clinical trials investigating immune checkpoint blockers (PD-1/PD-L1 inhibitors). 2017 , 84, 202-211	25
1977	The changing diagnostic pathway for lung cancer patients in Shanghai, China. 2017 , 84, 168-172	6
1976	New Immunotherapy and Lung Cancer. 2017 , 53, 682-687	6
1975	Lung Cancer in the Older Patient. 2017 , 33, 563-577	13
1974	Immunotherapy for triple-negative breast cancer: Existing challenges and exciting prospects. 2017 , 32, 1-15	76
1973	Multicenter Comparison of 22C3 PharmDx (Agilent) and SP263 (Ventana) Assays to Test PD-L1 Expression for NSCLC Patients to Be Treated with Immune Checkpoint Inhibitors. 2017 , 12, 1654-1663	68
1972	Learning the Roles of the Hepatic Adaptive Immune System in Hepatocellular Carcinoma-Nature's Guide for Successful Cancer Immunotherapy. 2017 , 37, 210-218	3

1971	PDL-1/PD1 inhibitors: antibody or antinobody?. 2017 , 13, 1669-1671	7
1970	Precision Diagnosis and Treatment for Advanced Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2017 , 377, 849-861	59.2 376
1969	ATS Core Curriculum 2017: Part IV. Adult Pulmonary Medicine. 2017 , 14, S196-S208	
1968	The Current Landscape of Anaplastic Lymphoma Kinase (ALK) in Non-Small Cell Lung Cancer: Emerging Treatment Paradigms and Future Directions. 2017 , 12, 709-718	13
1967	Symptomatic pseudo-progression followed by significant treatment response in two lung cancer patients treated with immunotherapy. 2017 , 113, 4-6	37
1966	Trial watch: Immune checkpoint blockers for cancer therapy. 2017 , 6, e1373237	53
1965	Cancer vaccines: Enhanced immunogenic modulation through therapeutic combinations. 2017 , 13, 2561-2574	56
1964	Challenges and Opportunities in Adapting Clinical Trial Design for Immunotherapies. 2017 , 23, 4950-4958	30
1963	A randomized phase II trial of erlotinib vs. S-1 as a third- or fourth-line therapy for patients with wild-type EGFR non-small cell lung cancer (HOT1002). 2017 , 80, 955-963	10
1962	Chemotherapy-induced immunomodulation in non-small-cell lung cancer: a rationale for combination chemoimmunotherapy. 2017 , 9, 913-927	24
1961	Late-occurring nivolumab-induced cryptogenic organising pneumonia mimicking lung progression in a patient with metastatic non-small cell lung cancer. 2017 , 85, 155-157	5
1960	Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors. 2017 , 57 Suppl 10, S26-S42	63
1959	Dabrafenib plus trametinib in patients with previously untreated BRAF-mutant metastatic non-small-cell lung cancer: an open-label, phase 2 trial. 2017 , 18, 1307-1316	461
1958	Immunosenescence and immunecheckpoint inhibitors in non-small cell lung cancer patients: Does age really matter?. 2017 , 60, 60-68	83
1957	PD-1 checkpoint inhibition: Toxicities and management. 2017 , 35, 701-707	44
1956	Thoracic Complications of Precision Cancer Therapies: A Practical Guide for Radiologists in the New Era of Cancer Care. 2017 , 37, 1371-1387	43
1955	Alteration of PD-L1 expression and its prognostic impact after concurrent chemoradiation therapy in non-small cell lung cancer patients. 2017 , 7, 11373	42
1954	Case report: pembrolizumab-induced Type 1 diabetes in a patient with metastatic cholangiocarcinoma. 2017 , 9, 797-804	23

1953	Economic Considerations in the Use of Novel Targeted Therapies for Lung Cancer: Review of Current Literature. 2017 , 35, 1195-1209	14
1952	The Challenge for Development of Valuable Immuno-oncology Biomarkers. 2017 , 23, 4970-4979	54
1951	Immuno-oncology Clinical Trial Design: Limitations, Challenges, and Opportunities. 2017 , 23, 4992-5002	26
1950	An update on the developing mitotic inhibitors for the treatment of non-small cell carcinoma. 2017 , 22, 213-222	5
1949	[Immunotherapy as modern tumor treatment]. 2017 , 57, 822-825	3
1948	Immunotherapy "Shock" a case series of PD-L1 100% and pembrolizumab first-line treatment. 2017 , 22, 197-202	7
1947	Osimertinib (AZD9291) decreases programmed death ligand-1 in EGFR-mutated non-small cell lung cancer cells. 2017 , 38, 1512-1520	35
1946	Atezolizumab for the treatment of non-small cell lung cancer. 2017 , 10, 935-945	21
1945	[Immunotherapy: Activation of a system not a pathway]. 2017 , 104, 462-475	
1944	In vivo CRISPR screening identifies Ptpn2 as a cancer immunotherapy target. 2017 , 547, 413-418	510
1943	Dosing immunotherapy combinations: Analysis of 3,526 patients for toxicity and response patterns. 2017 , 6, e1338997	22
1942	The Current Role of Whole Brain Radiation Therapy in Non-Small Cell Lung Cancer Patients. 2017 , 12, 1467-1477	16
1941	Cancer Immunotherapy in Older Patients. 2017 , 23, 219-222	14
1940	Lung cancer as a paradigm for precision oncology in solid tumours. 2017 , 471, 221-233	10
1939	Atypical responses in patients with advanced melanoma, lung cancer, renal-cell carcinoma and other solid tumors treated with anti-PD-1 drugs: A systematic review. 2017 , 59, 71-78	65
1938	Comparison of RECIST to immune-related response criteria in patients with non-small cell lung cancer treated with immune-checkpoint inhibitors. 2017 , 80, 591-598	34
1937	Comparative beneficiary effects of immunotherapy against chemotherapy in patients with advanced NSCLC: Meta-analysis and systematic review. 2017 , 14, 1568-1580	8
1936	Marked response to pembrolizumab in a patient with pulmonary pleomorphic carcinoma highly positive for PD-L1. 2017 , 112, 230-231	21

1935	Australian recommendations for EGFR T790M testing in advanced non-small cell lung cancer. 2017 , 13, 296-303	12
1934	Nivolumab and pembrolizumab: Monoclonal antibodies against programmed cell death-1 (PD-1) that are interchangeable. 2017 , 44, 132-135	64
1933	Incidence of Brain Metastases on Follow-up F-FDG PET/CT Scans of Non-Small Cell Lung Cancer Patients: Should We Include the Brain?. 2017 , 45, 193-197	8
1932	Meta-analysis of first-line therapies with maintenance regimens for advanced non-small-cell lung cancer (NSCLC) in molecularly and clinically selected populations. 2017 , 6, 1847-1860	16
1931	Cancer Immunotherapies: Are They as Effective in the Elderly?. 2017 , 34, 567-581	22
1930	The "value" of immune-checkpoint inhibitors for advanced lung cancer. 2017 , 55, 253-254	
1929	EGFR or PD-L1 decision for first line therapy in a case series of EGFR positive and PD-L1 >50. 2017 , 22, 7-10	3
1928	Immunotherapy: Who Is Eligible?. 2017 , 50, 867-874	4
1927	Mismatch repair status and PD-L1 expression in clear cell carcinomas of the ovary and endometrium. 2017 , 30, 1622-1632	41
1926	Phase I study of salazosulfapyridine in combination with cisplatin and pemetrexed for advanced non-small-cell lung cancer. 2017 , 108, 1843-1849	27
1925	National trends in prescription drug expenditures and projections for 2017. 2017 , 74, 1158-1173	38
1924	Lazarus syndrome in nonsmall cell lung cancer patients with poor performance status and major leukocytosis following nivolumab treatment. 2017 , 50,	12
1923	Checkpoint Inhibitors for Non-Small Cell Lung Cancer Among Older Adults. 2017 , 19, 62	11
1922	Programmed death-ligand 1 immunohistochemistry testing for non-small cell lung cancer in practice. 2017 , 125, 521-528	7
1921	[Radiotherapy enhances the effect of PD-1 checkpoint inhibitors]. 2017 , 193, 763-764	3
1920	Possible adverse effects of immunotherapy in non-small cell lung cancer; treatment and follow-up of three cases. 2017 , 22, 101-105	19
1919	Treatment of elderly patients or patients who are performance status 2 (PS2) with advanced Non-Small Cell Lung Cancer without epidermal growth factor receptor (EGFR) mutations and anaplastic lymphoma kinase (ALK) translocations - Still a daily challenge. 2017 , 83, 266-278	16
1918	Checkpoint inhibitors in the treatment of urological malignancies. 2017 , 2, e000165	15

1917	Comparison of 22C3 PD-L1 Expression between Surgically Resected Specimens and Paired Tissue Microarrays in Non-Small Cell Lung Cancer. 2017 , 12, 1536-1543	41
1916	Immune checkpoint inhibitors for advanced non-small cell lung cancer: emerging sequencing for new treatment targets. 2017 , 2, e000200	25
1915	Mitteilungsseiten der DGP. 2017 , 38, 345-350	
1914	Prädiktive molekulare Marker als therapeutische Weichensteller beim nichtkleinzelligen Lungenkarzinom. 2017 , 32, 307-311	
1913	Immune checkpoint inhibitors in first-line therapy of advanced non-small cell lung cancer. 2017 , 29, 97-104	29
1912	The importance for immunoregulation for long-term cancer control. 2017 , 13, 1619-1632	8
1911	Carboplatin versus two doses of cisplatin in combination with gemcitabine in the treatment of advanced non-small-cell lung cancer: Results from a British Thoracic Oncology Group randomised phase III trial. 2017 , 83, 302-312	12
1910	Lung cancer as a cardiotoxic state: a review. 2017 , 34, 159	7
1909	Temporal and spatial heterogeneity of programmed cell death 1-Ligand 1 expression in malignant mesothelioma. 2017 , 6, e1356146	23
1908	Immune checkpoint inhibitors in lung cancer: the holy grail has not yet been found. 2017 , 2, e000162	14
1907	Is immunotherapy a viable option in treating mesothelioma?. 2017 , 13, 1747-1750	6
1906	Tissue Acquisition in Clinical Trials-Essential for Progress. 2017 , 109,	
1905	Clinical characteristics of patient selection and imaging predictors of outcome in solid tumors treated with checkpoint-inhibitors. 2017 , 44, 2310-2325	34
1904	Neurological Complications of Therapeutic Monoclonal Antibodies: Trends from Oncology to Rheumatology. 2017 , 17, 75	13
1903	Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. 2017 , 50,	192
1902	Treatment of Lung Carcinosarcoma and Other Rare Histologic Subtypes of Non-small Cell Lung Cancer. 2017 , 18, 54	11
1901	Response rates to single-agent chemotherapy after exposure to immune checkpoint inhibitors in advanced non-small cell lung cancer. 2017 , 112, 90-95	128
1900	Immunotherapy in Breast Cancer: the Emerging Role of PD-1 and PD-L1. 2017 , 19, 64	71

1899	Hypothyroid ataxia complicating monoclonal antibody therapy. 2017 , 17, 482-484	3
1898	Programmed cell death ligands expression in pheochromocytomas and paragangliomas: Relationship with the hypoxic response, immune evasion and malignant behavior. 2017 , 6, e1358332	41
1897	Clinical Trials Investigating Immune Checkpoint Blockade in Glioblastoma. 2017 , 18, 51	56
1896	Tumour- and class-specific patterns of immune-related adverse events of immune checkpoint inhibitors: a systematic review. 2017 , 28, 2377-2385	372
1895	Impact of the Tumor Microenvironment on Tumor-Infiltrating Lymphocytes: Focus on Breast Cancer. 2017 , 11, 1178223417731565	25
1894	Emerging first line treatment options for bladder cancer: a review of phase II and III therapies in the pipeline. 2017 , 22, 347-355	
1893	Neutrophils and Snail Orchestrate the Establishment of a Pro-tumor Microenvironment in Lung Cancer. 2017 , 21, 3190-3204	96
1892	Immunotherapy of Cancer. 2017 , 244-266	
1891	Complications rhumatologiques de l'immunothérapie anticancéreuse. 2017 , 84, A29-A33	
1890	How to evaluate the immune status of lung cancer patients before immunotherapy. 2017 , 13, 291-296	7
1889	[Current Aspects of Diagnosis and Treatment of Lung Cancer]. 2017 , 142, 1808-1812	3
1888	Assessment of Concordance between 22C3 and SP142 Immunohistochemistry Assays regarding PD-L1 Expression in Non-Small Cell Lung Cancer. 2017 , 7, 16956	24
1887	New Immunotherapy and Lung Cancer. 2017 , 53, 682-687	3
1886	DNA double-strand break repair pathway regulates PD-L1 expression in cancer cells. 2017 , 8, 1751	300
1885	Quality matters: immunotherapy and the evolving landscape of advanced cancer care. 2017 , 2, 235-244	2
1884	Targeting immune checkpoints in breast cancer: an update of early results. 2017 , 2, e000255	79
1883	Can radiotherapy potentiate the effectiveness of immune checkpoint inhibitors in lung cancer?. 2017 , 13, 2503-2505	7
1882	Epigenetic Therapy Ties MYC Depletion to Reversing Immune Evasion and Treating Lung Cancer. 2017 , 171, 1284-1300.e21	215

1881	De-novo and acquired resistance to immune checkpoint targeting. 2017 , 18, e731-e741	383
1880	Personalised medicine for nonsmall cell lung cancer. 2017 , 26,	28
1879	Anti-SIRPB antibody immunotherapy enhances neutrophil and macrophage antitumor activity. 2017 , 114, E10578-E10585	136
1878	Non-small cell lung cancer clinical trials requiring biopsies with biomarker-specific results for enrollment provide unique challenges. 2017 , 123, 4800-4807	12
1877	Versorgungsrealität der molekularen Diagnostik maligner Erkrankungen. 2017 , 23, 900-910	1
1876	Implementation of precision medicine in clinical trials in thoracic oncology: Which are the hurdles?. 2017 , 123, 4764-4766	
1875	Quality of life: an important element of treatment value. 2017 , 18, 1557-1558	4
1874	Combining immunotherapies for the treatment of prostate cancer. 2017 , 35, 694-700	18
1873	[Autoimmune reactions to immune checkpoint inhibitors]. 2017 , 76, 57-62	1
1872	Very early response of circulating tumour-derived DNA in plasma predicts efficacy of nivolumab treatment in patients with non-small cell lung cancer. 2017 , 86, 349-357	59
1871	Pembrolizumab in the treatment of advanced urothelial cancer. 2017 , 13, 2745-2758	4
1870	What's new in chemotherapy for non-small cell lung cancer?. 2017 , 10, 123-126	
1869	Health-related quality-of-life results for pembrolizumab versus chemotherapy in advanced, PD-L1-positive NSCLC (KEYNOTE-024): a multicentre, international, randomised, open-label phase 3 trial. 2017 , 18, 1600-1609	185
1868	Immunotherapy and Targeted Therapy for Small Cell Lung Cancer: There Is Hope. 2017 , 19, 49	15
1867	Cancer immunotherapy: Breakthrough or "deja vu, all over again"?. 2017 , 39, 1010428317707764	5
1866	Checkpointinhibitoren. 2017 , 23, 619-625	
1865	Screening in der Pneumologie. 2017 , 14, 129-130	
1864	Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma. 2017 , 38, 899-907	50

1863	Immune checkpoint inhibitors and elderly people: A review. 2017 , 82, 155-166	99
1862	Lack of response to nivolumab in a patient with EGFR-mutant non-small cell lung cancer adenocarcinoma sub-type transformed to small cell lung cancer. 2017 , 111, 65-68	13
1861	Overcoming resistance to EGFR tyrosine kinase inhibitors in lung cancer, focusing on non-T790M mechanisms. 2017 , 17, 779-786	24
1860	Management of toxicities from immunotherapy: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2017 , 28, iv119-iv142	1100
1859	Metabolic Regulation of T Cell Longevity and Function in Tumor Immunotherapy. 2017 , 26, 94-109	206
1858	A molecular and preclinical comparison of the PD-1-targeted T-cell checkpoint inhibitors nivolumab and pembrolizumab. 2017 , 44, 136-140	119
1857	PD-1/PD-L1 checkpoint blockades in non-small cell lung cancer: New development and challenges. 2017 , 405, 29-37	51
1856	Immune checkpoints inhibitors for solid tumours after allogeneic haematopoietic stem-cell transplantation: About four clinical cases. 2017 , 81, 138-141	0
1855	Tumor Response Dynamics of Advanced Non-small Cell Lung Cancer Patients Treated with PD-1 Inhibitors: Imaging Markers for Treatment Outcome. 2017 , 23, 5737-5744	55
1854	Sequential Tracking of PD-L1 Expression and RAD50 Induction in Circulating Tumor and Stromal Cells of Lung Cancer Patients Undergoing Radiotherapy. 2017 , 23, 5948-5958	66
1853	PD-L1 and immune escape: insights from melanoma and other lineage-unrelated malignancies. 2017 , 66, 13-33	34
1852	What's new in small cell lung cancer - extensive disease? An overview on advances of systemic treatment in 2016. 2017 , 13, 1427-1435	4
1851	Biomarkers of response to PD-1/PD-L1 inhibition. 2017 , 116, 116-124	185
1850	NSCLC: Pembrolizumab in der Erstlinie. 2017 , 20, 24-24	
1849	Monitoring immune-checkpoint blockade: response evaluation and biomarker development. 2017 , 14, 655-668	498
1848	Optimale Therapie des nichtkleinzelligen Lungenkarzinoms im Stadium IIIB/C. 2017 , 20, 32-42	
1847	The Value of Cancer Immunotherapy Summit at the 2016 Society for Immunotherapy of Cancer 31st Anniversary Annual Meeting. 2017 , 5,	8
1846	Nivolumab as salvage treatment in a patient with HIV-related relapsed/refractory Hodgkin lymphoma and liver failure with encephalopathy. 2017 , 5, 49	20

1845	The second wave of immune checkpoint inhibitor tsunami: advance, challenges and perspectives. 2017 , 9, 647-657	15
1844	Myasthenia gravis induced by nivolumab in patients with non-small-cell lung cancer: a case report and literature review. 2017 , 9, 701-707	15
1843	Pembrolizumab as first-line therapy in programmed death ligand 1-positive advanced lung cancer: Is it as effective as we think it is?. 2017 , 123, 3872-3874	2
1842	SOX2 immunity and tissue resident memory in children and young adults with glioma. 2017 , 134, 41-53	20
1841	A pilot trial of nivolumab treatment for advanced non-small cell lung cancer patients with mild idiopathic interstitial pneumonia. 2017 , 111, 1-5	43
1840	PD-L1 immunohistochemistry in clinical diagnostics of lung cancer: inter-pathologist variability is higher than assay variability. 2017 , 30, 1411-1421	114
1839	Immune Checkpoint Inhibitors in Lung Cancer: Imaging Considerations. 2017 , 209, 567-575	22
1838	Immune checkpoints in chronic obstructive pulmonary disease. 2017 , 26,	16
1837	Immune checkpoint inhibitors. 2017 , 23, 575-584	
1836	Multi-Institutional Prospective Study of Reirradiation with Proton Beam Radiotherapy for Locoregionally Recurrent Non-Small Cell Lung Cancer. 2017 , 12, 281-292	66
1835	'Genotype/immunotype' correlations in resected NSCLC. 2017 , 28, 7-8	
1834	Crizotinib for ROS1 patients: One small step in biomarker testing, one giant leap for advanced NSCLC patients. 2017 , 104, 131-133	7
1833	New perspectives in the second-line treatment of non squamous NSCLC patients: Results from a large Italian Lung Cancer Working Group. 2017 , 109, 35-41	12
1832	Next generation predictive biomarkers for immune checkpoint inhibition. 2017 , 36, 179-190	67
1831	The End of Nihilism: Systemic Therapy of Advanced Non-Small Cell Lung Cancer. 2017 , 68, 153-168	20
1830	Brain metastasis in a patient with melanoma receiving Pembrolizumab therapy: A case report and review of the literature. 2017 , 96, e9278	1
1829	Efficacy and safety of nanoparticle albumin-bound paclitaxel monotherapy as second-line therapy of cytotoxic anticancer drugs in patients with advanced non-small cell lung cancer. 2017 , 96, e9320	7
1828	Risk of gastrointestinal toxicities with PD-1 inhibitors in cancer patients: A meta-analysis of randomized clinical trials. 2017 , 96, e8931	17

- 1827 Liste en sus, accès précoce à l'innovation, ATU. Vers un New Deal indispensable. Le point de vue du clinicien. **2017**, 19, 386-389
- 1826 Immune Checkpoint Blockade in Breast Cancer Therapy. **2017**, 1026, 383-402 22
- 1825 ASCO update: lung cancer. **2017**, 10, 224-227 12
- 1824 The Successful Treatment of Pulmonary Pleomorphic Carcinoma with Pembrolizumab: A Case Report. **2017**, 10, 752-757 27
- 1823 Traitement de première ligne et de maintenance dans les CBNPC avancés en l'absence d'addiction oncologique. **2017**, 9, 234-247
- 1822 Immunothérapie et cancer du poumon : où en sommes-nous ? **2017**, 9, 315-324 0
- 1821 Identification of candidate responders for anti-PD-L1/PD-1 immunotherapy, Rova-T therapy, or EZH2 inhibitory therapy in small-cell lung cancer. **2018**, 8, 310-314 16
- 1820 Les patients avec indice de performance supérieur à 1. **2017**, 9, 308-314
- 1819 A case of myasthenia gravis and myositis induced by nivolumab. **2017**, 57, 373-377 21
- 1818 Advanced squamous lung cancer: therapeutic options, future directions, unmet needs and results of a monocentric survey. **2017**, 6, 93-107 3
- 1817 "Lazarus response" of nivolumab in a frail patient with non-small-cell lung cancer. **2017**, 5, e00247 4
- 1816 Immun- statt Chemotherapie in der Firstline bei Lungenkarzinom. **2017**, 9, 62-62
- 1815 ESMO Copenhagen 2016: a lung cancer 'grand cru'. **2017**, 2, e000196
- 1814 Characteristics and outcomes of patients with advanced sarcoma enrolled in early phase immunotherapy trials. **2017**, 5, 100 67
- 1813 Management immunvermittelter Nebenwirkungen. **2017**, 20, 54-64
- 1812 Checkpointinhibitoren beim nichtkleinzelligen Lungenkarzinom. **2017**, 23, 838-844
- 1811 Immuntherapie in der Onkologie. **2017**, 12, 17-33 1
- 1810 A molecular signature of lung cancer: potential biomarkers for adenocarcinoma and squamous cell carcinoma. **2017**, 8, 105492-105509 16

1809	Tissue-Agnostic Drug Development. 2017 , 37, 222-230	12
1808	Pathology Issues in Thoracic Oncology: Histologic Characterization and Tissue/Plasma Genotyping May Resolve Diagnostic Dilemmas. 2017 , 37, 619-629	2
1807	Clinical Response to Anti-Programmed Death 1 After Response and Subsequent Progression on Anti-Programmed Death Ligand 1 Therapy. 2017 , 1,	1
1806	Cancer Immunotherapy in Older Patients. 2017 , 23, 219-222	4
1805	Clinical use of immune checkpoint inhibitors. 2017 ,	
1804	Novel tools to assist neoepitope targeting in personalized cancer immunotherapy. 2017 , 28, xii3-xii10	24
1803	A Case of Secondary Adrenocortical Insufficiency Developed due to ACTH Deficiency After Nivolumab Treatment. 2017 , 57, 226-231	0
1802	Prognostic value of Cox-2 and PD-L1 expression and its relationship with tumor-infiltrating lymphocytes in resected lung adenocarcinoma. 2017 , 9, 741-750	14
1801	Update on targeted therapies for advanced non-small cell lung cancer: nivolumab in context. 2017 , 13, 223-236	15
1800	Non-small cell lung cancer treatment (r)evolution: ten years of advances and more to come. 2017 , 11, 787	24
1799	Cytostatic Agents: Monoclonal Antibodies Utilized in the Treatment of Solid Malignancies. 2017 , 39, 465-482	1
1798	Current Diagnosis and Management of Immune Related Adverse Events (irAEs) Induced by Immune Checkpoint Inhibitor Therapy. 2017 , 8, 49	314
1797	Immune-Related Adverse Events Associated with Anti-PD-1/PD-L1 Treatment for Malignancies: A Meta-Analysis. 2017 , 8, 730	233
1796	Pneumonitis and pneumonitis-related death in cancer patients treated with programmed cell death-1 inhibitors: a systematic review and meta-analysis. 2017 , 13, 1259-1271	12
1795	Treating mutation resistance in non-small cell lung cancer - role of osimertinib. 2017 , 10, 49-56	18
1794	Mutational Landscape of cfDNA Identifies Distinct Molecular Features Associated With Therapeutic Response to First-Line Platinum-Based Doublet Chemotherapy in Patients with Advanced NSCLC. 2017 , 7, 4753-4762	21
1793	Bevacizumab in the treatment of NSCLC: patient selection and perspectives. 2017 , 8, 259-269	25
1792	New PD-L1 inhibitors in non-small cell lung cancer - impact of atezolizumab. 2017 , 8, 67-78	20

1791	The efficacy of anti-PD-1/PD-L1 therapy and its comparison with EGFR-TKIs for advanced non-small-cell lung cancer. 2017 , 8, 57826-57835	21
1790	Safety of checkpoint inhibitors for cancer treatment: strategies for patient monitoring and management of immune-mediated adverse events. 2017 , 6, 51-71	76
1789	Prognostic Significance of Host-related Biomarkers for Survival in Patients with Advanced Non-Small Cell Lung Cancer. 2017 , 8, 2974-2983	20
1788	Pembrolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. 2017 , 8, 1-11	6
1787	Cost analysis of adverse events associated with non-small cell lung cancer management in France. 2017 , 9, 443-449	4
1786	Profile of pembrolizumab in the treatment of head and neck squamous cell carcinoma: design development and place in therapy. 2017 , 11, 2537-2549	4
1785	PD-1 and PD-L1 as emerging therapeutic targets in gastric cancer: current evidence. 2017 , 7, 1-11	29
1784	Newly Emerging Immune Checkpoints: Promises for Future Cancer Therapy. 2017 , 18,	60
1783	Histologic Grade Is Predictive of Incidence of Epidermal Growth Factor Receptor Mutations in Metastatic Lung Adenocarcinoma. 2017 , 5,	5
1782	Synergies of Targeting Tumor Angiogenesis and Immune Checkpoints in Non-Small Cell Lung Cancer and Renal Cell Cancer: From Basic Concepts to Clinical Reality. 2017 , 18,	22
1781	CIMAvax-EGF: A New Therapeutic Vaccine for Advanced Non-Small Cell Lung Cancer Patients. 2017 , 8, 269	34
1780	PD-1/PD-L1 Blockade: Have We Found the Key to Unleash the Antitumor Immune Response?. 2017 , 8, 1597	145
1779	Acute and Late Toxicities of Concurrent Chemoradiotherapy for Locally-Advanced Non-Small Cell Lung Cancer. 2017 , 9,	41
1778	The between Now and Then of Lung Cancer Chemotherapy and Immunotherapy. 2017 , 18,	34
1777	Checkpoint Blockade Toxicity and Immune Homeostasis in the Gastrointestinal Tract. 2017 , 8, 1547	80
1776	Historical Evolution of Second-Line Therapy in Non-Small Cell Lung Cancer. 2017 , 4, 4	24
1775	Patient-Derived Xenograft Models of Non-Small Cell Lung Cancer and Their Potential Utility in Personalized Medicine. 2017 , 7, 2	46
1774	Current Treatment Algorithms for Patients with Metastatic Non-Small Cell, Non-Squamous Lung Cancer. 2017 , 7, 38	12

1773	Update on the Treatment of Metastatic Squamous Non-Small Cell Lung Cancer in New Era of Personalized Medicine. 2017 , 7, 50	21
1772	Antiangiogenesis for Advanced Non-Small-Cell Lung Cancer in the Era of Immunotherapy and Personalized Medicine. 2017 , 7, 52	22
1771	Update on Programmed Death-1 and Programmed Death-Ligand 1 Inhibition in the Treatment of Advanced or Metastatic Non-Small Cell Lung Cancer. 2017 , 7, 67	25
1770	Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitors in Treatment of Metastatic Non-Small Cell Lung Cancer, with a Focus on Afatinib. 2017 , 7, 97	10
1769	Immunotherapy Combined with Large Fractions of Radiotherapy: Stereotactic Radiosurgery for Brain Metastases-Implications for Intraoperative Radiotherapy after Resection. 2017 , 7, 147	16
1768	Emerging Therapies for Stage III Non-Small Cell Lung Cancer: Stereotactic Body Radiation Therapy and Immunotherapy. 2017 , 7, 197	18
1767	Radiotherapy Dosing for Locally Advanced Non-Small Cell Lung Carcinoma: "MTD" or "ALARA"? 2017 , 7, 205	6
1766	Radiotherapy for Oligometastatic Lung Cancer. 2017 , 7, 210	26
1765	Genetic Characterization of Brain Metastases in the Era of Targeted Therapy. 2017 , 7, 230	31
1764	Increased EGFR Phosphorylation Correlates with Higher Programmed Death Ligand-1 Expression: Analysis of TKI-Resistant Lung Cancer Cell Lines. 2017 , 2017, 7694202	6
1763	Targeting the Pd-1 Pathway in Renal Cell Carcinoma: A Review. 2017 , 1, 179-187	1
1762	Immunotherapy for Patients with Advanced Urothelial Cancer: Current Evidence and Future Perspectives. 2017 , 2017, 5618174	8
1761	Current Status of Immune Checkpoint Inhibitors in Gastrointestinal Cancers. 2017 , 8, 1460-1465	9
1760	Role of afatinib in the treatment of advanced lung squamous cell carcinoma. 2017 , 9, 147-157	3
1759	Osimertinib in the treatment of non-small-cell lung cancer: design, development and place in therapy. 2017 , 8, 109-125	34
1758	Prognostic value of KRAS mutation in advanced non-small-cell lung cancer treated with immune checkpoint inhibitors: A meta-analysis and review. 2017 , 8, 48248-48252	65
1757	Prognostic value of smoking status in non-small-cell lung cancer patients treated with immune checkpoint inhibitors: a meta-analysis. 2017 , 8, 93149-93155	45
1756	Which treatment is preferred for advanced non-small-cell lung cancer with wild-type epidermal growth factor receptor in second-line therapy? A meta-analysis comparing immune checkpoint inhibitor, tyrosine kinase inhibitor and chemotherapy. 2017 , 8, 66491-66503	1

1755	A systematic and genome-wide correlation meta-analysis of PD-L1 expression and targetable NSCLC driver genes. 2017 , 9, 2560-2571	16
1754	Emerging Family of Protein-protein Interaction Inhibitors Targeting PD-1 Checkpoint Pathway. 2017 , 13,	
1753	PD-L1 expression in pleomorphic, spindle cell and giant cell carcinoma of the lung is related to TTF-1, p40 expression and might indicate a worse prognosis. 2017 , 12, e0180346	25
1752	Clinical implications of the novel cytokine IL-38 expressed in lung adenocarcinoma: Possible association with PD-L1 expression. 2017 , 12, e0181598	25
1751	Use of the 22C3 anti-PD-L1 antibody to determine PD-L1 expression in multiple automated immunohistochemistry platforms. 2017 , 12, e0183023	50
1750	A study of PD-L1 expression in KRAS mutant non-small cell lung cancer cell lines exposed to relevant targeted treatments. 2017 , 12, e0186106	12
1749	Incidence of immune checkpoint inhibitor-related colitis in solid tumor patients: A systematic review and meta-analysis. 2017 , 6, e1344805	97
1748	Pathogenesis, clinical manifestations and management of immune checkpoint inhibitors toxicity. 2017 , 103, 405-421	31
1747	The need for a network to establish and validate predictive biomarkers in cancer immunotherapy. 2017 , 15, 223	18
1746	Ongoing clinical trials of PD-1 and PD-L1 inhibitors for lung cancer in China. 2017 , 10, 136	33
1745	Recent development in clinical applications of PD-1 and PD-L1 antibodies for cancer immunotherapy. 2017 , 10, 174	68
1744	Response to single agent PD-1 inhibitor after progression on previous PD-1/PD-L1 inhibitors: a case series. 2017 , 5, 66	27
1743	Safety in treatment of hepatocellular carcinoma with immune checkpoint inhibitors as compared to melanoma and non-small cell lung cancer. 2017 , 5, 93	41
1742	Retrospective review of safety and efficacy of programmed cell death-1 inhibitors in refractory high grade gliomas. 2017 , 5, 99	27
1741	A pilot study of an autologous tumor-derived autophagosome vaccine with docetaxel in patients with stage IV non-small cell lung cancer. 2017 , 5, 103	4
1740	Immunotherapie thorakaler Tumoren. 2017 , 20, 21-27	
1739	Prognostic value of programmed death-1, programmed death-ligand 1, programmed death-ligand 2 expression, and CD8(+) T cell density in primary tumors and metastatic lymph nodes from patients with stage T1-4N+M0 gastric adenocarcinoma. 2017 , 36, 61	29
1738	Impressive response to immunotherapy in a metastatic gastric cancer patient: could somatic copy number alterations help patient selection?. 2017 , 5, 84	4

1737 Pembrolizumab halbiert das Risiko f. Progression oder Tod. **2017**, 9, 56-56

1736 Molekularbiologische Grundlagen der immunonkologischen Therapie. **2017**, 20, 10-15

1

1735 Radiotherapie verstärkt Wirkung von PD-1-Checkpointinhibitoren. **2017**, 20, 19-20

1734 Checkpoint inhibitors in endometrial cancer: preclinical rationale and clinical activity. **2017**, 8, 90532-90544 60

1733 Evaluation of rare but severe immune related adverse effects in PD-1 and PD-L1 inhibitors in non-small cell lung cancer: a meta-analysis. **2017**, 6, S8-S20 67

1732 Harnessing the immune system through programmed death-1 blockade in the management of Hodgkin lymphoma. **2017**, 7, 1-7 1

1731 Checkpoint Inhibitors in Nonsmall Cell Lung Cancer. **2017**,

1730 First and Best Treatments for EGFR and PD-L1 - Competition for First Line Therapy in Adenocarcinoma. **2017**, 2, 138-141

1729 The ascent of immune checkpoint inhibitors: is the understudy ready for a leading role?. **2017**, 14, 341-347 3

1728 Atezolizumab in advanced non-small cell lung cancer. **2017**, 9, 3603-3606 6

1727 Programmed cell death-ligand 1 expression and immunoscore in stage II and III non-small cell lung cancer patients receiving adjuvant chemotherapy. **2017**, 8, 61618-61625 8

1726 Sustained Oligoclonal T Cell Expansion Correlates with Durable Response to Immune Checkpoint Blockade in Lung Cancer. **2017**, 9, 5

1725 Cancer Immunotherapy and Personalized Medicine: Emerging Technologies and Biomarker-Based Approaches. **2017**, 8, 14

1724 PD-1 targeted Immunotherapy as first-line therapy for advanced non-small-cell lung cancer patients. **2017**, 9, E384-E386 14

1723 Correlation of cancer stem cell markers and immune cell markers in resected non-small cell lung cancer. **2017**, 8, 3190-3197 5

1722 The coexpression of multi-immune inhibitory receptors on T lymphocytes in primary non-small-cell lung cancer. **2017**, 11, 3367-3376 4

1721 Altered status of programmed death-ligand 1 after recurrence in resected lung adenocarcinoma patients. **2017**, 10, 2003-2007 5

1720 Advances on immunotherapy in genitourinary and renal cell carcinoma. **2017**, 6, 17-29 8

1719	Locoregional and systemic therapy for hepatocellular carcinoma. 2017 , 8, 215-228	46
1718	Spotlight on necitumumab in the treatment of non-small-cell lung carcinoma. 2017 , 8, 13-19	13
1717	Survival significance of epidermal growth factor receptor tyrosine kinase inhibitors and current staging system for survival after recurrence in patients with completely resected lung adenocarcinoma. 2017 , 10, 4135-4141	
1716	Nuclear Molecular Imaging Strategies in Immune Checkpoint Inhibitor Therapy. 2017 , 7,	12
1715	Reasons for lack of referral to medical oncology for systemic therapy in stage IV non-small-cell lung cancer: comparison of 2003-2006 with 2010-2011. 2017 , 24, e486-e493	11
1714	PD-L1 expression in bladder cancer and metastasis and its influence on oncologic outcome after cystectomy. 2017 , 8, 66849-66864	38
1713	Tumor immunotherapy: drug-induced neoantigens (xenogenization) and immune checkpoint inhibitors. 2017 , 8, 41641-41669	13
1712	From targeting the tumor to targeting the immune system: Transversal challenges in oncology with the inhibition of the PD-1/PD-L1 axis. 2017 , 8, 37-53	40
1711	Future Genetic/Genomic Biomarker Testing in Non-Small Cell Lung Cancer. 2017 , 37, 12-17	1
1710	Treatment of Patients With Metastatic Cancer Using a Major Histocompatibility Complex Class II-Restricted T-Cell Receptor Targeting the Cancer Germline Antigen MAGE-A3. 2017 , 35, 3322-3329	126
1709	Pembrolizumab in Small-Cell Lung Cancer: In Search of the Best Biomarker. 2017 , 35, 3794-3795	0
1708	Pembrolizumab in Patients With Extensive-Stage Small-Cell Lung Cancer: Results From the Phase Ib KEYNOTE-028 Study. 2017 , 35, 3823-3829	298
1707	Combination of Arginine Depletion and Chemotherapy in Thoracic Malignancies. 2017 , 35, 1758-1759	
1706	Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update. 2017 , 35, 3484-3515	358
1705	Phase III Trial of Ipilimumab Combined With Paclitaxel and Carboplatin in Advanced Squamous Non-Small-Cell Lung Cancer. 2017 , 35, 3449-3457	223
1704	Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). 2017 , 35, 2781-2789	248
1703	Changing the Natural History of Non-Small-Cell Lung Cancer Through Upfront Programmed Death Protein 1/Programmed Death-Ligand 1 Blockade. 2017 , 35, 2735-2736	2
1702	Safety and Antitumor Activity of Pembrolizumab in Advanced Programmed Death Ligand 1-Positive Endometrial Cancer: Results From the KEYNOTE-028 Study. 2017 , 35, 2535-2541	244

1701	Programmed Death-Ligand 1 Immunohistochemistry Testing: A Review of Analytical Assays and Clinical Implementation in Non-Small-Cell Lung Cancer. 2017 , 35, 3867-3876	263
1700	Therapy of Advanced Non-Small-Cell Lung Cancer With an SN-38-Anti-Trop-2 Drug Conjugate, Sacituzumab Govitecan. 2017 , 35, 2790-2797	74
1699	Role of Chemotherapy and Targeted Therapy in Early-Stage Non-Small Cell Lung Cancer. 2017 , 37, 630-639	7
1698	Systemic Therapy for Stage IV Non-Small-Cell Lung Cancer: American Society of Clinical Oncology Clinical Practice Guideline Update Summary. 2017 , 13, 832-837	37
1697	Immunotherapy for Esophageal and Gastric Cancer. 2017 , 37, 292-300	38
1696	Molecular Biomarkers in Advanced Non-Small-Cell Lung Cancer: A Rapidly Changing Field. 2017 , 13, 231-232	1
1695	How Should We Choose the Best Therapy for Elderly Patients With Stage III Non-Small-Cell Lung Cancer?. 2017 , 35, 2860-2862	
1694	Cost Sharing in Insurance Coverage for Precision Medicine. 2017 ,	2
1693	Biomarkers for Checkpoint Inhibition. 2017 , 37, 205-209	8
1692	SABR Rattling With Radiation and Surgery: Paving a Path Toward Refined Treatment of Early-Stage Non-Small-Cell Lung Cancer. 2017 , 13, 77-78	1
1691	Hodgkin lymphoma and PD-1 blockade: an unfinished story. 2017 , 1, 1-1	4
1690	Downregulation of matrix metalloproteinase 14 by the antitumor miRNA, miR-150-5p, inhibits the aggressiveness of lung squamous cell carcinoma cells. 2018 , 52, 913-924	15
1689	Immune system and melanoma biology: a balance between immunosurveillance and immune escape. 2017 , 8, 106132-106142	109
1688	The significance of programmed cell death ligand 1 expression in resected lung adenocarcinoma. 2017 , 8, 16421-16429	43
1687	Emerging treatment options for the management of Hodgkin's lymphoma: clinical utility of nivolumab. 2017 , 8, 41-54	5
1686	Renal Toxicity in Patients Treated with Anti-Pd-1 Targeted Agents for Solid Tumors. 2017 , 1, 132-142	2
1685	Immunotherapy supplanting chemotherapy for upfront treatment of advanced non-small cell lung cancer: what's next?. 2017 , 9, E519-E521	3
1684	Unique distribution of programmed death ligand 1 (PD-L1) expression in East Asian non-small cell lung cancer. 2017 , 9, 2579-2586	32

1683	Transcriptional programs of tumor infiltrating T-cells provide insight into mechanisms of immune response and new targets for immunotherapy. 2017 , 9, 4162-4164	
1682	Predictive biomarkers of immunotherapy for non-small cell lung cancer: results from an Experts Panel Meeting of the Italian Association of Thoracic Oncology. 2017 , 6, 373-386	32
1681	Immunohistochemistry for predictive biomarkers in non-small cell lung cancer. 2017 , 6, 570-587	26
1680	Molecular diagnostics of lung cancer in the clinic. 2017 , 6, 560-569	34
1679	KEYNOTE-028: how do we use immunotherapy in small cell lung cancer?. 2017 , 6, S84-S87	0
1678	Osimertinib for advanced non-small cell lung cancer harboring EGFR mutation exon 20 T790M, acquired resistant mutation for first- or second-generation EGFR-TKI. 2017 , 9, 470-473	0
1677	Prognostic significance of PD-L1 expression and tumor infiltrating lymphocyte in surgically resectable non-small cell lung cancer. 2017 , 8, 83986-83994	45
1676	Checkpoint inhibitors in metastatic epidermal growth factor receptor-mutated non-small cell lung cancer patients: where we treating the wrong cancer?. 2017 , 9, 2771-2773	2
1675	Comments on the trial of cisplatin and etoposide plus thoracic radiotherapy followed by nivolumab or placebo for locally advanced non-small cell lung cancer (RTOG 3505). 2017 , 9, 3525-3528	
1674	Optimal pembrolizumab dosing for non-small cell lung cancer: further studies still needed. 2017 , 9, 4821-4824	10
1673	Reproducibility of PD-L1 assessment in non-small cell lung cancer-know your limits but never stop trying to exceed them. 2017 , 6, S51-S54	7
1672	Avelumab: another active immune checkpoint inhibitor in non-small cell lung cancer. 2017 , 6, S41-S43	2
1671	Programmed Cell Death 1 (PD-1) Ligand (PD-L1) Expression in Solid Tumors As a Predictive Biomarker of Benefit From PD-1/PD-L1 Axis Inhibitors: A Systematic Review and Meta-Analysis.. 2017 , 1, 1-15	31
1670	PD-L1 expression heterogeneity in non-small cell lung cancer: evaluation of small biopsies reliability. 2017 , 8, 90123-90131	64
1669	Correlating programmed death ligand 1 (PD-L1) expression, mismatch repair deficiency, and outcomes across tumor types: implications for immunotherapy. 2017 , 8, 77415-77423	55
1668	Genotypic and phenotypic signatures to predict immune checkpoint blockade therapy response in patients with colorectal cancer. 2018 , 196, 62-70	3
1667	Defining the Most Appropriate Primary End Point in Phase 2 Trials of Immune Checkpoint Inhibitors for Advanced Solid Cancers: A Systematic Review and Meta-analysis. 2018 , 4, 522-528	56
1666	Breaking the biomarker code: PD-L1 expression and checkpoint inhibition in advanced NSCLC. 2018 , 65, 65-77	25

1665	Immuno-PET Imaging of Zr Labeled Anti-PD-L1 Domain Antibody. 2018 , 15, 1674-1681	55
1664	Immune Checkpoint Inhibition in Hodgkin Lymphoma. 2018 , 2, e20	8
1663	Designing Late-Stage Randomized Clinical Trials with Cancer Immunotherapy: Can We Make It Simpler?. 2018 , 6, 250-254	3
1662	Gastrointestinal toxicity of immune checkpoint inhibitors: from mechanisms to management. 2018 , 15, 222-234	54
1661	PD-L1 mRNA expression in plasma-derived exosomes is associated with response to anti-PD-1 antibodies in melanoma and NSCLC. 2018 , 118, 820-824	117
1660	Effect of pembrolizumab on patients harboring uncommon epidermal growth factor receptor mutations. 2018 , 29, 1331-1333	4
1659	Relapse-free cure from multidrug-resistant tuberculosis in Germany. 2018 , 51,	10
1658	Checkpoint inhibitors: 'raising the bar' also in brain metastases from non-small-cell lung cancer?. 2018 , 10, 403-410	5
1657	Clinical performance of endobronchial ultrasound-guided transbronchial needle aspiration for assessing programmed death ligand-1 expression in nonsmall cell lung cancer. 2018 , 46, 378-383	32
1656	The PD-L1 Immunohistochemistry Biomarker: Two Steps Forward, One Step Back?. 2018 , 13, 291-294	17
1655	Putative lung adenocarcinoma with epidermal growth factor receptor mutation presenting as carcinoma of unknown primary site: A case report. 2018 , 97, e9942	7
1654	Use of the 22C3 anti-programmed death-ligand 1 antibody to determine programmed death-ligand 1 expression in cytology samples obtained from non-small cell lung cancer patients. 2018 , 126, 264-274	60
1653	PD-L1 Expression in Small'Cell Lung Cancer. 2018 , 13, e40-e41	25
1652	Time is up for PD-L1 testing standardization in lung cancer. 2018 , 29, 791-792	2
1651	Treatment effects measured by restricted mean survival time in trials of immune checkpoint inhibitors for cancer. 2018 , 29, 1320-1324	21
1650	IFN- γ -mediated inhibition of lung cancer correlates with PD-L1 expression and is regulated by PI3K-AKT signaling. 2018 , 143, 931-943	61
1649	Optimal management of immune-related adverse events resulting from treatment with immune checkpoint inhibitors: a review and update. 2018 , 23, 410-420	40
1648	Impaired Tumor-Infiltrating T Cells in Patients with Chronic Obstructive Pulmonary Disease Impact Lung Cancer Response to PD-1 Blockade. 2018 , 198, 928-940	38

1647	Development of Molecularly Targeted Agents and Immunotherapies in Glioblastoma: A Personalized Approach. 2018 , 12, 1179554918759079	4
1646	Overall Survival Results of the Feasibility Study of Adjuvant Chemotherapy With Docetaxel Plus Cisplatin Followed by Long-term Single-agent Administration of S-1 in Patients With Completely Resected Non-Small Cell Lung Cancer: Thoracic Oncology Research Group (TORG) 0809. 2018 , 41, 1113-1117	3
1645	Landscape of Tumor Mutation Load, Mismatch Repair Deficiency, and PD-L1 Expression in a Large Patient Cohort of Gastrointestinal Cancers. 2018 , 16, 805-812	114
1644	Sustained Persistence of IL2 Signaling Enhances the Antitumor Effect of Peptide Vaccines through T-cell Expansion and Preventing PD-1 Inhibition. 2018 , 6, 617-627	8
1643	Increase in PD-L1 expression after pre-operative radiotherapy for soft tissue sarcoma. 2018 , 7, e1442168	38
1642	Breathing New Life Into Hypoxia-Targeted Therapies for Non-Small Cell Lung Cancer. 2018 , 110,	22
1641	A Randomized Phase II Study of Metformin plus Paclitaxel/Carboplatin/Bevacizumab in Patients with Chemotherapy-Naïve Advanced or Metastatic Nonsquamous Non-Small Cell Lung Cancer. 2018 , 23, 859-865	45
1640	Cytology Smears in the Era of Molecular Biomarkers in Non-Small Cell Lung Cancer: Doing More With Less. 2018 , 142, 291-298	47
1639	Treatment of Advanced Non-Small Cell Lung Cancer in 2018. 2018 , 4, 569-570	60
1638	PD-L1 testing using the clone 22C3 pharmDx kit for selection of patients with non-small cell lung cancer to receive immune checkpoint inhibitor therapy: are cytology cell blocks a viable option?. 2018 , 7, 133-141	42
1637	Extracellular matrix functions in lung cancer. 2018 , 73, 105-121	27
1636	Association of preoperative serum CRP with PD-L1 expression in 508 patients with non-small cell lung cancer: A comprehensive analysis of systemic inflammatory markers. 2018 , 27, 88-94	27
1635	Baseline neutrophilia, derived neutrophil-to-lymphocyte ratio (dNLR), platelet-to-lymphocyte ratio (PLR), and outcome in non small cell lung cancer (NSCLC) treated with Nivolumab or Docetaxel. 2018 , 233, 6337-6343	65
1634	Retreatment with pembrolizumab in advanced non-small cell lung cancer patients previously treated with nivolumab: emerging reports of 12 cases. 2018 , 81, 1105-1109	49
1633	Chemotherapy treatment is associated with altered PD-L1 expression in lung cancer patients. 2018 , 144, 1219-1226	37
1632	Association between programmed cell death ligand-1 expression and extracranial metastasis in intracranial solitary fibrous tumor/hemangiopericytoma. 2018 , 139, 251-259	12
1631	The risk of immune-related endocrine disorders associated with anti-PD-1 inhibitors therapy for solid tumors: A systematic review and meta-analysis. 2018 , 59, 328-338	11
1630	Prognostic Impact of Tumor Mutation Burden in Patients With Completely Resected Non-Small Cell Lung Cancer: Brief Report. 2018 , 13, 1217-1221	83

1629	Predicting outcomes in patients with advanced non-small cell lung cancer enrolled in early phase immunotherapy trials. 2018 , 120, 137-141		22
1628	Characteristics and Predictive Value of PD-L1 Status in Real-World Non-Small Cell Lung Cancer Patients. 2018 , 41, 292-299		16
1627	The expression profile of PD-L1 and CD8 lymphocyte in pituitary adenomas indicating for immunotherapy. 2018 , 139, 89-95		45
1626	Gender and outcomes in non-small cell lung cancer: an old prognostic variable comes back for targeted therapy and immunotherapy?. 2018 , 3, e000344		60
1625	The clinical significance of PD-L1 in advanced gastric cancer is dependent on mutations and ATM expression. 2018 , 7, e1457602		6
1624	BRAF Adds an Additional Piece of the Puzzle to Precision Oncology-Based Treatment Strategies in Lung Cancer. 2018 , 142, 796-797		4
1623	PD-L1 expression in circulating tumor cells of advanced non-small cell lung cancer patients treated with nivolumab. 2018 , 120, 108-112		117
1622	Neoadjuvant PD-1 Blockade in Resectable Lung Cancer. <i>New England Journal of Medicine</i> , 2018 , 378, 1976-1986	59.2	865
1621	Pembrolizumab plus Chemotherapy in Metastatic Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018 , 378, 2078-2092	59.2	2820
1620	Nivolumab plus Ipilimumab in Lung Cancer with a High Tumor Mutational Burden. <i>New England Journal of Medicine</i> , 2018 , 378, 2093-2104	59.2	1704
1619	Immune Checkpoint Inhibitors: Game Changing Cancer Therapy With a Cardiac Cost. What Are the Mechanisms and Unresolved Questions in Cardiotoxicity?. 2018 , 34, 970-971		
1618	Combination of immunotherapy with chemotherapy and radiotherapy in lung cancer: is this the beginning of the end for cancer?. 2018 , 10, 1758835918762094		74
1617	PD-L1 expression testing in non-small cell lung cancer. 2018 , 10, 1758835918763493		90
1616	Radiotherapy and checkpoint inhibitors: a winning new combination?. 2018 , 10, 1758835918768240		58
1615	KMT2D Mutation Is Associated With Poor Prognosis in Non-Small-Cell Lung Cancer. 2018 , 19, e489-e501		20
1614	Optimal Evaluation of Programmed Death Ligand-1 on Tumor Cells Versus Immune Cells Requires Different Detection Methods. 2018 , 142, 982-991		24
1613	The Pulmonologist-Patient Relationship After the Lung Cancer Committee Decision. 2018 , 54, 179-180		
1612	The prognostic role of programmed cell death-ligand 1 expression in non-small cell lung cancer patients: An updated meta-analysis. 2018 , 482, 101-107		26

1611	Heterogeneity of PD-L1 Expression Among the Different Histological Components and Metastatic Lymph Nodes in Patients With Resected Lung Adenosquamous Carcinoma. 2018 , 19, e421-e430	28
1610	Programmed death-ligand 1 (PD-L1) expression in pleomorphic carcinoma of the lung. 2018 , 117, 1563-1569	15
1609	ALT-803, an IL-15 superagonist, in combination with nivolumab in patients with metastatic non-small cell lung cancer: a non-randomised, open-label, phase 1b trial. 2018 , 19, 694-704	201
1608	Monoclonal Antibody LMab-13 Detected Human PD-L1 in Lung Cancers. 2018 , 37, 110-115	31
1607	Antiangiogenic therapy for patients with aggressive or refractory advanced non-small cell lung cancer in the second-line setting. 2018 , 120, 62-69	18
1606	Clinical assessment of immune-related adverse events. 2018 , 10, 1758835918764628	74
1605	Science and biology drives the immune system to cure lung cancer patients: a revolution but not without challenges. 2018 , 10, 1758835918763723	2
1604	Consolidation systemic treatment after radiochemotherapy for unresectable stage III non-small cell lung cancer. 2018 , 66, 114-121	25
1603	NSCLC: State of the Art Diagnosis, Treatment, and Outcomes. 2018 , 7, 29-41	2
1602	The Immune Revolution: A Case for Priming, Not Checkpoint. 2018 , 33, 563-569	170
1601	Making Sense of Immunotherapy in Lung Cancer: What the Pulmonologist Needs to Know?. 2018 , 7, 42-48	
1600	Immunotherapy phase I trials in patients Older than 70 years with advanced solid tumours. 2018 , 95, 68-74	13
1599	Anti-Angiogenics: Their Value in Lung Cancer Therapy. 2018 , 41, 172-180	22
1598	Survival benefit from RectroNectin-activated cytokine-induced killer cells combined with chemotherapy in advanced EGFR wild-type lung adenocarcinoma. 2018 , 10, 501-510	4
1597	[Advanced bladder cancer : From chemo- to immunotherapy]. 2018 , 57, 686-692	
1596	Overcoming Tumor-Induced Immune Suppression: From Relieving Inhibition to Providing Costimulation with T Cell Agonists. 2018 , 32, 221-231	12
1595	PD-L1 expression in tumour-infiltrating lymphocytes is a poor prognostic factor for primary acral melanoma patients. 2018 , 73, 386-396	14
1594	Genomic Features of Response to Combination Immunotherapy in Patients with Advanced Non-Small-Cell Lung Cancer. 2018 , 33, 843-852.e4	525

1593	PD-1/PD-L1 pathway inhibitors in advanced prostate cancer. 2018 , 11, 475-486	52
1592	Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer. 2018 , 29, 1417-1422	61
1591	STAT3 as a potential immunotherapy biomarker in oncogene-addicted non-small cell lung cancer. 2018 , 10, 1758835918763744	17
1590	Canadian Cancer Trials Group (CCTG) IND211: A randomized trial of pelareorep (Reolysin) in patients with previously treated advanced or metastatic non-small cell lung cancer receiving standard salvage therapy. 2018 , 120, 142-148	18
1589	Anti-Podocalyxin Monoclonal Antibody 47-mG Detects Lung Cancers by Immunohistochemistry. 2018 , 37, 91-94	2
1588	Metformin for non-small cell lung cancer patients: Opportunities and pitfalls. 2018 , 125, 41-47	19
1587	Anticancer drug treatment for advanced lung cancer with interstitial lung disease. 2018 , 56, 307-311	11
1586	When is crossover desirable in cancer drug trials and when is it problematic?. 2018 , 29, 1079-1081	12
1585	Immunotherapy: a new standard of care in thoracic malignancies? A summary of the European Respiratory Society research seminar of the Thoracic Oncology Assembly. 2018 , 51,	7
1584	Correlation Between Programmed Death Receptor-1 Expression in Tumor-Infiltrating Lymphocytes and Programmed Death Ligand-1 Expression in Non-Small Cell Lung Carcinoma. 2018 , 142, 1388-1393	3
1583	[PD-L1 expression and PD-1/PD-L1 inhibitors in breast cancer]. 2018 , 105, 263-274	10
1582	Lung Cancer. 2018 , 1-21	
1581	3D-3-culture: A tool to unveil macrophage plasticity in the tumour microenvironment. 2018 , 163, 185-197	107
1580	Nab-paclitaxel plus carboplatin as an effective and safe chemotherapy regimen for pulmonary carcinosarcoma with interstitial lung disease: A case report. 2018 , 23, 131-135	1
1579	Pembrolizumab in patients with thymic carcinoma: a single-arm, single-centre, phase 2 study. 2018 , 19, 347-355	169
1578	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. 2018 , 13, 323-358	241
1577	Safety of Combined PD-1 Pathway Inhibition and Intracranial Radiation Therapy in Non-Small Cell Lung Cancer. 2018 , 13, 550-558	69
1576	PD-L1 expression in lung adenocarcinoma harboring EGFR mutations or ALK rearrangements. 2018 , 118, 36-40	51

1575	Primary and metastatic brain cancer genomics and emerging biomarkers for immunomodulatory cancer treatment. 2018 , 52, 259-268	9
1574	Development of leptomeningeal carcinomatosis during a marked response of brain metastases to pembrolizumab in a patient with non-small-cell lung cancer. 2018 , 29, 780-781	3
1573	Combining chemotherapy with PD-1 blockade in NSCLC. 2018 , 186, 130-137	56
1572	Cytologic-histologic correlation of programmed death-ligand 1 immunohistochemistry in lung carcinomas. 2018 , 126, 253-263	55
1571	Immune checkpoint inhibitors in non-small cell lung cancer (NSCLC): Approaches on special subgroups and unresolved burning questions. 2018 , 64, 21-29	31
1570	The New Age of -omics in Urothelial Cancer - Re-wording Its Diagnosis and Treatment. 2018 , 28, 43-50	11
1569	Immunological Aspects of Cryoablation of Non-Small Cell Lung Cancer: A Comprehensive Review. 2018 , 13, 624-635	14
1568	Clinicopathological characteristics of POLE mutation in patients with non-small-cell lung cancer. 2018 , 118, 57-61	31
1567	[Immune checkpoint inhibitors (antibodies to PD1 and PD-L1), a new therapeutic weapon against non-small cell bronchial carcinoma]. 2018 , 35, 197-205	3
1566	[The biological rationale for immunotherapy in cancer]. 2018 , 35, 206-222	4
1565	Immuno-oncology-101: overview of major concepts and translational perspectives. 2018 , 52, 1-11	30
1564	Immune Checkpoint Blockade: The New Frontier in Cancer Treatment. 2018 , 13, 1-20	23
1563	Osimertinib and other third-generation EGFR TKI in EGFR-mutant NSCLC patients. 2018 , 29, i20-i27	54
1562	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. 2018 , 142, 321-346	371
1561	RANKL blockade improves efficacy of PD1-PD-L1 blockade or dual PD1-PD-L1 and CTLA4 blockade in mouse models of cancer. 2018 , 7, e1431088	45
1560	[Durvalumab improves prognosis of stage III non-small-cell lung cancer after definitive chemoradiotherapy]. 2018 , 194, 269-271	
1559	Wide Expression and Significance of Alternative Immune Checkpoint Molecules, B7x and HHLA2, in PD-L1-Negative Human Lung Cancers. 2018 , 24, 1954-1964	40
1558	Pooled in vivo screens for cancer immunotherapy target discovery. 2018 , 10, 167-170	2

1557	The role of tumor-infiltrating lymphocytes (TILs) as a predictive biomarker of response to anti-PD1 therapy in patients with metastatic non-small cell lung cancer or metastatic melanoma. 2018 , 35, 25	79
1556	Interferon gamma, an important marker of response to immune checkpoint blockade in non-small cell lung cancer and melanoma patients. 2018 , 10, 1758834017749748	128
1555	Treatment-Related Adverse Events Predict Improved Clinical Outcome in NSCLC Patients on KEYNOTE-001 at a Single Center. 2018 , 6, 288-294	50
1554	Role of immune-checkpoint inhibitors in lung cancer. 2018 , 12, 1753465817750075	58
1553	Multicenter harmonization study for PD-L1 IHC testing in non-small-cell lung cancer. 2018 , 29, 953-958	133
1552	New Folate-Grafted Chitosan Derivative To Improve Delivery of Paclitaxel-Loaded Solid Lipid Nanoparticles for Lung Tumor Therapy by Inhalation. 2018 , 15, 899-910	82
1551	Impact of a five-dimensional framework on R&D productivity at AstraZeneca. 2018 , 17, 167-181	203
1550	Circulating tumor DNA evaluated by Next-Generation Sequencing is predictive of tumor response and prolonged clinical benefit with nivolumab in advanced non-small cell lung cancer. 2018 , 7, e1424675	36
1549	The use of combination immunotherapies as front-line therapy for non-small-cell lung cancer. 2018 , 14, 191-194	3
1548	Established, emerging and elusive molecular targets in the treatment of lung cancer. 2018 , 244, 565-577	11
1547	Safety and efficacy of anti-PD-1 therapy for metastatic melanoma and non-small-cell lung cancer in patients with viral hepatitis: a case series. 2018 , 28, 155-158	31
1546	Correlation between sex and efficacy of immune checkpoint inhibitors (PD-1 and CTLA-4 inhibitors). 2018 , 143, 45-51	52
1545	Updated Molecular Testing Guideline for the Selection of Lung Cancer Patients for Treatment With Targeted Tyrosine Kinase Inhibitors: Guideline From the College of American Pathologists, the International Association for the Study of Lung Cancer, and the Association for Molecular Pathology. 2018 , 20, 129-159	165
1544	PD-L1 expression in large cell neuroendocrine carcinoma of the lung. 2018 , 118, 76-82	21
1543	Translation in Immunology. 2018 , 1-11	
1542	Hypermutated Tumors and Immune Checkpoint Inhibition. 2018 , 78, 155-162	16
1541	Blood and lymphatic vessels contribute to the impact of the immune microenvironment on clinical outcome in non-small-cell lung cancer. 2018 , 53, 1205-1213	6
1540	Challenges and Perspectives for Immunotherapy in Adenocarcinoma of the Pancreas: The Cancer Immunity Cycle. 2018 , 47, 142-157	16

1539	Checkpoint Inhibitors, Palliative Care, or Hospice. 2018 , 20, 2	8
1538	Exacerbation of autoimmune hemolytic anemia induced by the first dose of programmed death-1 inhibitor pembrolizumab: a case report. 2018 , 36, 509-512	20
1537	The differences in the assessments of side effects at an oncology outpatient clinic. 2018 , 40, 386-393	3
1536	Treatment-related toxicities of immune checkpoint inhibitors in advanced cancers: A meta-analysis. 2018 , 14, 141-152	25
1535	Comprehensive Assessment of PD-L1 Staining Heterogeneity in Pulmonary Adenocarcinomas Using Tissue Microarrays: Impact of the Architecture Pattern and the Number of Cores. 2018 , 42, 687-694	21
1534	Safety, Activity, and Biomarkers of SHR-1210, an Anti-PD-1 Antibody, for Patients with Advanced Esophageal Carcinoma. 2018 , 24, 1296-1304	99
1533	Beyond Concurrent Chemoradiation: The Emerging Role of PD-1/PD-L1 Inhibitors in Stage III Lung Cancer. 2018 , 24, 1271-1276	24
1532	Panitumumab-Conjugated and Platinum-Cored pH-Sensitive Apoferritin Nanocages for Colorectal Cancer-Targeted Therapy. 2018 , 10, 6096-6106	19
1531	The biology and management of non-small cell lung cancer. 2018 , 553, 446-454	1499
1530	Immune-mediated thrombocytopenia and hypothyroidism in a lung cancer patient treated with nivolumab. 2018 , 10, 85-91	25
1529	Peripheral Blood Biomarkers Associated with Clinical Outcome in Non-Small Cell Lung Cancer Patients Treated with Nivolumab. 2018 , 13, 97-105	121
1528	Developing a Predictive Model for Clinical Outcomes of Advanced Non-Small Cell Lung Cancer Patients Treated With Nivolumab. 2018 , 19, 280-288.e4	38
1527	PD-L1 Expression in a Non-Small Cell Lung Cancer Specimen Obtained by EBUS-TBNA. 2018 , 54, 290-292	9
1526	[Hot topics in 2017 in oncology and hematology. A selection by the editorial board of Bulletin du Cancer]. 2018 , 105, 6-14	1
1525	Concurrent Immune Checkpoint Inhibitors and Stereotactic Radiosurgery for Brain Metastases in Non-Small Cell Lung Cancer, Melanoma, and Renal Cell Carcinoma. 2018 , 100, 916-925	162
1524	There and back again: An immunotherapy tale. 2018 , 155, 1771-1774	0
1523	Immunotherapy: The power of perseverance. 2018 , 155, 1775-1776	1
1522	What's happening next. 2018 , 155, 1781-1782	

1521	PD-L1 Expression of Tumor Cells, Macrophages, and Immune Cells in Non-Small Cell Lung Cancer Patients with Malignant Pleural Effusion. 2018 , 13, 447-453	28
1520	Current and Emergent Therapy Options for Advanced Squamous Cell Lung Cancer. 2018 , 13, 165-183	52
1519	Predictive Performance of Four Programmed Cell Death Ligand 1 Assay Systems on Nivolumab Response in Previously Treated Patients with Non-Small Cell Lung Cancer. 2018 , 13, 377-386	39
1518	Changing health care costs for NSCLC, what does it mean?. 2018 , 117, 62-63	2
1517	High expression of topoisomerase-II predicts favorable clinical outcomes in patients with relapsed small cell lung cancers receiving amrubicin. 2018 , 115, 42-48	7
1516	Prognostic role of the VeriStrat test in first line patients with non-small cell lung cancer treated with platinum-based chemotherapy. 2018 , 117, 64-69	10
1515	Pembrolizumab induced acute corneal toxicity after allogeneic stem cell transplantation. 2018 , 46, 698-700	7
1514	Durable Near-Complete Response to Anti-PD-1 Checkpoint Immunotherapy in a Refractory Malignant Solitary Fibrous Tumor of the Pleura. 2017 , 10, 998-1005	6
1513	Association of Immunotherapy With Durable Survival as Defined by Value Frameworks for Cancer Care. 2018 , 4, 326-332	36
1512	Therapeutic Cancer Vaccines: How Much Closer Are We?. 2018 , 32, 1-7	11
1511	Pembrolizumab for the treatment of bladder cancer. 2018 , 18, 107-114	9
1510	Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer. 2018 , 13, 106-111	130
1509	Immune Checkpoint Inhibition in Lung Cancer. 2018 , 333-344	
1508	PD-1 Blockade in Renal Cell Carcinoma. 2018 , 345-355	
1507	Synergy Between Radiotherapy and Immunotherapy. 2018 , 507-524	
1506	Programmed Death-Ligand 1 Expression and EGFR Mutations in Multifocal Lung Cancer. 2018 , 105, 448-454	12
1505	Magnetofluorescent Carbon Quantum Dot Decorated Multiwalled Carbon Nanotubes for Dual-Modal Targeted Imaging in Chemo-Photothermal Synergistic Therapy. 2018 , 4, 151-162	37
1504	[Lung cancer in HIV-infected patients]. 2018 , 105, 111-119	0

1503	Emerging biomarkers for immunomodulatory cancer treatment of upper gastrointestinal, pancreatic and hepatic cancers. 2018 , 52, 241-252	9
1502	Using Genome Sequence to Enable the Design of Medicines and Chemical Probes. 2018 , 118, 1599-1663	51
1501	Will liquid biopsies become our fluid transition to personalized immunotherapy?. 2018 , 29, 11-13	1
1500	Evaluation of Overall Response Rate and Progression-Free Survival as Potential Surrogate Endpoints for Overall Survival in Immunotherapy Trials. 2018 , 24, 2268-2275	53
1499	Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC). 2018 , 10, 1758834017745012	73
1498	Characteristics of Real-World Metastatic Non-Small Cell Lung Cancer Patients Treated with Nivolumab and Pembrolizumab During the Year Following Approval. 2018 , 23, 328-336	62
1497	Master protocols in lung cancer: experience from Lung Master Protocol. 2018 , 30, 92-97	10
1496	Improving immune-vascular crosstalk for cancer immunotherapy. 2018 , 18, 195-203	170
1495	Inflammation and PD-L1 expression in pulmonary neuroendocrine tumors. 2018 , 25, 339-350	27
1494	Precision Molecular Pathology of Liver Cancer. 2018 ,	1
1493	Safety and Efficacy of PD-1/PD-L1 Inhibitors in Treatment-Naive and Chemotherapy-Refractory Patients With Non-Small-Cell Lung Cancer: A Systematic Review and Meta-Analysis. 2018 , 19, e335-e348	39
1492	Mechanisms of resistance to immune checkpoint inhibitors. 2018 , 118, 9-16	576
1491	Reprogramming T-cells for adoptive immunotherapy of ovarian cancer. 2018 , 18, 359-367	5
1490	Retuning the Radio in Radiobiology. 2018 , 110, 325-326	
1489	Inhibitors of the PD-1 Pathway in Tumor Therapy. 2018 , 200, 375-383	82
1488	KEYNOTE-024: Unlocking a pathway to lung cancer cure?. 2018 , 155, 1777-1780	5
1487	Radiotherapy and anti-PD-1/PD-L1 combinations in lung cancer: building better translational research platforms. 2018 , 29, 301-310	56
1486	Biomarker Discovery and Validation in HCC Diagnosis, Prognosis, and Therapy. 2018 , 95-113	1

1485	Perspective on immune oncology with liquid biopsy, peripheral blood mononuclear cells, and microbiome with non-invasive biomarkers in cancer patients. 2018 , 20, 966-974	18
1484	Multimodality imaging of endocrine immune related adverse events: a primer for radiologists. 2018 , 50, 96-103	18
1483	PD-L1 expression according to the EGFR status in primary lung adenocarcinoma. 2018 , 116, 1-6	35
1482	Immune-Related Adverse Events Associated with Immune Checkpoint Blockade. <i>New England Journal of Medicine</i> , 2018 , 378, 158-168	59.2 1834
1481	Association of the Lung Immune Prognostic Index With Immune Checkpoint Inhibitor Outcomes in Patients With Advanced Non-Small Cell Lung Cancer. 2018 , 4, 351-357	357
1480	The efficacy and safety of anti-PD-1/PD-L1 antibodies combined with chemotherapy or CTLA4 antibody as a first-line treatment for advanced lung cancer. 2018 , 142, 2344-2354	35
1479	Composition of the immune microenvironment differs between carcinomas metastatic to the lungs and primary lung carcinomas. 2018 , 33, 62-68	4
1478	A review of systemic anticancer therapy in disease palliation. 2018 , 125, 43-53	4
1477	Clinical response to PD-1 blockade correlates with a sub-fraction of peripheral central memory CD4+ T cells in patients with malignant melanoma. 2018 , 30, 13-22	53
1476	The Basics of Cancer Immunotherapy. 2018 ,	2
1475	Therapeutic Targets of FDA-Approved Immunotherapies in Oncology. 2018 , 21-37	1
1474	Significance of Immune Checkpoints in Lung Cancer. 2018 , 59-77	
1473	Supportive care in the era of immunotherapies for advanced non-small-cell lung cancer. 2018 , 30, 98-104	3
1472	Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis. 2018 , 360, k793	262
1471	Tumor Mutational Burden and Efficacy of Nivolumab Monotherapy and in Combination with Ipilimumab in Small-Cell Lung Cancer. 2018 , 33, 853-861.e4	471
1470	Updated Correlation of 22C3-PD-L1 $\geq 50\%$ Expression with Driver Oncogene Mutations and Response to Pembrolizumab in the Kinase Inhibitor-Resistant Setting. 2018 , 13, e81-e83	
1469	Re-challenging immune checkpoint inhibitor in a patient with advanced non-small cell lung cancer: a case report. 2018 , 18, 302	13
1468	Radiotherapy-induced anti-tumor immune response and immune-related adverse events in a case of recurrent nasopharyngeal carcinoma undergoing anti-PD-1 immunotherapy. 2018 , 18, 395	12

1467	Distinctive features of immunostaining and mutational load in primary pulmonary enteric adenocarcinoma: implications for differential diagnosis and immunotherapy. 2018 , 16, 81	14
1466	Lessons learned from the blockade of immune checkpoints in cancer immunotherapy. 2018 , 11, 31	141
1465	CONFIRM: a double-blind, placebo-controlled phase III clinical trial investigating the effect of nivolumab in patients with relapsed mesothelioma: study protocol for a randomised controlled trial. 2018 , 19, 233	33
1464	Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis. 2018 , 6, 26	89
1463	Aktuelle Systemtherapie des metastasierten Harnblasenkarzinoms. 2018 , 13, 140-147	
1462	BRAF Mutant Lung Cancer: Programmed Death Ligand 1 Expression, Tumor Mutational Burden, Microsatellite Instability Status, and Response to Immune Check-Point Inhibitors. 2018 , 13, 1128-1137	84
1461	Pembrolizumab combined with stereotactic body radiotherapy in a patient with human immunodeficiency virus and advanced non-small cell lung cancer: a case report. 2018 , 12, 104	11
1460	The impact of PD-L1 on survival and value of the immune check point inhibitors in non-small-cell lung cancer; proposal, policies and perspective. 2018 , 6, 15	13
1459	Therapeutic antibodies: A new era in the treatment of respiratory diseases?. 2018 , 189, 149-172	18
1458	Immune Checkpoint Inhibition in Gastro-Oesophageal Cancer. 2018 , 41, 272-280	23
1457	Correlation between 22C3-PD-L1 Expression and EGFR Mutations in Japanese Patients with Advanced Lung Adenocarcinoma. 2018 , 13, e79-e81	4
1456	Psoriatic arthritis due to nivolumab administration a case report and review of the literature. 2018 , 23, 182-187	14
1455	Assessment of programmed cell death ligand-1 expression by 4 diagnostic assays and its clinicopathological correlation in a large cohort of surgical resected non-small cell lung carcinoma. 2018 , 31, 1381-1390	34
1454	A Multi-center Phase I Trial of Ipilimumab in Patients with Myelodysplastic Syndromes following Hypomethylating Agent Failure. 2018 , 24, 3519-3527	49
1453	Rationale and emerging strategies for immune checkpoint blockade in soft tissue sarcoma. 2018 , 124, 3819-3829	25
1452	CHECKPOINT INHIBITOR IMMUNE THERAPY: Systemic Indications and Ophthalmic Side Effects. 2018 , 38, 1063-1078	164
1451	Safety and Efficacy of PD-1 Inhibitors Among HIV-Positive Patients With Non-Small Cell Lung Cancer. 2018 , 13, 1037-1042	58
1450	Expression Patterns, Prognostic Value, and Intratumoral Heterogeneity of PD-L1 and PD-1 in Thymoma and Thymic Carcinoma. 2018 , 13, 1204-1212	33

1449	Efficacy and safety of immune checkpoint inhibitors in non-small cell lung cancer. 2018 , 7, e1457600	14
1448	Recent progress in systemic treatment for lung cancer. 2018 , 24, 355-366	7
1447	BRAF in non-small cell lung cancer (NSCLC): Pickaxing another brick in the wall. 2018 , 66, 82-94	66
1446	CD8 lymphocytes in tumors and nonsynonymous mutational load correlate with prognosis of bladder cancer patients treated with immune checkpoint inhibitors. 2018 , 1, e1002	3
1445	Vaccine Therapy and Immunotherapy for Pancreatic Cancer. 2018 , 1461-1505	
1444	New data: new options for front-line therapy in NSCLC?. 2018 , 3, e000369	2
1443	CD103 Tumor-Resident CD8 T Cells Are Associated with Improved Survival in Immunotherapy-Naïve Melanoma Patients and Expand Significantly During Anti-PD-1 Treatment. 2018 , 24, 3036-3045	163
1442	Improved Overall Survival and Locoregional Disease Control With Concurrent PD-1 Pathway Inhibitors and Stereotactic Radiosurgery for Lung Cancer Patients With Brain Metastases. 2018 , 101, 624-629	67
1441	Clinical Features and Management of Acquired Resistance to PD-1 Axis Inhibitors in 26 Patients With Advanced Non-Small Cell Lung Cancer. 2018 , 13, 831-839	57
1440	Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer. 2018 , 29, 1437-1444	376
1439	Tumor Microenvironment Properties are Associated With Low CD68-positive Cell Infiltration and Favorable Disease-free Survival in EGFR-mutant Lung Adenocarcinoma. 2018 , 19, e551-e558	7
1438	B7-H3 Negatively Modulates CTL-Mediated Cancer Immunity. 2018 , 24, 2653-2664	57
1437	Pembrolizumab-Induced Rhabdomyolysis With Myositis in a Patient With Lung Adenocarcinoma. 2018 , 54, 346-348	4
1436	WITHDRAWN: Biomarqueurs prédictifs de réponse aux inhibiteurs de points de contrôle immuns. 2018 ,	
1435	The CDK4/6 Inhibitor Abemaciclib Induces a T Cell Inflamed Tumor Microenvironment and Enhances the Efficacy of PD-L1 Checkpoint Blockade. 2018 , 22, 2978-2994	201
1434	Progress in the Management of Malignant Pleural Mesothelioma in 2017. 2018 , 13, 606-623	45
1433	Translation of Knowledge to Practice-Improving Awareness in NSCLC Molecular Testing. 2018 , 13, 1004-1011	4
1432	Cetuximab for treating non-small cell lung cancer. 2018 , 18, 483-493	22

1431	A Placebo-Controlled Phase II Study of Ruxolitinib in Combination With Pemetrexed and Cisplatin for First-Line Treatment of Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer and Systemic Inflammation. 2018 , 19, e567-e574	12
1430	Immune checkpoint blockade therapy. 2018 , 142, 1403-1414	44
1429	Pseudoprogression and hyperprogression after checkpoint blockade. 2018 , 58, 125-135	89
1428	Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer. 2018 , 13, e55-e56	3
1427	Understanding the Hurdles in Lung Cancer Immunotherapy in the Context of Chronic Obstructive Pulmonary Disease. 2018 , 198, 835-837	1
1426	[PD-L1 testing in non-small cell lung carcinoma: Guidelines from the PATTERN group of thoracic pathologists]. 2018 , 38, 110-125	14
1425	Response to Costantini et al. "Comments on Increased Response Rates to Salvage Chemotherapy Administered after PD-1/PD-L1 Inhibitors in Patients with Non-Small Cell Lung Cancer". 2018 , 13, e56-e57	1
1424	Are We Ready to Safely Combine Anti-PD-1/PD-L1 with Cranial Irradiation in Non-Small Cell Lung Cancer Patients?. 2018 , 13, 475-477	4
1423	Progress in the Treatment and Outcomes for Early-Stage Non-Small Cell Lung Cancer. 2018 , 196, 351-358	12
1422	Management of gastrointestinal adverse events induced by immune-checkpoint inhibitors. 2018 , 4, 1-7	5
1421	Regulation and Function of the PD-L1 Checkpoint. 2018 , 48, 434-452	783
1420	Correlation of tumor-related immunity with 18F-FDG-PET in pulmonary squamous-cell carcinoma. 2018 , 119, 71-77	31
1419	Engineering nanoparticle strategies for effective cancer immunotherapy. 2018 , 178, 597-607	78
1418	Molecular and Immune Biomarker Testing in Squamous-Cell Lung Cancer: Effect of Current and Future Therapies and Technologies. 2018 , 19, 331-339	13
1417	Family history of cancer as surrogate predictor for immunotherapy with anti-PD1/PD-L1 agents: preliminary report of the FAMI-L1 study. 2018 , 10, 643-655	9
1416	Comprehensive Evaluation of Programmed Death-Ligand 1 Expression in Primary and Metastatic Prostate Cancer. 2018 , 188, 1478-1485	79
1415	Comprehensive analysis of cancers of unknown primary for the biomarkers of response to immune checkpoint blockade therapy. 2018 , 94, 179-186	53
1414	Distinguishing between immune-related pneumonitis and disease progression in advanced Non Small Cell Lung Cancer treated with PD-1 inhibitors: Can serum tumour markers have a role?. 2018 , 95, 127-129	4

1413	Late-Onset Adrenal Insufficiency More Than 1 Year after Stopping Pembrolizumab. 2018 , 13, e39-e40	14
1412	Immune signatures predicting responses to immunomodulatory antibody therapy. 2018 , 51, 91-96	5
1411	Chronic Obstructive Pulmonary Disease: Clinical Implications for Patients With Lung Cancer. 2018 , 22, 184-192	2
1410	Targeting immune checkpoints in non small cell lung cancer. 2018 , 40, 46-50	36
1409	Genomic Testing in Lung Cancer: Past, Present, and Future. 2018 , 16, 323-334	17
1408	Clinical and Molecular Predictors of PD-L1 Expression in Non-Small-Cell Lung Cancer: Systematic Review and Meta-analysis. 2018 , 19, 315-322	25
1407	Nivolumab in routine practice for older patients with advanced or metastatic non-small cell lung cancer. 2018 , 9, 494-500	12
1406	CLEC1B Expression and PD-L1 Expression Predict Clinical Outcome in Hepatocellular Carcinoma with Tumor Hemorrhage. 2018 , 11, 552-558	21
1405	Rhesus CE expression on patient red blood cells is an independent prognostic factor for adenocarcinoma of the lung. 2018 , 12, 1106-1117	3
1404	Phase I study of Nedaplatin, a platinum based antineoplastic drug, combined with nab-paclitaxel in patients with advanced squamous non-small cell lung cancer. 2018 , 36, 45-52	1
1403	Meta-Analysis of the Risk of Immune-Related Adverse Events With Anticytotoxic T-Lymphocyte-Associated Antigen 4 and Antiprogrammed Death 1 Therapies. 2018 , 103, 318-331	16
1402	Treatment of lung adenocarcinoma by molecular-targeted therapy and immunotherapy. 2018 , 48, 1-8	44
1401	The "Achilles' Heel" of Cancer and Its Implications for the Development of Novel Immunotherapeutic Strategies. 2018 , 8,	8
1400	A Network Meta-Analysis of Short and Long-Term Efficacy of Targeted Therapy With Single or Double-Drug Regimens in the Treatment of Stage III/IV Malignant Melanoma Based on 16 Randomized Controlled Trials. 2018 , 119, 640-649	4
1399	Metabolic rewiring in mutant Kras lung cancer. 2018 , 285, 28-41	33
1398	An Evolving Algorithm to Select and Sequence Therapies in EGFR Mutation-positive NSCLC: A Strategic Approach. 2018 , 19, 42-50	5
1397	Treatment Rationale and Design for J-SONIC: A Randomized Study of Carboplatin Plus Nab-paclitaxel With or Without Nintedanib for Advanced Non-Small-cell Lung Cancer With Idiopathic Pulmonary Fibrosis. 2018 , 19, e5-e9	29
1396	Combination Strategies on the Basis of Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer: Where Do We Stand?. 2018 , 19, 1-11	34

1395	Preclinical investigation of combined gene-mediated cytotoxic immunotherapy and immune checkpoint blockade in glioblastoma. 2018 , 20, 225-235	38
1394	Prognostic impact of programmed death-ligand 1 expression in correlation with human leukocyte antigen class I expression status in stage I adenocarcinoma of the lung. 2018 , 155, 382-392.e1	20
1393	Combination Therapy of Radiotherapy and Anti-PD-1/PD-L1 Treatment in Non-Small-cell Lung Cancer: A Mini-review. 2018 , 19, 12-16	48
1392	Programmed death-ligand 1 testing of lung cancer cytology specimens obtained with bronchoscopy. 2018 , 126, 122-128	45
1391	Analytical Validation of a Next-Generation Sequencing Assay to Monitor Immune Responses in Solid Tumors. 2018 , 20, 95-109	32
1390	Phase II trial of pembrolizumab in patients with platinum refractory germ-cell tumors: a Hoosier Cancer Research Network Study GU14-206. 2018 , 29, 209-214	98
1389	Detection of PD-L1 in circulating tumor cells and white blood cells from patients with advanced non-small-cell lung cancer. 2018 , 29, 193-199	111
1388	A fatal allo- and immune-mediated thrombocytopenia with a PD-L1 inhibitor. 2018 , 29, 514-515	11
1387	Companion and Complementary Diagnostics-Focus on PD-L1 Expression Assays for PD-1/PD-L1 Checkpoint Inhibitors in Non-Small Cell Lung Cancer. 2018 , 40, 9-16	69
1386	A 2-in-1 adaptive phase 2/3 design for expedited oncology drug development. 2018 , 64, 238-242	27
1385	Genomic Characterization of Lung Cancer and Its Impact on the Use and Timing of PET in Therapeutic Response Assessment. 2018 , 13, 33-42	2
1384	Positron Emission Tomography-Adjusted Intensity Modulated Radiation Therapy for Locally Advanced Non-Small Cell Lung Cancer. 2018 , 102, 709-715	10
1383	Mechanistic overview of immune checkpoints to support the rational design of their combinations in cancer immunotherapy. 2018 , 29, 71-83	154
1382	Impact of Chronic Obstructive Pulmonary Disease on Immune-based Treatment for Lung Cancer. Moving toward Disease Interception. 2018 , 197, 278-280	3
1381	Combination therapy strategies for improving PD-1 blockade efficacy: a new era in cancer immunotherapy. 2018 , 283, 110-120	104
1380	Looking for the best immune-checkpoint inhibitor in pre-treated NSCLC patients: An indirect comparison between nivolumab, pembrolizumab and atezolizumab. 2018 , 142, 1277-1284	55
1379	Effects of Co-occurring Genomic Alterations on Outcomes in Patients with -Mutant Non-Small Cell Lung Cancer. 2018 , 24, 334-340	173
1378	Comparison of the toxicity profile of PD-1 versus PD-L1 inhibitors in non-small cell lung cancer: A systematic analysis of the literature. 2018 , 124, 271-277	173

1377	Clinical Outcomes in Patients With Metastatic Lung Cancer Treated With PD-1/PD-L1 Inhibitors and Thoracic Radiotherapy. 2018 , 4, 253-255	57
1376	Association of Immune-Related Adverse Events With Nivolumab Efficacy in Non-Small-Cell Lung Cancer. 2018 , 4, 374-378	517
1375	Adverse glycaemic effects of cancer therapy: indications for a rational approach to cancer patients with diabetes. 2018 , 78, 141-154	28
1374	CD4 and CD8 T lymphocyte interplay in controlling tumor growth. 2018 , 75, 689-713	208
1373	A review of immune therapy in cancer and a question: can thermal therapy increase tumor response?. 2018 , 34, 840-852	16
1372	Emerging targets in cancer immunotherapy. 2018 , 52, 39-52	164
1371	Endocrinopathies with use of cancer immunotherapies. 2018 , 88, 327-332	16
1370	The application and mechanism of PD pathway blockade for cancer therapy. 2018 , 94, 53-60	9
1369	The Pulmonologist-Patient Relationship After the Lung Cancer Committee Decision. 2018 , 54, 179-180	
1368	PD-L1 in breast cancer: comparative analysis of 3 different antibodies. 2018 , 72, 28-34	32
1367	Frontline Systemic Therapy Options in Nonsmall Cell Lung Cancer. 2018 , 418-433.e6	
1366	Immunotherapy and Lung Cancer. 2018 , 501-511.e3	2
1365	Diagnostic Algorithms. 2018 , 651-658.e1	
1364	Interlaboratory concordance of PD-L1 immunohistochemistry for non-small-cell lung cancer. 2018 , 72, 449-459	54
1363	Killing two birds with one stone: response to pembrolizumab in a patient with metastatic melanoma and B-cell chronic lymphocytic leukaemia. 2018 , 32, e72-e74	3
1362	Metabolic activity by F-FDG-PET/CT is predictive of early response after nivolumab in previously treated NSCLC. 2018 , 45, 56-66	124
1361	Sequential, Multiple Assignment, Randomized Trial Designs in Immuno-oncology Research. 2018 , 24, 730-736	8
1360	Chronic Obstructive Pulmonary Disease Alters Immune Cell Composition and Immune Checkpoint Inhibitor Efficacy in Non-Small Cell Lung Cancer. 2018 , 197, 325-336	46

1359	HPV Integration in HNSCC Correlates with Survival Outcomes, Immune Response Signatures, and Candidate Drivers. 2018 , 16, 90-102	91
1358	Lung cancer epigenetics: From knowledge to applications. 2018 , 51, 116-128	142
1357	Emerging biomarkers for cancer immunotherapy in melanoma. 2018 , 52, 207-215	31
1356	Adverse prognostic value of PD-L1 expression in primary resected pulmonary squamous cell carcinomas and paired mediastinal lymph node metastases. 2018 , 31, 101-110	21
1355	Hiding from the good guys. 2018 , 155, 363-364	
1354	Programmed death ligand 1-associated antitumor immunity in early-stage non-small cell lung cancer: Expression of major histocompatibility complex I as a prerequisite. 2018 , 155, 393-394	
1353	Chimeric Antigen Receptor (CAR) T-Cell Therapy for Thoracic Malignancies. 2018 , 13, 16-26	50
1352	Pembrolizumab for treatment of advanced gastric and gastroesophageal junction adenocarcinoma. 2018 , 14, 417-430	41
1351	Long non-coding RNA AGER-1 functionally upregulates the innate immunity gene AGER and approximates its anti-tumor effect in lung cancer. 2018 , 57, 305-318	22
1350	Prognostic value of PD-L1 expression in combination with CD8 TILs density in patients with surgically resected non-small cell lung cancer. 2018 , 7, 32-45	31
1349	Role of Immunotherapy in Head and Neck Cancer. 2018 , 28, 12-16	47
1348	Integrated functional and mass spectrometry-based flow cytometric phenotyping to describe the immune microenvironment in acute myeloid leukemia. 2018 , 453, 44-52	11
1347	Electromagnetic Navigational Bronchoscopy versus CT-guided Percutaneous Sampling of Peripheral Indeterminate Pulmonary Nodules: A Cohort Study. 2018 , 286, 1052-1061	19
1346	Immune-related tumour response assessment criteria: a comprehensive review. 2018 , 91, 20170457	38
1345	Durvalumab in non-small-cell lung cancer patients: current developments. 2018 , 14, 205-222	7
1344	Pembrolizumab as first-line therapy for metastatic non-small-cell lung cancer. 2018 , 10, 93-105	72
1343	Molecular Diagnosis and Targeting for Lung Cancer. 2018 , 1-32	
1342	Current status of cancer immunotherapy for esophageal squamous cell carcinoma. 2018 , 15, 1-9	17

1341	Patterns of responses in metastatic NSCLC during PD-1 or PDL-1 inhibitor therapy: Comparison of RECIST 1.1, irRECIST and iRECIST criteria. 2018 , 88, 38-47	178
1340	Correlation between immune-related adverse events and efficacy in non-small cell lung cancer treated with nivolumab. 2018 , 115, 71-74	234
1339	Molecular Diagnosis and Targeting for Thoracic and Gastrointestinal Malignancy. 2018 ,	0
1338	Concordance between the response evaluation criteria in solid tumors version 1.1 and the immune-related response criteria in patients with non-small cell lung cancer treated with nivolumab: a multicenter retrospective cohort study. 2018 , 81, 333-337	5
1337	Neutrophil-lymphocyte ratio kinetics in patients with advanced solid tumours on phase I trials of PD-1/PD-L1 inhibitors. 2018 , 89, 56-63	46
1336	Investigational PD-1 inhibitors in HL and NHL and biomarkers for predictors of response and outcome. 2018 , 27, 55-70	3
1335	High PD-L1 expression indicates poor prognosis of HIV-infected patients with non-small cell lung cancer. 2018 , 67, 495-505	10
1334	Synergy of Immune Checkpoint Blockade with a Novel Synthetic Consensus DNA Vaccine Targeting TERT. 2018 , 26, 435-445	28
1333	Implications of the tumor immune microenvironment for staging and therapeutics. 2018 , 31, 214-234	182
1332	Personalized medicine for non-small cell lung cancer: where are we now and where can we go?. 2018 , 12, 81-82	5
1331	Product review on the Anti-PD-L1 antibody atezolizumab. 2018 , 14, 269-276	22
1330	Association of Immunotherapy With Overall Survival in Elderly Patients With Melanoma. 2018 , 154, 82-87	35
1329	Immune checkpoint inhibitors in advanced non-small cell lung cancer. 2018 , 124, 248-261	65
1328	Mismatch repair-deficient colorectal cancer: a model of immunogenic and immune cell-rich tumor despite nonsignificant programmed cell death ligand-1 expression in tumor cells. 2018 , 72, 135-143	10
1327	Lung cancer in 2017: Giant steps and stumbling blocks. 2018 , 15, 71-72	13
1326	Characterization of PD-L1 expression in Chinese non-small cell lung cancer patients with PTEN expression as a means for tissue quality screening. 2018 , 67, 471-481	4
1325	PD-L1. 2018 , 71, 189-194	129
1324	Molecular and Genomic Determinants of Response to Immune Checkpoint Inhibition in Cancer. 2018 , 69, 333-347	28

1323 Immunotherapeutic Biomarkers and Selection Strategies. **2018**, 69-114

1322 Impact of PD-L1 expression, driver mutations and clinical characteristics on survival after anti-PD-1/PD-L1 immunotherapy versus chemotherapy in non-small-cell lung cancer: A meta-analysis of randomized trials. **2018**, 7, e1396403 34

1321 PD-L1 expression associated with worse survival outcome in malignant pleural mesothelioma. **2018**, 14, 69-73 33

1320 Immune Checkpoint Combinations with Inflammatory Pathway Modulators. **2018**, 219-241

1319 The Significance of the PD-L1 Expression in Non-Small-Cell Lung Cancer: Trenchant Double Swords as Predictive and Prognostic Markers. **2018**, 19, 120-129 48

1318 Early Phase Cancer Immunotherapy. **2018**, 1

1317 Thoracic Immunotherapy. **2018**, 281-305

1316 Pharmacokinetics and Pharmacodynamics of Immunotherapy. **2018**, 29-67 2

1315 Combinatorial Immunotherapy and Chemotherapy. **2018**, 199-218 4

1314 Eight-Color Multiplex Immunohistochemistry for Simultaneous Detection of Multiple Immune Checkpoint Molecules within the Tumor Microenvironment. **2018**, 200, 347-354 122

1313 Immune checkpoint inhibitors: new strategies to checkmate cancer. **2018**, 191, 133-148 48

1312 PD-1 blockade in advanced NSCLC: A focus on pembrolizumab. **2018**, 62, 39-49 67

1311 Hepatocellular carcinoma in the era of immunotherapy. **2018**, 42, 40-48 71

1310 Immune checkpoint inhibitors in epidermal growth factor receptor mutant non-small cell lung cancer: Current controversies and future directions. **2018**, 115, 12-20 98

1309 PD-L1 expression is mainly regulated by interferon gamma associated with JAK-STAT pathway in gastric cancer. **2018**, 109, 43-53 141

1308 EGFR monoclonal antibody biomarkers in advanced NSCLC: from translational research to clinical implementation. **2018**, 19, 10-12 4

1307 Progress and challenges of predictive biomarkers of anti PD-1/PD-L1 immunotherapy: A systematic review. **2018**, 414, 166-173 132

1306 Perspectives on the integration of Immuno-Oncology Biomarkers and drugs in a Health Care setting. **2018**, 52, 166-177 8

1305	Imaging the multiple facets of immuno-oncology. 2018 , 45, 121-122	
1304	PD-L1 Testing in Guiding Patient Selection for PD-1/PD-L1 Inhibitor Therapy in Lung Cancer. 2018 , 22, 1-10	89
1303	Smoking and EGFR status may predict outcomes of advanced NSCLC treated with PD-(L)1 inhibitors beyond first line: A meta-analysis. 2018 , 12, 1809-1819	18
1302	Impact of Clinicopathologic Features on the Efficacy of PD-1/PD-L1 Inhibitors in Patients With Previously Treated Non-small-cell Lung Cancer. 2018 , 19, e177-e184	5
1301	Liquid Biopsies. 2018 , 275-286	
1300	Immune reprogramming via PD-1 inhibition enhances early-stage lung cancer survival. 2018 , 3,	27
1299	The role of immune checkpoint inhibitors in non-small cell lung cancer. 2018 , 2, 35-35	
1298	More Frequent Surveillance Following Lung Cancer Resection Is Not Associated With Improved Survival: A Nationally Representative Cohort Study. 2018 , 268, 632-639	16
1297	"My Patient Was Diagnosed With Nontargetable Advanced Non-Small Cell Lung Cancer. What Now?" Diagnosis and Initial Treatment Options for Newly Diagnosed Patients With Advanced NSCLC. 2018 , 38, 696-707	5
1296	Breaking the Glass Ceiling of Overall Survival in Non-Small-Cell Lung Cancer. 2018 , 36, 1647-1648	3
1295	Treatment of Advanced Non-Small-Cell Lung Cancer: From Chemotherapy to Chemoimmunotherapy. 2018 , 14, 537-538	6
1294	Immunotherapy in Older Adults With Advanced Cancers: Implications for Clinical Decision-Making and Future Research. 2018 , 38, 400-414	37
1293	Safety of Programmed Death-1 Pathway Inhibitors Among Patients With Non-Small-Cell Lung Cancer and Preexisting Autoimmune Disorders. 2018 , 36, 1905-1912	189
1292	Navigating Through New, First-Line Treatment Options for Lung Cancer. 2018 , 14, 539-540	
1291	Checkpointhemmer beim Thymuskarzinom. 2018 , 21, 18-20	
1290	Systemic Therapy for Elderly Patients With Advanced Non-Small-Cell Lung Cancers. 2018 , 36, 2571-2574	6
1289	Clinical and molecular characteristics of pulmonary sarcomatoid carcinoma. 2018 , 33, 737-744	14
1288	Impact of Baseline Steroids on Efficacy of Programmed Cell Death-1 and Programmed Death-Ligand 1 Blockade in Patients With Non-Small-Cell Lung Cancer. 2018 , 36, 2872-2878	477

1287	"How Much Time Do I Have?": Communicating Prognosis in the Era of Exceptional Responders. 2018 , 38, 787-794	29
1286	Molecular Determinants of Response to Anti-Programmed Cell Death (PD)-1 and Anti-Programmed Death-Ligand 1 (PD-L1) Blockade in Patients With Non-Small-Cell Lung Cancer Profiled With Targeted Next-Generation Sequencing. 2018 , 36, 633-641	730
1285	Keeping Expectations in Check With Immune Checkpoint Inhibitors. 2018 , 36, 1654-1657	32
1284	Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase II Study of Fruquintinib After Two Prior Chemotherapy Regimens in Chinese Patients With Advanced Nonsquamous Non-Small-Cell Lung Cancer. 2018 , 36, 1207-1217	17
1283	Impact on Oncology Practices of Including Drug Costs in Bundled Payments. 2018 , 14, e259-e268	4
1282	Epacadostat Plus Pembrolizumab in Patients With Advanced Solid Tumors: Phase I Results From a Multicenter, Open-Label Phase I/II Trial (ECHO-202/KEYNOTE-037). 2018 , 36, 3223-3230	176
1281	Immune Checkpoint Inhibitors in the Management of Lung Cancer. 2018 , 38, 682-695	17
1280	Wie sich die NSCLC-Therapie verändern wird. 2018 , 10, 51-52	
1279	Tumor Mutation Burden: Is It Ready for the Clinic?. 2018 , 36, 2978-2979	11
1278	Managing Patients With Oligometastatic Non-Small-Cell Lung Cancer. 2018 , 14, 23-31	29
1277	A tertiary care cancer center experience with carboplatin and pemetrexed in combination with pembrolizumab in comparison with carboplatin and pemetrexed alone in non-squamous non-small cell lung cancer. 2018 , 10, 3575-3584	14
1276	Neoadjuvant immunotherapy for non-small cell lung cancer: can early intervention result in durable clinical benefit?. 2018 , 10, S3203-S3206	4
1275	Lung cancer in never smokers-the East Asian experience. 2018 , 7, 450-463	47
1274	Measuring tumor mutation burden in non-small cell lung cancer: tissue versus liquid biopsy. 2018 , 7, 668-677	40
1273	PD-L1 expression and its effect on clinical outcomes of EGFR-mutant NSCLC patients treated with EGFR-TKIs. 2018 , 15, 434-442	16
1272	Predictive markers for anti-PD-1/PD-L1 therapy in non-small cell lung cancer-where are we?. 2018 , 7, 682-690	17
1271	Immunotherapy in treatment naïve advanced non-small cell lung cancer. 2018 , 10, S412-S421	8
1270	Neoadjuvant PD-1 blockade in non-small cell lung cancer: what else do we need to do?. 2018 , 10, S3162-S3165	

1269	Clinical utility of tumor mutational burden in patients with non-small cell lung cancer treated with immunotherapy. 2018 , 7, 647-660	50
1268	Atezolizumab for first-line treatment of metastatic nonsquamous non-small cell lung cancer: what makes the difference?. 2018 , 10, S3241-S3243	1
1267	PD-1 and PD-L1 inhibitor toxicities in non-small cell lung cancer. 2018 , 10, S4034-S4037	3
1266	Challenges and unanswered questions for the next decade of immune-oncology research in NSCLC. 2018 , 7, 691-702	3
1265	Immunotherapy in tyrosine kinase inhibitor-naïve advanced epidermal growth factor receptor-mutant non-small cell lung cancer-driving down a precarious road in driver-mutated lung cancer. 2018 , 7, S377-S380	3
1264	Immunotherapies in the management of epidermal growth factor receptor mutated non-small cell lung cancer: a role will be found?. 2018 , 7, S370-S372	2
1263	The combination strategies will be ready the right first-line choice for squamous lung cancer patients?. 2018 , 7, S349-S351	1
1262	Circulating programmed death ligand-1 (cPD-L1) in non-small-cell lung cancer (NSCLC). 2018 , 9, 17554-17563	16
1261	Combination immunotherapy and radiation therapy strategies for pancreatic cancer-targeting multiple steps in the cancer immunity cycle. 2018 , 9, 1014-1026	25
1260	Stereotactic ablative radiotherapy for oligometastatic non-small cell lung cancer. 2018 , 10, 21-24	1
1259	Ablative therapy in oligometastatic non-small cell lung cancer-an editorial on recent evidence. 2018 , 10, 138-140	1
1258	Square peg, round hole? Programmed death-1 inhibitors in epidermal growth factor receptor-mutant non-small cell lung cancer. 2018 , 10, 25-29	3
1257	A pooled analysis of advanced nonsquamous non-small cell lung cancer patients with stable treated brain metastases in two phase II trials receiving bevacizumab and pemetrexed as second-line therapy. 2018 , 10, 219-227	4
1256	Immune-related adverse events with immune checkpoint inhibitors in thoracic malignancies: focusing on non-small cell lung cancer patients. 2018 , 10, S1516-S1533	36
1255	Locally-advanced non-small cell lung cancer: shall immunotherapy be a new chance?. 2018 , 10, S1461-S1467	15
1254	Immunotherapy in surgically resectable non-small cell lung cancer. 2018 , 10, S404-S411	41
1253	Neoadjuvant and consolidation immuno-oncology therapy in stage III non-small cell lung cancer. 2018 , 10, S451-S459	22
1252	Do immune checkpoint inhibitors need new studies methodology?. 2018 , 10, S1564-S1580	35

1251	Immunotherapy in previously treated non-small cell lung cancer (NSCLC). 2018 , 10, S422-S432	6
1250	Immune checkpoint blockade for advanced non-small cell lung cancer: challenging clinical scenarios. 2018 , 10, S1494-S1502	11
1249	Oncogene-addicted non-small cell lung cancer and immunotherapy. 2018 , 10, S1547-S1555	24
1248	A population-based analysis of outcomes after radiotherapy in intensive care unit patients with lung cancer. 2018 , 10, 1440-1448	4
1247	Early radiological response as predictor of overall survival in non-small cell lung cancer (NSCLC) patients with epidermal growth factor receptor mutations. 2018 , 10, 1386-1393	3
1246	Current PD-L1 immunohistochemistry for non-small cell lung cancer. 2018 , 10, 1217-1219	15
1245	Immune checkpoint blockade in esophageal squamous cell carcinoma: is it ready for prime time?. 2018 , 10, 1276-1279	3
1244	Personalized medicine in immuno-oncology: a novel prognostic index in non-small cell lung cancer. 2018 , 10, S995-S998	1
1243	The evolving understanding of immunoediting and the clinical impact of immune escape. 2018 , 10, 1248-1252	8
1242	Durvalumab after chemo-radiotherapy in stage III non-small cell lung cancer. 2018 , 10, S991-S994	4
1241	Shining light on advanced NSCLC in 2017: combining immune checkpoint inhibitors. 2018 , 10, S1534-S1546	5
1240	Vaccine and immune cell therapy in non-small cell lung cancer. 2018 , 10, S1602-S1614	21
1239	Nivolumab in pretreated non-small cell lung cancer: continuing the immunolution. 2018 , 7, S91-S94	14
1238	Targeting DNA damage repair in small cell lung cancer and the biomarker landscape. 2018 , 7, 50-68	57
1237	Patient-related outcomes with the use of checkpoint inhibitors for the treatment of metastatic non-small cell lung cancer. 2018 , 7, S138-S141	1
1236	Durvalumab for non-resectable stage IIIB non-small cell lung cancer-a small step or a big leap?. 2018 , 7, S153-S157	1
1235	Proton beam therapy and immunotherapy: an emerging partnership for immune activation in non-small cell lung cancer. 2018 , 7, 180-188	17
1234	Autochthonous murine models for the study of smoker and never-smoker associated lung cancers. 2018 , 7, 464-486	8

1233	Tumor mutational burden assessment as a predictive biomarker for immunotherapy in lung cancer patients: getting ready for prime-time or not?. 2018 , 7, 631-638	47
1232	Reirradiation for locoregionally recurrent non-small cell lung cancer. 2018 , 10, S2522-S2536	17
1231	Moving away (finally) from doublet therapy in lung cancer: immunotherapy and KEYNOTE-189. 2018 , 10, 5186-5189	0
1230	Evaluation of combined anti-PD-1 immunotherapy and radiation therapy in a preclinical mouse model of pneumonitis and fibrosis. 2018 , 10, 6254-6260	3
1229	Predictive biomarkers for immune checkpoint inhibitor therapy: we need to keep searching. 2018 , 10, S2195-S2197	3
1228	Tumor mutation burden in lung cancer: a new predictive biomarker for immunotherapy or too soon to tell?. 2018 , 10, S3994-S3998	16
1227	A new era of treating advanced lung cancer is upon us. 2018 , 7, S202-S205	2
1226	Combination chemotherapy and immunotherapy in metastatic non-small cell lung cancer: a setback for personalized medicine?. 2018 , 7, S208-S210	6
1225	Is there a room for immune checkpoint inhibitors in early stage non-small cell lung cancer?. 2018 , 10, S1427-S1437	4
1224	VISTA/PD-1H: a potential target for non-small cell lung cancer immunotherapy. 2018 , 10, 6378-6382	6
1223	Treatment redirection from cure to palliation, then cure again?-a cautious, but urgent matter. 2018 , 7, S5-S8	
1222	Putting the brakes on CTLA-4 inhibition in lung cancer?. 2018 , 7, S35-S38	7
1221	Hunting for transcription factors: STAT3 decoy in non-small cell lung cancer. 2018 , 7, S254-S257	1
1220	PD-L1 immunohistochemistry in patients with non-small cell lung cancer. 2018 , 10, S2127-S2129	4
1219	Harmonization study of antibodies and platforms for programmed death ligand 1 immunostaining in non-small cell lung cancer: does shuffling couples settle the troubles?. 2018 , 10, S2124-S2126	1
1218	Atezolizumab in non-squamous non-small cell lung cancer. 2018 , 10, S3155-S3159	4
1217	Non-small cell lung cancer: land of conquest for immunotherapy. 2018 , 10, 5184-5185	
1216	Cytology versus histology for programmed death-ligand 1 expression evaluation in the landscape of non-small cell lung cancer patients selection for immunotherapy. 2018 , 7, S221-S224	2

1215	Treatment outcomes of patients with localized anal squamous cell carcinoma according to HIV infection: systematic review and meta-analysis. 2019 , 10, 48-60	10
1214	Combining stereotactic body radiation therapy with immunotherapy: current data and future directions. 2019 , 8, 107-115	22
1213	Targeting IL22: a potential therapeutic approach for Kras mutant lung cancer?. 2018 , 7, S243-S247	2
1212	Prognostic significance of tumor immune microenvironment and immunotherapy: Novel insights and future perspectives in gastric cancer. 2018 , 24, 3583-3616	74
1211	Combining immunotherapy with radiation therapy in thoracic oncology. 2018 , 10, S2492-S2507	10
1210	Programmed death ligand-1 inhibitors potentially carry a lower risk of pneumonitis compared with programmed death-1 inhibitors in patients with non-small cell lung cancer. 2018 , 10, S4082-S4084	0
1209	Strategies for first-line immunotherapy in squamous cell lung cancer: are combinations a game changer?. 2018 , 7, S198-S201	3
1208	Upfront surgery in patients with clinical skip N2 lung cancer based on results of modern radiological examinations. 2018 , 10, 6828-6837	6
1207	Management of Advanced Non-Small Cell Lung Cancer. 2018 , 99-115	1
1206	Do toxicity patterns vary between programmed death-1 and programmed death ligand-1 inhibitors?. 2018 , 10, S4069-S4072	1
1205	Quality of life for non-small cell lung cancer patients in the age of immunotherapy. 2018 , 7, S149-S152	10
1204	Classification of tumor microenvironment immune types based on immune response-associated gene expression. 2019 , 54, 219-228	9
1203	Cons: should immunotherapy be incorporated in the treatment of oncogene-driven lung cancer?. 2018 , 7, S290-S293	0
1202	Companion and complementary diagnostics for first-line immune checkpoint inhibitor treatment in non-small cell lung cancer. 2018 , 7, S95-S99	7
1201	The importance of PD-L1 diagnostic assay harmonization for the selection of lung cancer immunotherapy. 2018 , 10, S4096-S4100	3
1200	The clinical utility of tumor mutational burden in non-small cell lung cancer. 2018 , 7, 639-646	61
1199	Circulating immune biomarkers as predictors of the response to pembrolizumab and weekly low dose carboplatin and paclitaxel in NSCLC and poor PS: An interim analysis. 2019 , 17, 1349-1356	19
1198	30-day mortality after the start of systemic anticancer therapy for lung cancer: is it really a useful performance indicator?. 2018 , 4,	9

1197	Role of immunotherapy in kidney cancer. 2018 , 12, 325-333	6
1196	Hematological adverse events related to the immune system with immune checkpoint inhibitors, a comprehensive review as a basis for clinical guidelines. 2018 , 24, 183-193	
1195	Two cases of response to pembrolizumab in epidermal growth factor receptor mutated lung adenocarcinoma patients with programmed death-ligand 1 overexpression. 2018 , 6, 444	2
1194	Systemic immunological biomarkers of clinical responses in immune checkpoint blockade therapies. 2018 , 7, LMT07	1
1193	ROS1-rearranged high-PD-L1-expressing lung adenocarcinoma manifesting as mediastinal tumor: A case report. 2019 , 17, 488-491	2
1192	Using the Spleen as an Systemic Immune Barometer Alongside Osteosarcoma Disease Progression and Immunotherapy with -PD-L1. 2018 , 2018, 8694397	14
1191	Combining immunotherapy and radiotherapy in lung cancer. 2018 , 10, S1447-S1460	43
1190	Increased serum levels of Galectin-9 in patients with chronic lymphocytic leukemia. 2019 , 17, 1019-1029	4
1189	Severe pneumonitis refractory to steroids following anti-PD-1 immunotherapy. 2018 , 2018,	10
1188	Immunotherapy in Advanced Lung Cancer Treatment. 2018 ,	
1187	Biomarqueurs prédictifs de réponse aux inhibiteurs de points de contrôle immuns. 2018 , 105 Suppl 1, S80-S91	0
1186	Taxanes for advanced non-small cell lung cancer. 2018 ,	78
1185	First-Line Therapies for Metastatic Lung Adenocarcinoma Without a Driver Mutation. 2018 , 14, 529-535	17
1184	The effectiveness of PD-1 inhibitors in non-small cell lung cancer (NSCLC) patients of different ages. 2018 , 9, 7942-7948	18
1183	Immune RECIST criteria and symptomatic pseudoprogression in non-small cell lung cancer patients treated with immunotherapy. 2018 , 52, 365-369	27
1182	Future of anti-PD-1/PD-L1 applications: Combinations with other therapeutic regimens. 2018 , 30, 157-172	26
1181	Significance of Tumor Microenvironment Scoring and Immune Biomarkers in Patient Stratification and Cancer Outcomes. 2018 ,	7
1180	Immunotherapy and new frontiers in the treatment of lung cancer. 2018 , 2, 77-77	

- 1179 Prognoseplus in Erstlinie durch PD1-Hemmer beim nichtplattenepithelialen NSCLC. **2018**, 10, 24-24
- 1178 Der Einsatz von Checkpoint-Hemmern beim Lungenkarzinom wird breiter. **2018**, 10, 34-42
- 1177 Deutlich verbesserte Prognose bei NSCLC. **2018**, 10, 53-53
- 1176 Immune Checkpoint Inhibitors in Pediatric Solid Tumors: Status in 2018. **2018**, 18, 370-376 21
- 1175 Integrin $\alpha 8$ -expressing tumor cells evade host immunity by regulating TGF- β activation in immune cells. **2018**, 3, 55
- 1174 Personalisierte Therapie des Lungenkarzinoms. **2018**, 21, 30-36
- 1173 Neue Therapieoptionen beim Lungenkarzinom. **2018**, 21, 18-24
- 1172 PD-1-Hemmer ist neuer First-line-Standard. **2018**, 10, 64-64
- 1171 [Efficacy and toxicity of immune checkpoint inhibitors in elderly patients - 5th edition of the congress of pharmacology of anticancer drugs]. **2018**, 105, 1202-1208 1
- 1170 8. Molekularpathologie. **2018**, 303-350
- 1169 Immuntherapien mit Checkpoint-Inhibitoren – Eine Übersicht. **2018**, 50, 120-123
- 1168 Small Biopsies Misclassify up to 35% of PD-L1 Assessments in Advanced Lung Non-Small Cell Lung Carcinomas. **2018**, 26, 701-708 15
- 1167 Medikamentöse Therapie des metastasierten oder rezidierten mutationsnegativen NSCLC. **2018**, 24, 1003-1008 0
- 1166 Real-world PD-L1 testing and distribution of PD-L1 tumor expression by immunohistochemistry assay type among patients with metastatic non-small cell lung cancer in the United States. **2018**, 13, e0206370 37
- 1165 Comparative safety of immune checkpoint inhibitors in cancer: systematic review and network meta-analysis. **2018**, 363, k4226 191
- 1164 Immunotherapy for non-small cell lung cancers: biomarkers for predicting responses and strategies to overcome resistance. **2018**, 18, 1082 29
- 1163 Rheumatic immune-related adverse events secondary to anti-programmed death-1 antibodies and preliminary analysis on the impact of corticosteroids on anti-tumour response: A case series. **2018**, 105, 88-102 37
- 1162 Pneumonitis in Patients with Lung Cancer Following Treatment: the Effects of Chemotherapy, Immunotherapy, and Tyrosine Kinase Inhibitors. **2018**, 7, 214-219

1161	Advances in evidence-based medicine for immunotherapy of non-small cell lung cancer. 2018 , 11, 278-287	13
1160	An LC-MS/MS Method for Absolute Quantification of Nivolumab in Human Plasma: Application to Clinical Therapeutic Drug Monitoring. 2018 , 40, 716-724	15
1159	Risk of fatigue in cancer patients treated with anti programmed cell death-1/anti programmed cell death ligand-1 agents: a systematic review and meta-analysis. 2018 , 10, 1303-1313	1
1158	and in the genetic landscape of immunotolerance in lung cancer. 2018 , 9, 35603-35604	2
1157	Resistance to anti-PD-1-based immunotherapy in basal cell carcinoma: a case report and review of the literature. 2018 , 6, 126	17
1156	A phase I/II study of bexarotene with carboplatin and weekly paclitaxel for the treatment of patients with advanced non-small cell lung cancer. 2018 , 10, 5531-5537	1
1155	Clinical and molecular characteristics associated with the efficacy of PD-1/PD-L1 inhibitors for solid tumors: a meta-analysis. 2018 , 11, 7529-7542	20
1154	Canadian perspectives: update on inhibition of -positive tumours in advanced non-small-cell lung cancer. 2018 , 25, 317-328	9
1153	Monoclonal antibodies for the treatment of non-hematological tumors: a safety review. 2018 , 17, 1197-1209	8
1152	A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. 2018 , 6, 128	138
1151	Peripheral blood biomarkers correlate with outcomes in advanced non-small cell lung Cancer patients treated with anti-PD-1 antibodies. 2018 , 6, 129	62
1150	Non-small cell to small cell lung cancer on PD-1 inhibitors: two cases on potential histologic transformation. 2018 , 9, 85-90	12
1149	Lung cancer, elderly and immune checkpoint inhibitors. 2018 , 10, S1474-S1481	17
1148	Current Status and Future Perspectives on Neoadjuvant Therapy in Lung Cancer. 2018 , 13, 1818-1831	73
1147	Management of immunotherapy toxicities in older adults. 2018 , 45, 226-231	12
1146	Combination of PD-1 blockade and RetroNectin-activated cytokine-induced killer in preheavily treated non-small-cell lung cancer: a retrospective study. 2018 , 10, 1315-1323	3
1145	Immunotherapy in Advanced Non-small Cell Lung Cancer Patients: Ushering Chemotherapy Through the Checkpoint Inhibitors?. 2018 , 10, e3254	6
1144	Link between tumor-promoting fibrous microenvironment and an immunosuppressive microenvironment in stage I lung adenocarcinoma. 2018 , 126, 64-71	20

1143	Immunotherapy in Non-Small Cell Lung Cancer: Biological Principles and Future Opportunities. 2017 , 17, 527-540	14
1142	Successful response to the combination of immunotherapy and chemotherapy in cholangiocarcinoma with high tumour mutational burden and PD-L1 expression: a case report. 2018 , 18, 1105	40
1141	Functionally impaired follicular helper T cells induce regulatory B cells and CD14 human leukocyte antigen-DR cell differentiation in non-small cell lung cancer. 2018 , 109, 3751-3761	16
1140	Contrasting impact of corticosteroids on anti-PD-1 immunotherapy efficacy for tumor histologies located within or outside the central nervous system. 2018 , 7, e1500108	34
1139	FDA analyses of survival in older adults with metastatic non-small cell lung cancer in controlled trials of PD-1/PD-L1 blocking antibodies. 2018 , 45, 220-225	48
1138	33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) : Washington, D.C., USA. 7-11 November 2018. 2018 , 6, 114	29
1137	33rd Annual Meeting & Pre-Conference Programs of the Society for Immunotherapy of Cancer (SITC 2018) : Washington, D.C., USA. 7-11 November 2018. 2018 , 6, 115	13
1136	Current landscape of immunotherapy in the treatment of solid tumours, with future opportunities and challenges. 2018 , 25, e373-e384	61
1135	Afatinib and Erlotinib in the treatment of squamous-cell lung cancer. 2018 , 19, 2055-2062	18
1134	Combination immuno-oncology therapy with pembrolizumab, an anti-PD-1 monoclonal antibody targeting immune evasion, and standard chemotherapy for patients with the squamous and non-squamous subtypes of non-small cell lung cancer. 2018 , 10, 5178-5183	1
1133	Hospitalization and Survival of Medicare Patients Treated With Carboplatin Plus Paclitaxel or Pemetrexed for Metastatic, Nonsquamous, Non-Small Cell Lung Cancer. 2018 , 1, e183023	3
1132	Linear Endobronchial Ultrasound: What's New?. 2018 , 39, 649-660	5
1131	Comprehensive immunoproteogenomic analyses of malignant pleural mesothelioma. 2018 , 3,	25
1130	New therapeutic targets for pulmonary sarcomatoid carcinomas based on their genomic and phylogenetic profiles. 2018 , 9, 10635-10649	32
1129	Actualité et perspectives concernant l'immunothérapie en oncologie thoracique. 2018 , 105 Suppl 1, S16-S23	
1128	Identification of ADAR1 adenosine deaminase dependency in a subset of cancer cells. 2018 , 9, 5450	83
1127	ASCO 2018 NSCLC highlights-combination therapy is key. 2018 , 11, 266-271	9
1126	A multifactorial model of T cell expansion and durable clinical benefit in response to a PD-L1 inhibitor. 2018 , 13, e0208422	10

1125	Radiation, Immune Checkpoint Blockade and the Abscopal Effect: A Critical Review on Timing, Dose and Fractionation. 2018 , 8, 612	89
1124	The Relative Risk and Incidence of Immune Checkpoint Inhibitors Related Pneumonitis in Patients With Advanced Cancer: A Meta-Analysis. 2018 , 9, 1430	54
1123	Recent advances in non-surgical management of cancer in the elderly. 2018 , 7,	
1122	The Role of Yes-Associated Protein (YAP) in Regulating Programmed Death-Ligand 1 (PD-L1) in Thoracic Cancer. 2018 , 6,	20
1121	Gene code : from molecular basis toward cancer immunotherapy. 2018 , 10, 1758835918815598	20
1120	Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis. 2018 , 6, 155	48
1119	Tumor mutational burden (TMB) as a biomarker of response to immunotherapy in small cell lung cancer. 2018 , 10, 4689-4693	36
1118	Immune-Related Adverse Events: Pneumonitis. 2018 , 995, 131-149	14
1117	Programmed cell death ligand-1 (PD-L1) as a biomarker for non-small cell lung cancer (NSCLC) treatment-are we barking up the wrong tree?. 2018 , 7, S275-S279	22
1116	Impact de lâ€™amélioration de la filière diagnostique sur le pronostic. 2018 , 10, 222-227	
1115	Chimiothérapie de première ligne incluant le traitement de maintenance et les anti-angiogéniques dans les CBNPC avancés en lâ€™absence dâ€™addiction oncogénique. 2018 , 10, 369-379	
1114	Lâ€™immunothérapie de première ligne pour les CBNPC de stades avancés (sans addiction oncogénique). 2018 , 10, 380-384	
1113	Traitements de deuxième ligne et ultérieure des cancers broncho-pulmonaires non ^petites cellules sans addiction oncogénique. 2018 , 10, 385-390	
1112	Prise en charge des métastases cœbrales des cancers bronchiques non ^petites cellules. 2018 , 10, 391-397	
1111	Immune checkpoint inhibitors: recent progress and potential biomarkers. 2018 , 50, 1-11	814
1110	Real-world evaluation of carboplatin plus a weekly dose of nab-paclitaxel for patients with advanced non-small-cell lung cancer with interstitial lung disease. 2018 , 10, 7013-7019	7
1109	Association between PD-L1 expression and driver gene status in non-small-cell lung cancer: a meta-analysis. 2018 , 9, 7684-7699	38
1108	[An elderly case of squamous cell lung cancer treated continuously with pembrolizumab without any decline in the life function]. 2018 , 55, 679-685	

1107	Effect of Gender on the Outcome of Patients Receiving Immune Checkpoint Inhibitors for Advanced Cancer: A Systematic Review and Meta-Analysis of Phase III Randomized Clinical Trials. 2018 , 7,	38
1106	Immunotherapy. 2018 ,	3
1105	Comparison of PD-L1 Assays in Non-small Cell Lung Cancer: 22C3 pharmDx and SP263. 2018 , 38, 6891-6895	14
1104	Lack of correlation between the costs of anticancer drugs and clinical benefits in Japan. 2018 , 109, 3896-3901	6
1103	Successful Use of Pembrolizumab to Treat Refractory Thymic Carcinoma with High PD-L1 Expression. 2018 , 11, 688-692	5
1102	Risk score for non-small cell lung cancer patients starting checkpoint inhibitor treatment. 2018 , 10, 5537-5544	1
1101	Les essais cliniques princeps en immuno-oncologie dans les cancers broncho-pulmonaires. 2018 , 10, 469-480	
1100	Durable Clinical Responses and Long-Term Follow-Up of Stage III-IV Non-Small-Cell Lung Cancer (NSCLC) Patients Treated With IDO Peptide Vaccine in a Phase I Study-A Brief Research Report. 2018 , 9, 2145	25
1099	The usefulness of various cytologic specimen preparations for PD-L1 immunostaining in non-small cell lung carcinoma. 2018 , 7, 324-332	8
1098	The immune checkpoint, HVEM may contribute to immune escape in non-small cell lung cancer lacking PD-L1 expression. 2018 , 125, 115-120	16
1097	Comparative study of programmed cell death ligand-1 immunohistochemistry assays using 22C3 and 28-8 antibodies for non-small cell lung cancer: Analysis of 420 surgical specimens from Japanese patients. 2018 , 125, 230-237	5
1096	The Budget Impact of Including Necitumumab on the Formulary for First-Line Treatment of Metastatic Squamous Non-Small Cell Lung Cancer: U.S. Commercial Payer and Medicare Perspectives. 2018 , 24, 534-543	6
1095	Distribution of CD4 and CD8 exhausted tumor-infiltrating lymphocytes in molecular subtypes of Chinese breast cancer patients. 2018 , 11, 6139-6145	6
1094	Immunotherapy combined with epidermal growth factor receptor-tyrosine kinase inhibitors in non-small-cell lung cancer treatment. 2018 , 11, 6189-6196	35
1093	A review of guidelines for lung cancer. 2018 , 10, S1556-S1563	41
1092	Immune Checkpoint Immunotherapy for Non-Small Cell Lung Cancer: Benefits and Pulmonary Toxicities. 2018 , 154, 1416-1423	111
1091	Activation of viral defense signaling in cancer. 2018 , 10, 1758835918793105	9
1090	The role of radiology in the evaluation of the immunotherapy efficacy. 2018 , 10, S1438-S1446	17

1089	Avoiding chemotherapy for advanced nononcogene addicted NSCLC overexpressing PD-L1: Rule or option?. 2018 , 45, 176-180	3
1088	Characteristics, incidence, and risk factors of immune checkpoint inhibitor-related pneumonitis in patients with non-small cell lung cancer. 2018 , 125, 150-156	89
1087	Profile of atezolizumab in the treatment of metastatic non-small-cell lung cancer: patient selection and perspectives. 2018 , 12, 2857-2873	7
1086	Hedgehog Signaling in Lung Cancer: From Oncogenesis to Cancer Treatment Resistance. 2018 , 19,	52
1085	[IoNESCO trial: Immune neoajuvant therapy in early stage non-small cell lung cancer]. 2018 , 35, 983-988	5
1084	Immune-related adverse events and atypical radiological response with checkpoint inhibitor immunotherapy in an elderly patient with high PD-L1 expressing lung adenocarcinoma. 2018 , 9, 33043-33049	8
1083	Zielgerichtete Therapie und immunonkologische Ansätze beim Lungenkarzinom. 2018 , 39, 367-370	
1082	Immuntherapien beim fortgeschrittenen NSCLC. 2018 , 39, 371-384	
1081	MicroRNA-145 inhibits migration and induces apoptosis in human non-small cell lung cancer cells through regulation of the EGFR/PI3K/AKT signaling pathway. 2018 , 40, 2944-2954	15
1080	Predictive and on-treatment monitoring biomarkers in advanced melanoma: Moving toward personalized medicine. 2018 , 71, 8-18	36
1079	Pre-existing pulmonary fibrosis is a risk factor for anti-PD-1-related pneumonitis in patients with non-small cell lung cancer: A retrospective analysis. 2018 , 125, 212-217	63
1078	PD-L2 Expression as a Potential Predictive Biomarker for the Response to Anti-PD-1 Drugs in Patients with Non-small Cell Lung Cancer. 2018 , 38, 5897-5901	13
1077	Prominent Nucleoli and Non-glandular Feature Are Independent Predictors of PD-L1 Expression in Lung Adenocarcinoma. 2018 , 38, 6003-6008	
1076	Metastatic non-small cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. 2018 , 29, iv192-iv237	897
1075	Interpretation of Results from Under-accruing Studies. 2018 , 23, 755-756	
1074	PD-1/PD-L1 pathway blockade works as an effective and practical therapy for cancer immunotherapy. 2018 , 15, 116-123	31
1073	Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer. <i>New England Journal of Medicine</i> , 2018 , 379, 2040-2051	59.2 1582
1072	T Cell Calcium Signaling Regulation by the Co-Receptor CD5. 2018 , 19,	11

1071	Local ablative treatment for synchronous single organ oligometastatic lung cancer-A propensity score analysis of 180 patients. 2018 , 125, 164-173	10
1070	Using 22C3 Anti-PD-L1 Antibody Concentrate on Biopsy and Cytology Samples from Non-small Cell Lung Cancer Patients. 2018 ,	0
1069	Differential regulation of PD-L1 expression by immune and tumor cells in NSCLC and the response to treatment with atezolizumab (anti-PD-L1). 2018 , 115, E10119-E10126	128
1068	On the Road to Immunotherapy-Prospects for Treating Head and Neck Cancers With Checkpoint Inhibitor Antibodies. 2018 , 9, 2182	10
1067	Fibrotic lung toxicity induced by cytotoxic drugs, radiation and immunotherapy in patients treated for lung cancer. 2018 , 88, 917	5
1066	Diagnostic and Predictive Immunohistochemistry for Non-Small Cell Lung Carcinomas. 2018 , 25, 374-386	10
1065	A case of interstitial lung disease with alveolar hemorrhage induced by pembrolizumab. 2018 , 11, 5879-5883	7
1064	Stereotactic Radiosurgery and Immune Checkpoint Inhibitors in the Management of Brain Metastases. 2018 , 19,	27
1063	Low Baseline Serum Sodium Concentration Is Associated with Poor Clinical Outcomes in Metastatic Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. 2018 , 13, 795-800	14
1062	Potential Regulatory Roles of MicroRNAs and Long Noncoding RNAs in Anticancer Therapies. 2018 , 13, 233-243	28
1061	Combination immuno-oncology therapy with immune checkpoint blockers targeting PD-L1, PD-1 or CTLA4 and epigenetic drugs targeting MYC and immune evasion for precision medicine. 2018 , 10, 1294-1299	3
1060	[Predictive value of PD-L1 'diagnostics']. 2018 , 39, 498-519	35
1059	Recent advances in gold and silver nanoparticle based therapies for lung and breast cancers. 2018 , 553, 483-509	39
1058	Factors affecting bacterial culture positivity in specimens from bronchoscopy in patients with suspected lung cancer. 2018 , 56, 457-463	2
1057	Checkpoint Inhibition: Will Combination with Radiotherapy and Nanoparticle-Mediated Delivery Improve Efficacy?. 2018 , 5,	11
1056	Recent advances in immunotherapies: from infection and autoimmunity, to cancer, and back again. 2018 , 10, 79	23
1055	Correlation between image characteristics and pathologic findings in non small cell lung cancer patients after anatomic resection. 2018 , 13, e0206386	3
1054	Should chemotherapy plus immune checkpoint inhibition be the standard front-line therapy for patients with metastatic non-small cell lung cancer?. 2018 , 124, 4592-4596	6

1053	Toxicity of radiation and immunotherapy combinations. 2018 , 3, 506-511	22
1052	Generating antitumor immunity by targeted radiation therapy: Role of dose and fractionation. 2018 , 3, 486-493	34
1051	Next generation immune-checkpoints for cancer therapy. 2018 , 10, S1581-S1601	38
1050	Pneumonitis in Non-Small Cell Lung Cancer Patients Receiving Immune Checkpoint Immunotherapy: Incidence and Risk Factors. 2018 , 13, 1930-1939	160
1049	[IHC, FISH, CISH, NGS in non-small cell lung cancer: What changes in the biomarker era?]. 2018 , 74, 327-338	2
1048	Anti-PD-1/PD-L1 Antibody Therapy for Pretreated Advanced or Metastatic Nonsmall Cell Lung Carcinomas and the Correlation between PD-L1 Expression and Treatment Effectiveness: An Update Meta-Analysis of Randomized Clinical Trials. 2018 , 2018, 3820956	14
1047	Durvalumab in NSCLC: latest evidence and clinical potential. 2018 , 10, 1758835918804151	16
1046	FIR: Efficacy, Safety, and Biomarker Analysis of a Phase II Open-Label Study of Atezolizumab in PD-L1-Selected Patients With NSCLC. 2018 , 13, 1733-1742	79
1045	Immune Marker Profiling and Programmed Death Ligand 1 Expression Across NSCLC Mutations. 2018 , 13, 1884-1896	47
1044	Case 33-2018: A 57-Year-Old Man with Confusion, Fever, Malaise, and Weight Loss. <i>New England Journal of Medicine</i> , 2018 , 379, 1658-1669	59.2 1
1043	Radiological Features of Programmed Cell Death-Ligand 2-positive Lung Adenocarcinoma: A Single-institution Retrospective Study. 2018 , 32, 1541-1550	4
1042	Pembrolizumab as Palliative Immunotherapy in Malignant Pleural Mesothelioma. 2018 , 13, 1784-1791	57
1041	Hyperprogressive disease: recognizing a novel pattern to improve patient management. 2018 , 15, 748-762	206
1040	Aging, immune senescence, and immunotherapy: A comprehensive review. 2018 , 45, 187-200	40
1039	Personalized biomarker-based treatment strategy for patients with squamous cell carcinoma of the head and neck: EORTC position and approach. 2018 , 29, 2313-2327	37
1038	Tobacco smoking and cessation and PD-L1 inhibitors in non-small cell lung cancer (NSCLC): a review of the literature. 2018 , 3, e000406	45
1037	The Protein Expression of PDL1 Is Highly Correlated with Those of eIF2 and ATF4 in Lung Cancer. 2018 , 2018, 5068701	10
1036	Advancing therapies in metastatic castration-resistant prostate cancer. 2018 , 19, 1797-1804	13

1035	The Evolution of Carcinogenesis. 2018 , 165, 272-276	13
1034	Targeting VEGFR2 with Ramucirumab strongly impacts effector/ activated regulatory T cells and CD8 T cells in the tumor microenvironment. 2018 , 6, 106	85
1033	[Tumour assessment criteria for immune checkpoint inhibitors]. 2018 , 35, 828-845	2
1032	[Sarcoid-like granulomatosis in cancer patients treated with immune checkpoints inhibitors]. 2018 , 35, 963-967	12
1031	A phase I trial of pembrolizumab with hypofractionated radiotherapy in patients with metastatic solid tumours. 2018 , 119, 1200-1207	59
1030	Association of antithyroglobulin antibodies with the development of thyroid dysfunction induced by nivolumab. 2018 , 109, 3583-3590	68
1029	Treatment of metastatic non-small cell lung cancer with NY-ESO-1 specific TCR engineered-T cells in a phase I clinical trial: A case report. 2018 , 16, 6998-7007	12
1028	Prognostic and predictive role of CD8 and PD-L1 determination in lung tumor tissue of patients under anti-PD-1 therapy. 2018 , 119, 950-960	83
1027	Infliximab associated with faster symptom resolution compared with corticosteroids alone for the management of immune-related enterocolitis. 2018 , 6, 103	89
1026	Analysis of response rate with ANTI PD1/PD-L1 monoclonal antibodies in advanced solid tumors: a meta-analysis of randomized clinical trials. 2018 , 9, 8706-8715	52
1025	A machine learning texture model for classifying lung cancer subtypes using preliminary bronchoscopic findings. 2018 , 45, 5509-5514	4
1024	Immunotherapy for oncogenic-driven advanced non-small cell lung cancers: Is the time ripe for a change?. 2018 , 71, 47-58	28
1023	[Biomarkers predictive of PD1/PD-L1 immunotherapy in non-small cell lung cancer]. 2018 , 74, 339-350	4
1022	RET fusions observed in lung and colorectal cancers are sensitive to ponatinib. 2018 , 9, 29654-29664	15
1021	Chronic p27 Induction by Dexamethasone Causes Senescence Phenotype and Permanent Cell Cycle Blockade in Lung Adenocarcinoma Cells Over-expressing Glucocorticoid Receptor. 2018 , 8, 16006	3
1020	Pembrolizumab-induced agranulocytosis in a pulmonary pleomorphic carcinoma patient who developed interstitial lung disease and ocular myasthenia gravis. 2018 , 2018, omy094	12
1019	Stereotactic Body Radiation Therapy for Spinal Malignancies. 2018 , 17, 1533033818802304	16
1018	Cost-effectiveness of nivolumab in the treatment of head and neck cancer. 2018 , 87, 104-110	10

1017	Liver toxicity in the era of immune checkpoint inhibitors: A practical approach. 2018 , 132, 125-129	14
1016	Validation of the immunohistochemical expression of programmed death ligand 1 (PD-L1) on cytological smears in advanced non small cell lung cancer. 2018 , 126, 9-14	23
1015	Updates in the Clinical Development of Epacadostat and Other Indoleamine 2,3-Dioxygenase 1 Inhibitors (IDO1) for Human Cancers. 2018 , 8, 423	95
1014	[Data from the AACR 2018 meeting on the combination chimio-immunotherapy on advanced non-small cells lung cancer (NSCLC)]. 2018 , 105, 854-856	
1013	Cancer immunotherapy-associated hypophysitis. 2018 , 45, 181-186	31
1012	Programmed death-ligand 1 expression and CD8+ tumor-infiltrating lymphocytes in advanced non-small cell lung cancer treated with microwave ablation and chemotherapy. 2018 , 35, 591-598	1
1011	Local angiotensin II contributes to tumor resistance to checkpoint immunotherapy. 2018 , 6, 88	28
1010	Comparable immunoreactivity rates of PD-L1 in archival and recent specimens from non-small cell lung cancer. 2018 , 9, 1476-1482	5
1009	New strategies in immunotherapy for lung cancer: beyond PD-1/PD-L1. 2018 , 12, 1753466618794133	27
1008	Adjuvant and Neoadjuvant Therapy, Treatment for Advanced Disease, and Genetic Considerations for Adrenocortical Carcinoma: An Update from the SSO Endocrine and Head and Neck Disease Site Working Group. 2018 , 25, 3453-3459	9
1007	Updates in Lung Cancer Cytopathology. 2018 , 11, 515-522	3
1006	Low-dose cyclophosphamide depletes circulating naïve and activated regulatory T cells in malignant pleural mesothelioma patients synergistically treated with dendritic cell-based immunotherapy. 2018 , 7, e1474318	16
1005	Chromogenic Multiplex Immunohistochemistry Reveals Modulation of the Immune Microenvironment Associated with Survival in Elderly Patients with Lung Adenocarcinoma. 2018 , 10,	15
1004	Fatal enteric plexus neuropathy after one dose of ipilimumab plus nivolumab: a case report. 2018 , 6, 82	21
1003	Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy. 2018 , 4, 1543-1552	380
1002	Combining radiation therapy and cancer immune therapies: From preclinical findings to clinical applications. 2018 , 22, 567-580	17
1001	Altered editing level of microRNAs is a potential biomarker in lung adenocarcinoma. 2018 , 109, 3326-3335	27
1000	Immune Checkpoint Inhibitors: Toward New Paradigms in Renal Cell Carcinoma. 2018 , 78, 1443-1457	41

999	Haematological toxicities with immunotherapy in patients with cancer: a systematic review and meta-analysis. 2018 , 103, 7-16		32
998	New drugs in thoracic oncology: needs and knowledge - an online ERS Lung Cancer Assembly survey. 2018 , 4,		2
997	Monitoring immunotherapy outcomes with circulating tumor DNA. 2018 , 10, 1023-1025		9
996	Cost-effectiveness of pembrolizumab in combination with chemotherapy in the 1st line treatment of non-squamous NSCLC in the US. 2018 , 21, 1191-1205		44
995	Selecting immuno-oncology-based drug combinations - what should we be considering?. 2018 , 11, 971-985		3
994	Behandlung des nichtkleinzelligen Lungenkarzinoms. 2018 , 24, 831-842		0
993	Long-term remission in advanced stage hepatocellular carcinoma? A chance for cure?. 2018 , 11, 185-192		4
992	Long-Term Outcomes of a Phase 2 Trial of Chemotherapy With Consolidative Radiation Therapy for Oligometastatic Non-Small Cell Lung Cancer. 2018 , 102, 527-535		27
991	Roles of the RANKL-RANK axis in antitumour immunity - implications for therapy. 2018 , 15, 676-693		46
990	Atezolizumab Treatment of Nonsquamous NSCLC. <i>New England Journal of Medicine</i> , 2018 , 379, 1188	59.2	7
989	Different pattern of PD-L1, IDO, and FOXP3 Tregs expression with survival in thymoma and thymic carcinoma. 2018 , 125, 35-42		18
988	Clinical utility of reflex testing using focused next-generation sequencing for management of patients with advanced lung adenocarcinoma. 2018 , 71, 1108-1115		21
987	Quick efficacy seeking trial (QuEST1): a novel combination immunotherapy study designed for rapid clinical signal assessment metastatic castration-resistant prostate cancer. 2018 , 6, 91		40
986	Prognostic Impact of Immune-Related Gene Expression in Preoperative Peripheral Blood from Gastric Cancer Patients. 2018 , 25, 3755-3763		7
985	Non-Small Cell Lung Cancer in the Elderly: a Practical Approach to Screening, Diagnosis, and Treatment. 2018 , 7, 160-168		
984	Pembrolizumab plus Chemotherapy in Lung Cancer. <i>New England Journal of Medicine</i> , 2018 , 379, e18	59.2	38
983	Pembrolizumab for the first-line treatment of non-small cell lung cancer. 2018 , 18, 1015-1021		15
982	Pembrolizumab Plus Chemotherapy in Patients With Previously Untreated Metastatic Non-small Cell Lung Cancer Without EGFR or ALK Mutations is Superior to Chemotherapy Alone. 2018 , 25, 194-195		

981	Profiling targetable immune checkpoints in osteosarcoma. 2018 , 7, e1475873	19
980	Radiological Features of IDO1/PDL1 Lung Adenocarcinoma: A Retrospective Single-institution Study. 2018 , 38, 5295-5303	2
979	Design and conduct of early clinical studies of immunotherapy agent combinations: recommendations from the task force on Methodology for the Development of Innovative Cancer Therapies. 2018 , 29, 2175-2182	13
978	Programmed death-ligand 1 expression in uncommon epidermal growth factor receptor mutation-positive non-small-cell lung cancer. 2018 , 29, 2262-2263	3
977	Incidence, Risk Factors, and Effect on Survival of Immune-related Adverse Events in Patients With Non-Small-cell Lung Cancer. 2018 , 19, e893-e900	61
976	Organ-specific response to nivolumab in patients with non-small cell lung cancer (NSCLC). 2018 , 67, 1825-1832	49
975	PD-1 and PD-L1 Protein Expression Predict Survival in Completely Resected Lung Adenocarcinoma. 2018 , 19, e957-e963	17
974	Immune Checkpoint Inhibition for Pancreatic Ductal Adenocarcinoma: Current Limitations and Future Options. 2018 , 9, 1878	69
973	Treatment of mycophenolate-resistant immune-related organizing pneumonia with infliximab. 2018 , 6, 85	14
972	Overall survival of stage IV non-small cell lung cancer patients treated with Viscum album L. in addition to chemotherapy, a real-world observational multicenter analysis. 2018 , 13, e0203058	24
971	sLAG-3 in non-small-cell lung cancer patients' serum. 2018 , 11, 4781-4784	12
970	A B7-CD28 family based signature demonstrates significantly different prognoses and tumor immune landscapes in lung adenocarcinoma. 2018 , 143, 2592-2601	14
969	Comparative analysis of immune checkpoint inhibitors and chemotherapy in the treatment of advanced non-small cell lung cancer: A meta-analysis of randomized controlled trials. 2018 , 97, e11936	56
968	Post-progression survival after cessation of treatment with nivolumab for advanced non-small cell lung cancer: A retrospective study. 2018 , 13, e0203070	6
967	Durvalumab: an investigational anti-PD-L1 monoclonal antibody for the treatment of urothelial carcinoma. 2018 , 12, 209-215	20
966	Strategies for Predicting Response to Checkpoint Inhibitors. 2018 , 13, 383-395	17
965	Immune checkpoint inhibitors and cardiovascular toxicity. 2018 , 19, e447-e458	221
964	EGFR TKIs and Immune Checkpoint Inhibitors: Is This an Optimal Combination?. 2018 , 13, 1245-1247	1

963	PD-L1 Testing in Lung Cancer: An International Pathologist's Initiative in an Unknown "Middle Earth". 2018 , 13, 1239-1241	
962	Diverse EGFR Exon 20 Insertions and Co-Occurring Molecular Alterations Identified by Comprehensive Genomic Profiling of NSCLC. 2018 , 13, 1560-1568	75
961	Cost-effectiveness of pembrolizumab as first-line therapy for advanced non-small cell lung cancer. 2018 , 124, 248-254	40
960	PD-L1 expression, tumor mutational burden, and response to immunotherapy in patients with MET exon 14 altered lung cancers. 2018 , 29, 2085-2091	127
959	Comutations in DNA Damage Response Pathways Serve as Potential Biomarkers for Immune Checkpoint Blockade. 2018 , 78, 6486-6496	104
958	Effectiveness and safety of PD-1/PD-L1 or CTLA4 inhibitors combined with chemotherapy as a first-line treatment for lung cancer: A meta-analysis. 2018 , 10, 6636-6652	25
957	A Case of Nivolumab-induced Severe Neutropenia with Stomatitis, Enteritis and Liver Dysfunction. 2018 , 58, 996-1000	1
956	Systemic Therapy of Lung Cancer CNS Metastases Using Molecularly Targeted Agents and Immune Checkpoint Inhibitors. 2018 , 32, 527-542	9
955	Role of Imaging in Early-Phase Trials. 2018 , 129-149	1
954	Clinical Trial Design in Immuno-Oncology. 2018 , 151-173	
953	Hepatocellular Carcinoma: Review of Targeted and Immune Therapies. 2018 , 49, 227-236	21
952	Is there a role for immunotherapy in malignant pleural mesothelioma?. 2018 , 35, 98	4
951	PD-L1 Expression Heterogeneity in Non-Small Cell Lung Cancer: Defining Criteria for Harmonization between Biopsy Specimens and Whole Sections. 2018 , 13, 1113-1120	91
950	, and Mutations Predict Tumor Immune Profile and the Response to Anti-PD-1 in Lung Adenocarcinoma. 2018 , 24, 5710-5723	150
949	Programmed Cell Death Ligand 1 Expression in Non-Small-cell Lung Cancer Patients With Interstitial Lung Disease: A Matched Case-control Study. 2018 , 19, e667-e673	9
948	Advancements in Nanomedicine for Multiple Myeloma. 2018 , 24, 560-574	14
947	Pembrolizumab-induced acute thrombosis: A case report. 2018 , 97, e10772	29
946	Mutations and PD-1 Inhibitor Resistance in -Mutant Lung Adenocarcinoma. 2018 , 8, 822-835	648

945	Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer. 2018 , 78, 4270-4281	72
944	Budding and tumor-infiltrating lymphocytes - combination of both parameters predicts survival in colorectal cancer and leads to new prognostic subgroups. 2018 , 79, 160-167	19
943	Defining and Understanding Adaptive Resistance in Cancer Immunotherapy. 2018 , 39, 624-631	101
942	Efficacy and safety of nivolumab in non-small cell lung cancer with preexisting interstitial lung disease. 2018 , 9, 847-855	64
941	Mapping the HLA Ligandome of Colorectal Cancer Reveals an Imprint of Malignant Cell Transformation. 2018 , 78, 4627-4641	27
940	Clinically Relevant Cytotoxic Immune Cell Signatures and Clonal Expansion of T-Cell Receptors in High-Risk -Not-Amplified Human Neuroblastoma. 2018 , 24, 5673-5684	45
939	[A retrospective analysis of chemotherapy for gastric cancer in later-stage elderly patients]. 2018 , 55, 244-250	1
938	Immune Checkpoint Inhibitor Toxicity Review for the Palliative Care Clinician. 2018 , 56, 460-472	13
937	Keeping Tumors in Check: A Mechanistic Review of Clinical Response and Resistance to Immune Checkpoint Blockade in Cancer. 2018 , 430, 2014-2029	30
936	Radiologic Pseudoprogression during Anti-PD-1 Therapy for Advanced Non-Small Cell Lung Cancer. 2018 , 13, 978-986	60
935	Emerging biomarkers for immune checkpoint inhibition in lung cancer. 2018 , 52, 269-277	54
934	Immunotherapy in non-metastatic non-small cell lung cancer: Can the benefits of stage IV therapy be translated into earlier stages?. 2018 , 10, 1758835918772810	11
933	Factor XIIIa-expressing inflammatory monocytes promote lung squamous cancer through fibrin cross-linking. 2018 , 9, 1988	39
932	Immuno-Oncology Biomarkers for Gastric and Gastroesophageal Junction Adenocarcinoma: Why PD-L1 Testing May Not Be Enough. 2018 , 23, 1171-1177	19
931	Survivin knockdown induces senescence in TTF-1-expressing, KRAS-mutant lung adenocarcinomas. 2018 , 53, 33-46	8
930	Widespread Nivolumab-induced Enteropathy in a Long Responder Non-Small-cell Lung Cancer Patient. 2018 , 19, e591-e596	2
929	Perspectives on Acquired Resistance to PD-1 Axis Inhibitors in Patients with Non-Small Cell Lung Cancer. 2018 , 13, 741-744	4
928	A New Standard of Care for Advanced Lung Cancer. <i>New England Journal of Medicine</i> , 2018 , 378, 2135-2137	15

927	Non-small cell lung cancer brain metastases and the immune system: From brain metastases development to treatment. 2018 , 68, 69-79	36
926	Oral Metronomic Vinorelbine in Advanced Non-small Cell Lung Cancer Patients Unfit for Chemotherapy. 2018 , 38, 3689-3697	23
925	Survival analysis and pathological features of advanced non-small cell lung cancer with miliary pulmonary metastases in patients harboring epidermal growth factor receptor mutations. 2018 , 144, 1601-1611	6
924	Management of co-existent tuberculosis and lung cancer. 2018 , 122, 83-87	35
923	Reptin drives tumour progression and resistance to chemotherapy in nonsmall cell lung cancer. 2018 , 52,	3
922	Epithelial-mesenchymal transition-converted tumor cells can induce T-cell apoptosis through upregulation of programmed death ligand 1 expression in esophageal squamous cell carcinoma. 2018 , 7, 3321	20
921	Pembrolizumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib (KEYNOTE-224): a non-randomised, open-label phase 2 trial. 2018 , 19, 940-952	1120
920	Effect of mutant variants of the KRAS gene on PD-L1 expression and on the immune microenvironment and association with clinical outcome in lung adenocarcinoma patients. 2018 , 121, 70-75	29
919	Aktuelle Systemtherapie des metastasierten Harnblasenkarzinoms. 2018 , 24, 55-63	
918	Management immunvermittelter Nebenwirkungen. 2018 , 34, 38-48	
917	Correlation of Neutrophil to Lymphocyte Ratio and Absolute Neutrophil Count With Outcomes With PD-1 Axis Inhibitors in Patients With Advanced Non-Small-Cell Lung Cancer. 2018 , 19, 426-434.e1	64
916	The Immune Landscape of Non-Small-Cell Lung Cancer. Utility of Cytologic and Histologic Samples Obtained through Minimally Invasive Pulmonary Procedures. 2018 , 198, 24-38	11
915	Nanomaterial-Based Organelles Protect Normal Cells against Chemotherapy-Induced Cytotoxicity. 2018 , 30, e1801304	29
914	Cancer immunotherapy efficacy and patients' sex: a systematic review and meta-analysis. 2018 , 19, 737-746	353
913	Successful treatment by pembrolizumab in a patient with end-stage renal disease with advanced non-small cell lung cancer and high PD-L1 expression. 2018 , 56, 361-364	12
912	Genetic, transcriptional and post-translational regulation of the programmed death protein ligand 1 in cancer: biology and clinical correlations. 2018 , 37, 4639-4661	133
911	Development of targeted therapy and immunotherapy for treatment of small cell lung cancer. 2018 , 48, 603-608	16
910	Vogt-Koyanagi-Harada Syndrome Induced by Pembrolizumab in a Patient with Non-Small Cell Lung Cancer. 2018 , 13, 1606-1607	13

909	Heterogeneity of PD-L1 Expression and Relationship with Biology of NSCLC. 2018 , 38, 3789-3796	39
908	Clinical, histological and molecular predictors of metastatic melanoma responses to anti-PD-1 immunotherapy. 2018 , 119, 193-199	7
907	Risk of Immune-Related Pancreatitis in Patients with Solid Tumors Treated with Immune Checkpoint Inhibitors: Systematic Assessment with Meta-Analysis. 2018 , 2018, 1027323	26
906	Association of Immune-Related Adverse Events with Clinical Benefit in Patients with Advanced Non-Small-Cell Lung Cancer Treated with Nivolumab. 2018 , 23, 1358-1365	139
905	Immune-checkpoint inhibitors in non-small cell lung cancer: A tool to improve patients' selection. 2018 , 129, 27-39	28
904	Evaluating the PD-1 Axis and Immune Effector Cell Infiltration in Oropharyngeal Squamous Cell Carcinoma. 2018 , 102, 137-145	15
903	Advanced Non-Small-Cell Lung Cancer in Elderly Patients: Patient Features and Therapeutic Management. 2018 , 2018, 8202971	13
902	Repeated in-field radiosurgery for locally recurrent brain metastases: Feasibility, results and survival in a heavily treated patient cohort. 2018 , 13, e0198692	31
901	Clinicopathological analysis and prognostic significance of programmed cell death-ligand 1 protein and mRNA expression in non-small cell lung cancer. 2018 , 13, e0198634	18
900	Significance of PD-L1 expression in pulmonary metastases from head and neck squamous cell carcinoma. 2018 , 27, 259-265	11
899	Optimization and validation of PD-L1 immunohistochemistry staining protocols using the antibody clone 28-8 on different staining platforms. 2018 , 31, 1630-1644	22
898	Indirect comparison of efficacy and safety between immune checkpoint inhibitors and antiangiogenic therapy in advanced non-small-cell lung cancer. 2018 , 8, 9686	0
897	Programmed death-ligand 1 immunoexpression in matched biopsy and liquid-based cytology samples of advanced stage non-small cell lung carcinomas. 2018 , 29, 550-557	30
896	Nonsmall Cell Lung Carcinoma with Giant Cell Features Expressing Programmed Death-Ligand 1: A Report of a Patient Successfully Treated with Pembrolizumab. 2018 , 2018, 5863015	4
895	Immunotherapy for pancreatic cancer: Barriers and breakthroughs. 2018 , 2, 274-281	87
894	Expression of CD3, PD-L1 and CTLA-4 in mammary and extra-mammary Paget disease. 2018 , 67, 1297-1303	15
893	30 Immunotherapy in advanced NSCLC-from the 'tsunami' of therapeutic knowledge to a clinical practice algorithm: results from an international expert panel meeting of the Italian Association of Thoracic Oncology (AIOT). 2018 , 3, e000298	7
892	Proliferative CD8(+) PD-1(+) T-cell infiltration in a pembrolizumab-induced cutaneous adverse reaction. 2018 , 36, 1138-1142	9

891	Pediatric Cancer Immunotherapy: Opportunities and Challenges. 2018 , 20, 395-408	53
890	The changing scenario of 1 line therapy in non-oncogene addicted NSCLCs in the era of immunotherapy. 2018 , 130, 1-12	16
889	Association Between Imaging Findings of Airway Obstruction Adjacent to Lung Tumors and the Onset of Interstitial Lung Disease After Nivolumab. 2018 , 32, 887-891	6
888	Management of KRAS-Mutant Non-Small Cell Lung Cancer in the Era of Precision Medicine. 2018 , 19, 43	8
887	[Immune checkpoints inhibitors: Recent data from ASCO's meeting 2017 and perspectives]. 2018 , 105, 686-695	4
886	Real-World Pseudoprogression: an Uncommon Phenomenon. 2018 , 13, 880-882	9
885	[Immunotherapy in lung cancer: New concepts]. 2018 , 35, 642-651	1
884	MicroRNA-206 suppresses TGF- β signalling to limit tumor growth and metastasis in lung adenocarcinoma. 2018 , 50, 25-36	18
883	Clinicopathological correlation of PD-L1 expression in primary and metastatic breast cancer and infiltrating immune cells. 2018 , 80, 170-178	30
882	Lipid Accumulation in Peripheral Blood Dendritic Cells and Anticancer Immunity in Patients with Lung Cancer. 2018 , 2018, 5708239	9
881	Therapeutic perspectives for brain metastases in non-oncogene addicted non-small cell lung cancer (NSCLC): Towards a less dismal future?. 2018 , 128, 19-29	7
880	Immune Characteristics of Chinese Diffuse Large B-Cell Lymphoma Patients: Implications for Cancer Immunotherapies. 2018 , 33, 94-104	6
879	HIV-Positive Patients with Lung Cancer: Is Immunotherapy a Safe and Active Option for Them?. 2018 , 13, 874-876	4
878	Standardizing biomarker testing for Canadian patients with advanced lung cancer. 2018 , 25, 73-82	16
877	Peripheral monocytes and neutrophils predict response to immune checkpoint inhibitors in patients with metastatic non-small cell lung cancer. 2018 , 67, 1365-1370	12
876	Expression of PD-L1/PD-1 in lymphoepithelioma-like carcinoma of the thymus. 2018 , 31, 1801-1806	6
875	Assessing Therapeutic Efficacy of MEK Inhibition in a KRAS-Driven Mouse Model of Lung Cancer. 2018 , 24, 4854-4864	26
874	A miRNA Panel Predicts Sensitivity of FGFR Inhibitor in Lung Cancer Cell Lines. 2018 , 19, 450-456	3

873	Massive Hemoptysis after the First Administration of Pembrolizumab in a Strongly Positive, Centrally Located NSCLC. 2018 , 13, e76-e77	3
872	New developments in brain metastases. 2018 , 11, 1756286418785502	21
871	A Comparison of Response Patterns for Progression-Free Survival and Overall Survival Following Treatment for Cancer With PD-1 Inhibitors: A Meta-analysis of Correlation and Differences in Effect Sizes. 2018 , 1, e180416	30
870	Immune Checkpoint Inhibitors in Early-Stage and Locally Advanced Non-Small Cell Lung Cancer. 2018 , 19, 39	9
869	Personalising Treatment for High-Grade Serous Ovarian Carcinoma. 2018 , 30, 515-524	10
868	Checkpoint inhibitors as treatment for malignant gliomas: "A long way to the top". 2018 , 69, 121-131	27
867	Biomarkers for checkpoint inhibition in hematologic malignancies. 2018 , 52, 198-206	9
866	Immune Checkpoint Inhibitors (ICIs) in Non-Small Cell Lung Cancer (NSCLC). 2018 , 40, 173-189	22
865	Combining vaccines and immune checkpoint inhibitors to prime, expand, and facilitate effective tumor immunotherapy. 2018 , 17, 697-705	23
864	Current landscape of immunotherapy for the treatment of metastatic non-small-cell lung cancer. 2018 , 25, S94-S102	28
863	Rapidly changing treatment algorithms for metastatic nonsquamous non-small-cell lung cancer. 2018 , 25, S68-S76	6
862	Effects of zoledronic acid and ibandronate in the treatment of cancer pain in rats with lung cancer combined with bone metastases. 2018 , 16, 1696-1700	3
861	Tumor Immunology and Immune Checkpoint Inhibitors in Non-Small Cell Lung Cancer. 2018 , 81, 29-41	12
860	Introduction to expert opinion on endocrine complications of new anticancer therapies. 2018 , 79, 535-538	3
859	Role of Immunotherapy for Oncogene-Driven Non-Small Cell Lung Cancer. 2018 , 10,	24
858	Immunotherapy for esophageal squamous cell carcinoma: a review. 2018 , 64, 46-53	22
857	Concordance levels of PD-L1 expression by immunohistochemistry, mRNA in situ hybridization, and outcome in lung carcinomas. 2018 , 82, 282-288	3
856	Disease Response with the Addition of Platinum-Based Chemotherapy to Pembrolizumab after Progression on Pembrolizumab Monotherapy in PD-L1-Expressing Non-Small Cell Lung Cancer. 2018 , 13, e135-e136	2

855	Impact of PD-L1 Expression in EGFR-Positive NSCLC? The Answer Remains the Same— 2018 , 13, 1060-1061	3
854	KRAS-Mutant non-small cell lung cancer: From biology to therapy. 2018 , 124, 53-64	133
853	A case of pulmonary adenocarcinoma showing rapid progression of peritoneal dissemination after immune checkpoint inhibitor therapy. 2018 , 18, 620	6
852	Risk of hematologic toxicities with programmed cell death-1 inhibitors in cancer patients: a meta-analysis of current studies. 2018 , 12, 1645-1657	13
851	Impact of COX2 Inhibitor for Regulation of PD-L1 Expression in Non-small Cell Lung Cancer. 2018 , 38, 4637-4644	19
850	Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells. 2018 , 10,	155
849	Immunotherapy for Gastric Cancer: Time for a Personalized Approach?. 2018 , 19,	32
848	Programmed cell death protein-1 inhibitor-induced granuloma annulare and hypertrophic lichen planus masquerading as squamous cell carcinoma. 2018 , 4, 636-639	13
847	An update on the Society for Immunotherapy of Cancer consensus statement on tumor immunotherapy for the treatment of cutaneous melanoma: version 2.0. 2018 , 6, 44	39
846	Biomarkers of response to immune checkpoint blockade in cancer treatment. 2018 , 130, 108-120	46
845	2-Deoxy-2-[fluorine-18] fluoro-d-glucose uptake on positron emission tomography is associated with programmed death ligand-1 expression in patients with pulmonary adenocarcinoma. 2018 , 101, 181-190	51
844	Tyrosine Kinase Inhibition in a Lung Adenocarcinoma Patient With Dual G719S and S768I EGFR Mutations. 2018 , 13, e136-e137	0
843	Raising the bar in education: the Thoracic Academy experience. 2018 , 14, 1-2	
842	Immunotherapy treatment: an issue for metabolic response. 2018 , 62, 140-151	4
841	Characterization of dermatitis after PD-1/PD-L1 inhibitor therapy and association with multiple oncologic outcomes: A retrospective case-control study. 2018 , 79, 1047-1052	69
840	Blood-based tumor mutational burden as a predictor of clinical benefit in non-small-cell lung cancer patients treated with atezolizumab. 2018 , 24, 1441-1448	581
839	Necitumumab in the treatment of non-small-cell lung cancer: clinical controversies. 2018 , 18, 937-945	10
838	Pemetrexed Continuation Maintenance versus Conventional Platinum-Based Doublet Chemotherapy in EGFR-Negative Lung Adenocarcinoma: Retrospective Analysis. 2018 , 81, 148-155	2

837	The Mediastinal Mass. 2018 ,	
836	Tumor PD-L1 Expression and Clinical Outcomes in Advanced-stage Non-Small Cell Lung Cancer Patients Treated with Nivolumab or Pembrolizumab: Real-World Data in Taiwan. 2018 , 9, 1813-1820	34
835	Redox-Responsive Dual Chemophotothermal Therapeutic Nanomedicine for Imaging-Guided Combinational Therapy. 2018 , 6, 5362-5367	16
834	A Network Meta-analysis Comparing the Efficacy and Safety of Anti-PD-1 with Anti-PD-L1 in Non-small Cell Lung Cancer. 2018 , 9, 1200-1206	22
833	Consistency of tumor and immune cell programmed cell death ligand-1 expression within and between tumor blocks using the VENTANA SP263 assay. 2018 , 13, 47	24
832	Distribution of KRAS, DDR2, and TP53 gene mutations in lung cancer: An analysis of Iranian patients. 2018 , 13, e0200633	20
831	Durvalumab: a potential maintenance therapy in surgery-ineligible non-small-cell lung cancer. 2018 , 10, 931-940	8
830	Impact of smoking on efficacy of PD-1/PD-L1 inhibitors in non-small cell lung cancer patients: a meta-analysis. 2018 , 11, 3691-3696	28
829	A phase II study of carboplatin, pemetrexed, and bevacizumab followed by erlotinib and bevacizumab maintenance for non-squamous non-small cell lung cancer with wild-type EGFR (HOT1101). 2018 , 23, 1060-1069	
828	The evolving immunotherapeutic landscape in advanced oesophagogastric cancer. 2018 , 10, 1758835918786228	
827	New PDL1 inhibitors for non-small cell lung cancer: focus on pembrolizumab. 2018 , 11, 4051-4064	10
826	Adaptive expansion of biomarker populations in phase 3 clinical trials. 2018 , 71, 181-185	6
825	Comparative efficacy and safety of licensed treatments for previously treated non-small cell lung cancer: A systematic review and network meta-analysis. 2018 , 13, e0199575	7
824	Efficacy of pemetrexed-based regimens in advanced non-small cell lung cancer patients with activating epidermal growth factor receptor mutations after tyrosine kinase inhibitor failure: a systematic review. 2018 , 11, 2121-2129	8
823	[Rebiopsy for Patients with Lung Cancer - Joint Opinion from both the Endoscopic and Thoracic Oncology Sections of the German Society of Pneumology (DGP)]. 2018 , 72, 617-623	1
822	Current views on molecularly targeted therapy for lung cancer - a review of literature from the last five years. 2018 , 15, 119-124	4
821	Activity and Immune Correlates of a Programmed Death-1 Blockade Antibody in the treatment of Refractory Solid Tumors. 2018 , 9, 205-212	5
820	Early Use of Systemic Corticosteroids in Patients with Advanced NSCLC Treated with Nivolumab. 2018 , 13, 1771-1775	96

819	Cost-effectiveness and budget impact of lung cancer immunotherapy in South America: strategies to improve access. 2018 , 10, 887-897	7
818	Overview of ongoing clinical trials investigating combined radiotherapy and immunotherapy. 2018 , 10, 851-0	20
817	Tissue-Dependent Tumor Microenvironments and Their Impact on Immunotherapy Responses. 2018 , 9, 70	64
816	Fatal Necrotizing Encephalopathy after Treatment with Nivolumab for Squamous Non-Small Cell Lung Cancer: Case Report and Review of the Literature. 2018 , 9, 108	37
815	Modulation of Gut Microbiota: A Novel Paradigm of Enhancing the Efficacy of Programmed Death-1 and Programmed Death Ligand-1 Blockade Therapy. 2018 , 9, 374	35
814	Targeting LAG-3 and PD-1 to Enhance T Cell Activation by Antigen-Presenting Cells. 2018 , 9, 385	88
813	Biomarkers for Clinical Benefit of Immune Checkpoint Inhibitor Treatment-A Review From the Melanoma Perspective and Beyond. 2018 , 9, 1474	126
812	Immune Dysregulation in Cancer Patients Undergoing Immune Checkpoint Inhibitor Treatment and Potential Predictive Strategies for Future Clinical Practice. 2018 , 8, 80	28
811	Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, Efficacy, and Limitations. 2018 , 8, 86	529
810	Editorial: Controversies in the Local Management of Lung Cancer. 2018 , 8, 233	0
809	Immune Profiling of Cancer Patients Treated with Immunotherapy: Advances and Challenges. 2018 , 6,	6
808	Coronary Toxicities of Anti-PD-1 and Anti-PD-L1 Immunotherapies: a Case Report and Review of the Literature and International Registries. 2018 , 13, 509-515	21
807	Indoleamine 2,3-dioxygenase 1 and programmed cell death-ligand 1 co-expression correlates with aggressive features in lung adenocarcinoma. 2018 , 101, 20-29	23
806	New windows open for immunotherapy in lung cancer. 2018 , 558, 376-377	22
805	Isolation and molecular analysis of circulating tumor cells from lung cancer patients using a microfluidic chip type cell sorter. 2018 , 109, 2539-2548	24
804	The association of genomic lesions and PD-1/PD-L1 expression in resected triple-negative breast cancers. 2018 , 20, 71	36
803	Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination. 2018 , 6, 46	86
802	Oncogene addicted non-small-cell lung cancer: current standard and hot topics. 2018 , 14, 3-17	17

801	New options on the horizon for nononcogene addicted non-small-cell lung cancer. 2018 , 14, 19-28	1
800	Tackling Cancer Resistance by Immunotherapy: Updated Clinical Impact and Safety of PD-1/PD-L1 Inhibitors. 2018 , 10,	37
799	Precision Immuno-Oncology: Prospects of Individualized Immunotherapy for Pancreatic Cancer. 2018 , 10,	33
798	Clinical Importance of Epstein-Barr Virus-Associated Gastric Cancer. 2018 , 10,	44
797	Efficacy of mesna, doxorubicin, ifosfamide, and dacarbazine (MAID) in patients with advanced pulmonary pleomorphic carcinoma. 2018 , 122, 160-164	5
796	Biomarker discovery by integrated joint non-negative matrix factorization and pathway signature analyses. 2018 , 8, 9743	15
795	Immune checkpoint blockade therapy for cancer: An overview of FDA-approved immune checkpoint inhibitors. 2018 , 62, 29-39	496
794	How I treat primary mediastinal B-cell lymphoma. 2018 , 132, 782-790	40
793	Patient selection for anti-PD-1/PD-L1 therapy in advanced non-small-cell lung cancer: implications for clinical practice. 2018 , 14, 2415-2431	19
792	An observational study of concomitant immunotherapies and denosumab in patients with advanced melanoma or lung cancer. 2018 , 7, e1480301	32
791	Phenotype molding of stromal cells in the lung tumor microenvironment. 2018 , 24, 1277-1289	607
790	The Role of the Estrogen Pathway in the Tumor Microenvironment. 2018 , 19,	81
789	Current Molecular Targeted Therapies for Bone and Soft Tissue Sarcomas. 2018 , 19,	32
788	Immunotherapy in Non-Small Cell Lung Cancer: Shifting Prognostic Paradigms. 2018 , 7,	8
787	An Update on Predictive Biomarkers for Treatment Selection in Non-Small Cell Lung Cancer. 2018 , 7,	36
786	Diagnosing Lung Cancer: The Complexities of Obtaining a Tissue Diagnosis in the Era of Minimally Invasive and Personalised Medicine. 2018 , 7,	30
785	Advances in cancer immunotherapy for gastroenterological malignancy. 2018 , 2, 244-245	9
784	Immunohistochemical expression and prognostic value of PD-L1 in Extrapulmonary small cell carcinoma: a single institution experience. 2018 , 6, 42	8

783	Immunotherapy in non-small-cell lung cancer: potential predictors of response and new strategies to assess activity. 2018 , 10, 797-805	17
782	Treatment for Patients With Malignant Pheochromocytomas and Paragangliomas: A Perspective From the Hallmarks of Cancer. 2018 , 9, 277	32
781	Tumor Resistance against ALK Targeted Therapy-Where It Comes From and Where It Goes. 2018 , 10,	54
780	Current landscape and future of dual anti-CTLA4 and PD-1/PD-L1 blockade immunotherapy in cancer; lessons learned from clinical trials with melanoma and non-small cell lung cancer (NSCLC). 2018 , 6, 39	202
779	Perspectives in immunotherapy: meeting report from the Immunotherapy Bridge (29-30 November, 2017, Naples, Italy). 2018 , 6, 69	10
778	Immune profiles of desmoplastic small round cell tumor and synovial sarcoma suggest different immunotherapeutic susceptibility upfront compared to relapse specimens. 2018 , 65, e27313	7
777	MHC proteins confer differential sensitivity to CTLA-4 and PD-1 blockade in untreated metastatic melanoma. 2018 , 10,	227
776	Vitamin D Supplementation and Survival of Patients with Non-small Cell Lung Cancer: A Randomized, Double-Blind, Placebo-Controlled Trial. 2018 , 24, 4089-4097	41
775	Pan-cancer adaptive immune resistance as defined by the Tumor Inflammation Signature (TIS): results from The Cancer Genome Atlas (TCGA). 2018 , 6, 63	165
774	The Society for Immunotherapy of Cancer consensus statement on immunotherapy for the treatment of non-small cell lung cancer (NSCLC). 2018 , 6, 75	107
773	A Case of Nivolumab-Induced Bullous Pemphigoid: Review of Dermatologic Toxicity Associated with Programmed Cell Death Protein-1/Programmed Death Ligand-1 Inhibitors and Recommendations for Diagnosis and Management. 2018 , 23, 1119-1126	54
772	Immune checkpoint inhibitors plus chemotherapy versus chemotherapy or immunotherapy for first-line treatment of advanced non-small cell lung cancer: a generic protocol. 2018 ,	5
771	A clinical analysis of 114 cases of sarcomatoid carcinoma of the lung. 2018 , 18, 555-562	11
770	Systemic treatment of advanced non-small cell lung cancer: controversies and perspectives. 2018 , 11, 112-115	2
769	CORR Tumor Board: Micrometastatic Drug Screening Platform Shows Heterogeneous Response to MAP Chemotherapy in Osteosarcoma Cell Lines. 2018 , 476, 1396-1399	
768	New Immunotherapies in Oncology Treatment and Their Side Effect Profiles. 2018 , 31, 620-627	5
767	[Early phase trials at the "Institut de cancérologie de l'Ouest": Clinical outcome and validation of prognostic scores]. 2018 , 105, 896-906	
766	Future Developments in Neoadjuvant Therapy for Triple-Negative Breast Cancer. 2018 , 98, 773-785	5

765	Frontline immunotherapy for NSCLC: alone or not alone?. 2018 , 15, 593-594	6
764	Pembrolizumab for advanced prostate adenocarcinoma: findings of the KEYNOTE-028 study. 2018 , 29, 1807-1813	165
763	Immunotherapy in non-small-cell lung cancer: a bridge between research and clinical practice. 2018 , 14, 41-60	7
762	Safety of Combined Immunotherapy and Thoracic Radiation Therapy: Analysis of 3 Single-Institutional Phase I/II Trials. 2018 , 101, 1141-1148	44
761	Safety and tolerability of PD-1/PD-L1 inhibitors in the treatment of non-small cell lung cancer: a meta-analysis of randomized controlled trials. 2018 , 144, 1851-1859	39
760	Nanotheranostics and Their Potential in the Management of Metastatic Cancer. 2018 , 199-244	2
759	Molecular and clinical characterization of PTPN2 expression from RNA-seq data of 996 brain gliomas. 2018 , 15, 145	5
758	RNA-sequencing in non-small cell lung cancer shows gene downregulation of therapeutic targets in tumor tissue compared to non-malignant lung tissue. 2018 , 13, 131	5
757	Towards Molecular Profiling in Multiple Myeloma: A Literature Review and Early Indications of Its Efficacy for Informing Treatment Strategies. 2018 , 19,	12
756	Radiation Pneumonitis: Old Problem, New Tricks. 2018 , 10,	57
755	A Review of Recent Advances in the Treatment of Elderly and Poor Performance NSCLC. 2018 , 10,	20
754	Necitumumab: a new option for first-line treatment of squamous cell lung cancer. 2018 , 14, 765-772	3
753	Significant response to nivolumab for metastatic chromophobe renal cell carcinoma with sarcomatoid differentiation: a case report. 2018 , 18, 26	12
752	PD-L1 Expression in a Non-Small Cell Lung Cancer Specimen Obtained by EBUS-TBNA. 2018 , 54, 290-292	1
751	Toward innovative combinational immunotherapy: A systems biology perspective. 2018 , 68, 1-8	11
750	Versorgungsrealität der molekularen Diagnostik maligner Erkrankungen. 2018 , 21, 172-177	
749	Safety, anti-tumour activity, and pharmacokinetics of fixed-dose SHR-1210, an anti-PD-1 antibody in advanced solid tumours: a dose-escalation, phase 1 study. 2018 , 119, 538-545	73
748	Anti-PD-1 Therapy Leads to Near-Complete Remission in a Patient with Metastatic Basal Cell Carcinoma. 2018 , 41, 391-394	30

747	Medianes Gesamtüberleben von 14 auf 30 Monate verlängert. 2018 , 10, 58-58	
746	Activity of pembrolizumab in relapsed/refractory NK/T-cell lymphoma. 2018 , 11, 15	93
745	Biomarkers of immunotherapy in urothelial and renal cell carcinoma: PD-L1, tumor mutational burden, and beyond. 2018 , 6, 4	86
744	Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: a comprehensive review of registration trials and future considerations. 2018 , 6, 8	606
743	Erlotinib treatment after platinum-based therapy in elderly patients with non-small-cell lung cancer in routine clinical practice - results from the ElderTac study. 2018 , 18, 333	7
742	Durvalumab verbessert die Prognose nach definitiver Radiochemotherapie. 2018 , 21, 28-29	
741	Personalized medicine in non-small cell lung cancer: a review from a pharmacogenomics perspective. 2018 , 8, 530-538	27
740	Evaluation of a Dual ALK/ROS1 Fluorescent In Situ Hybridization Test in Non-Small-cell Lung Cancer. 2018 , 19, e647-e653	8
739	Programmed cell death-1 and programmed cell death ligand-1 antibodies-induced dysthyroidism. 2018 , 7, R196-R211	9
738	Personalized Dosing Versus Fixed Dosing of Immune Checkpoint Inhibitors: A Cost Analysis Study. 2018 , 25, e767-e768	7
737	The Safety and Efficacy of Treatment with Nab-paclitaxel and Carboplatin for Patients with Advanced Squamous Non-small Cell Lung Cancer Concurrent with Idiopathic Interstitial Pneumonias. 2018 , 57, 1827-1832	8
736	Conservative management of nivolumab-induced pericardial effusion: a case report and review of literature. 2018 , 7, 11	25
735	Targeted Treatments for Common Solid Tumors. 2018 , 187-257	
734	Treating brain metastases in non-small cell lung cancer patients: what have we learnt from pharmaceutical recent clinical trials?. 2018 , 19, 851-864	4
733	Differential efficacy of cisplatin plus pemetrexed between L858R and Del-19 in advanced EGFR-mutant non-squamous non-small cell lung cancer. 2018 , 18, 6	5
732	Combination Immunotherapy in Non-small Cell Lung Cancer. 2018 , 20, 55	20
731	Abscopal effect of radiotherapy combined with immune checkpoint inhibitors. 2018 , 11, 104	164
730	Economic sustainability of immune-checkpoint inhibitors: the looming threat. 2018 , 15, 721-722	13

729	Anti-PD-1/PD-L1 antibodies versus docetaxel in patients with previously treated non-small-cell lung cancer. 2018 , 9, 7672-7683	10
728	Implementation of immunotherapy in the treatment of advanced non-small cell lung cancer (NSCLC). 2018 , 6, 144	17
727	Pemetrexed, Vitamin B12, and Thoracic Tumors: The Times, They Are A-Changin'. 2018 , 19, 461-463	1
726	A cost-effectiveness analysis of consolidative local therapy in oligometastatic non-squamous non-small cell lung cancer (NSCLC). 2018 , 129, 257-263	6
725	Treatment of advanced non-small cell lung cancer in the elderly. 2018 , 12, 783-792	4
724	Rare targetable drivers (RTDs) in non-small cell lung cancer (NSCLC): Outcomes with immune check-point inhibitors (ICPi). 2018 , 124, 117-124	19
723	Current and future developments of immunotherapy in lung cancer. 2018 , 11, 122-131	0
722	Immune-checkpoint inhibitors in previously treated patients with advanced or metastatic urothelial carcinoma: A systematic review and meta-analysis. 2018 , 129, 124-132	11
721	Multisite stereotactic body radiotherapy for metastatic non-small-cell lung cancer: Delaying the need to start or change systemic therapy?. 2018 , 124, 219-226	26
720	Phase II study assessing the benefit of cisplatin re-introduction (stop-and-go strategy) in patients with advanced non-squamous non-small cell lung cancer: the IFCT-1102 BUCiL study (a Better Use of Cisplatin in Lung cancer). 2018 , 3, e000394	1
719	Is smoking history the truly best biomarker for immune checkpoint inhibitor treatment in advanced non-small cell lung cancer?. 2018 , 3, e000421	8
718	Combining Immune Checkpoint Inhibitors With Conventional Cancer Therapy. 2018 , 9, 1739	112
717	Algorithm for the treatment of advanced or metastatic squamous non-small-cell lung cancer: an evidence-based overview. 2018 , 25, S77-S85	7
716	Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis. 2018 , 144, 2245-2261	16
715	Prognostic models for patients with brain metastases after stereotactic radiosurgery with or without whole brain radiotherapy: a validation study. 2018 , 140, 341-349	8
714	CMTM6 overexpression is associated with molecular and clinical characteristics of malignancy and predicts poor prognosis in gliomas. 2018 , 35, 233-243	60
713	Change in the lymphocyte-to-monocyte ratio is an early surrogate marker of the efficacy of nivolumab monotherapy in advanced non-small-cell lung cancer. 2018 , 124, 179-188	35
712	Design considerations for early-phase clinical trials of immune-oncology agents. 2018 , 6, 81	33

711	Expression Analysis of Autophagy Related Markers LC3B, p62 and HMGB1 Indicate an Autophagy-Independent Negative Prognostic Impact of High p62 Expression in Pulmonary Squamous Cell Carcinomas. 2018 , 10,	9
710	Pembrolizumab-Induced Rhabdomyolysis With Myositis in a Patient With Lung Adenocarcinoma. 2018 , 54, 346-348	1
709	Differences in PD-L1 expression on tumor and immune cells between lung metastases and corresponding primary tumors. 2018 , 27, 637-641	8
708	Biomarkers for predicting efficacy of PD-1/PD-L1 inhibitors. 2018 , 17, 129	280
707	Effectiveness and safety of immune checkpoint inhibitors: A retrospective study in Taiwan. 2018 , 13, e0202725	11
706	Pembrolizumab and platinum-based chemotherapy as first-line therapy for advanced non-small-cell lung cancer: Phase 1 cohorts from the KEYNOTE-021 study. 2018 , 125, 273-281	40
705	Targeting the PD-1/PD-L1 axis for the treatment of non-small-cell lung cancer. 2018 , 25, e324-e334	38
704	Recent Advances and Challenges in Cancer Immunotherapy. 2022 , 14, 3972	3
703	Evaluation of the Molecular Landscape in PD-L1 Positive Metastatic NSCLC: Data from Campania, Italy. 2022 , 23, 8541	0
702	Bias and inconsistency in the estimation of tumour mutation burden. 2022 , 22,	0
701	Immunotherapy in non-small cell lung cancer: Past, present, and future directions. 12,	2
700	Overall Survival, Progression-Free Survival, and Tumor Response Benefit Supporting Initial US Food and Drug Administration Approval and Indication Extension of New Cancer Drugs, 2003-2021.	3
699	Immune checkpoint inhibitors: the mechanisms, limitations, and improvements. 8, 14-22	
698	High interobserver and intraobserver reproducibility among pathologists assessing PD-L1 CPS across multiple indications.	0
697	Evaluation of the prognostic impact of SP263-evaluated PD-L1 expression in patients with non-small cell lung cancer (NSCLC) stage III treated with radio-chemotherapy.	
696	A New Approach to Simplifying and Harmonizing Cancer Clinical TrialsâStandardizing Eligibility Criteria.	
695	Immunohistochemical expression of CD8, CTLA4, and PD-L1 in NSCLC of smokers versus non smokers and its effect on prognosis. 2022 , 58, 92-101	
694	Clinical Significance of Interstitial Lung Abnormalities and Immune Checkpoint Inhibitor- Induced Interstitial Lung Disease in Patients with Non-Small Cell Lung Cancer.	

- 693 Camrelizumab in patients with advanced non-squamous non-small cell lung cancer: a cost-effective analysis in China. **2022**, 12, e061592 ○
- 692 A risk model including eight tumor microenvironment-related genes for prediction of lung cancer prognosis.
- 691 Analysis of Cancer Survival Associated With Immune Checkpoint Inhibitors After Statistical Adjustment. **2022**, 5, e2227211 ○
- 690 Predicting systemic therapy toxicity in older adult patients with advanced non-small cell lung cancer: A prospective multicenter study of National Hospital Organization in Japan. **2022**, ○
- 689 Immunotherapy-chemotherapy combinations for non-small cell lung cancer: current trends and future perspectives. ○
- 688 Efficacy and safety of combined immunotherapy and antiangiogenesis with or without chemotherapy for advanced non-small-cell lung cancer: A systematic review and pooled analysis from 23 prospective studies. 13, ○
- 687 PD-L1 expression, tumor mutational burden, and immune cell infiltration in non-small cell lung cancer patients with epithelial growth factor receptor mutations. 12, 1
- 686 PD-1 inhibitors plus oxaliplatin or cisplatin-based chemotherapy in first-line treatments for advanced gastric cancer: A network meta-analysis. 13, 1
- 685 Various impacts of driver mutations on the PD-L1 expression of NSCLC. **2022**, 17, e0273207
- 684 Emerging PD-1/PD-L1 targeting immunotherapy in non-small cell lung cancer: Current status and future perspective in Japan, US, EU, and China. 12, ○
- 683 Clinical Features, Survival, and Burden of Toxicities in Survivors More Than One Year After Lung Cancer Immunotherapy. ○
- 682 Live Biotherapeutic *Lactococcus lactis* GEN3013 Enhances Antitumor Efficacy of Cancer Treatment via Modulation of Cancer Progression and Immune System. **2022**, 14, 4083 ○
- 681 From rough to precise: PD-L1 evaluation for predicting the efficacy of PD-1/PD-L1 blockades. 13, 1
- 680 Sex-specific differences in immunogenomic features of response to immune checkpoint blockade. 12, ○
- 679 Immune checkpoint inhibitors for PD-1/PD-L1 axis in combination with other immunotherapies and targeted therapies for non-small cell lung cancer. 12, 1
- 678 Salvage chemotherapy in patients with nonsmall cell lung cancer after prior immunotherapy: a retrospective, real-life experience study. **2022**, 33, 752-757
- 677 Insomnia in patients treated with checkpoint inhibitors for cancer: A meta-analysis. 12, 2
- 676 Non-invasive early prediction of immune checkpoint inhibitor efficacy in non-small-cell lung cancer patients using on-treatment serum CRP and NLR.

675	Advances in the Treatment of Postoperative Recurrence of Non-Small Cell Lung Cancer and Their Impact on Survival in Asian Patients. 2022 ,	0
674	Real-World Efficacy and Safety of Sintilimab-Based Regimens against Advanced Esophageal Cancer: A Single-Center Retrospective Observational Study. 2022 , 2022, 1-9	0
673	T-Cell Receptor Repertoire Sequencing and Its Applications: Focus on Infectious Diseases and Cancer. 2022 , 23, 8590	0
672	Successful immune checkpoint inhibitor rechallenge after immune-related pericarditis: Clinical case series. 9,	0
671	Efficacy and safety of pembrolizumab monotherapy in EGFR-mutant squamous cell lung cancer with PD-L1 over-expression: A case report. 2022 , 101, e30099	0
670	Molecular Biomarkers in Glioblastoma: A Systematic Review and Meta-Analysis. 2022 , 23, 8835	2
669	Choosing the optimal immunotherapeutic strategies for non-small cell lung cancer based on clinical factors. 12,	0
668	Special issue âThe advance of solid tumor research in ChinaâFGFR4 alterations predict efficacy of immune checkpoint inhibitors in non-small cell lung cancer.	
667	Next Steps for Immunotherapy in Glioblastoma. 2022 , 14, 4023	1
666	Characterizing the Shifting Real-World Treatment Landscape by PD-L1 Testing Status and Expression Level in Advanced Non-Small Cell Lung Cancer.	
665	Neoadjuvant immunotherapy of locoregionally advanced solid tumors. 2022 , 10, e005036	0
664	Novel anticancer strategy by targeting the gut microbial neurotransmitter signaling to overcome immunotherapy resistance.	
663	Immunotherapeutic targets in non-small cell lung cancer.	1
662	Correlation between the Immune Checkpoint Inhibitors Prognostic Index and Outcomes in Nonsmall Cell Lung Cancer: A Multicentre Analysis. 2022 , 2022, 1-15	
661	Microwave ablation plus camrelizumab monotherapy or combination therapy in non-small cell lung cancer. 12,	0
660	Temporally restricted activation of IFN γ signaling underlies response to immune checkpoint therapy in mice. 2022 , 13,	1
659	Identification and validation of miR-509-5p as a prognosticator for favorable survival in osteosarcoma. 2022 , 101, e29705	
658	EGFR Inhibition Strongly Modulates the Tumour Immune Microenvironment in EGFR-Driven Non-Small-Cell Lung Cancer. 2022 , 14, 3943	2

- 657 Placebo effect in the treatment of non-small cell lung cancer: a meta-analysis. Publish Ahead of Print,
- 656 Impact of radiotherapy schedule on survival of patients treated with immune-checkpoint inhibitors for advanced melanoma and non-small cell lung cancer. **2022**, ○
- 655 Expression, correlation, and prognostic significance of different nicotinic acetylcholine receptors, programmed death ligand 1, and dopamine receptor D2 in lung adenocarcinoma. 12,
- 654 Is ICI-based therapy better than chemotherapy for metastatic NSCLC patients who develop EGFR-TKI resistance? A real-world investigation. 12, ○
- 653 Serum cytokine levels for predicting immune-related adverse events and the clinical response in lung cancer treated with immunotherapy. 12, 1
- 652 Nivolumabâ€¦pilimumab combination therapy-induced seronegative encephalitis; rapid response to steroid plus intravenous immunoglobulin (IVIG) treatment. 107815522211185
- 651 Subphenotypes in acute kidney injury: a narrative review. **2022**, 26, ○
- 650 Artificial intelligence-based prediction of clinical outcome in immunotherapy and targeted therapy of lung cancer. **2022**, ○
- 649 Surgical resection after neoadjuvant durvalumab and radiation is feasible and safe in nonâ€¦small cell lung cancer: Results from a randomized trial. **2022**, ○
- 648 PD-L1 Over-Expression Varies in Different Subtypes of Lung Cancer: Will This Affect Future Therapies?. **2022**, 12, 653-671 1
- 647 First-Line Pembrolizumab Monotherapy for Advanced NSCLC With Programmed Death-Ligand 1 Expression Greater Than or Equal to 50%: Real-World Study Including Older Patients in Japan. **2022**, 3, 100397 1
- 646 Significant response to Pembrolizumab for metastatic cutaneous squamous cell carcinoma in patient with Netherton syndrome. **2022**, 81, 104323
- 645 The evolving role of liquid biopsy in lung cancer. **2022**, 172, 53-64 ○
- 644 PVR/TIGIT and PD-L1/PD-1 expression predicts survival and enlightens combined immunotherapy in lung squamous cell carcinoma. **2022**, 24, 101501
- 643 Impact of immune checkpoint inhibitors on the management of locally advanced or metastatic non-small cell lung cancer in real-life practice in patients initiating treatment between 2015 and 2018 in France and Germany. **2022**, 172, 65-74 ○
- 642 Associations between patient and disease characteristics and severe adverse events during immune checkpoint inhibitor treatment: An observational study. **2022**, 174, 113-120 ○
- 641 Targeting tumor microenvironment for cholangiocarcinoma: Opportunities for precision medicine. **2022**, 25, 101514 ○
- 640 Differential RNA expression of immune-related genes and tumor cell proximity from intratumoral M1 macrophages in acral lentiginous melanomas treated with PD-1 blockade. **2022**, 1868, 166516

- 639 Programmed cell death ligand 1 measurement study in granulocyte colony-stimulating factor-producing lung cancer: an observational study. **2022**, 22, ○
- 638 Correlation between PD-L1 expression and radiomic features in early-stage lung adenocarcinomas manifesting as ground-glass nodules. 12, ○
- 637 Plasma autoantibodies IgG and IgM to PD1/PDL1 as potential biomarkers and risk factors of lung cancer. ○
- 636 EGFR Mutations and PD-L1 Expression in Early-Stage Non-Small Cell Lung Cancer: A Real-World Data From a Single Center in Brazil. ○
- 635 Pembrolizumab versus placebo as adjuvant therapy for completely resected stage IB-IIIA non-small-cell lung cancer (PEARLS/KEYNOTE-091): an interim analysis of a randomised, triple-blind, phase 3 trial. **2022**, 23, 1274-1286 8
- 634 Cost-effectiveness analysis of pembrolizumab for patients with advanced esophageal cancer at PD-L1 combined positive score ≥10. **2022**, 11, 1095-1103 ○
- 633 The efficacy of immune checkpoint inhibitors in elderly patients: a meta-analysis and meta-regression. **2022**, 7, 100577 ○
- 632 Aqueous extract of *Taxus chinensis* var. *mairei* targeting CD47 enhanced antitumor effects in non-small cell lung cancer. **2022**, 154, 113628 ○
- 631 Prognostic scores including peripheral blood-derived inflammatory indices in patients with advanced non-small-cell lung cancer treated with immune checkpoint inhibitors. **2022**, 179, 103806 ○
- 630 Early change in the clearance of pembrolizumab reflects the survival and therapeutic response: A population pharmacokinetic analysis in real-world non-small cell lung cancer patients. **2022**, 173, 35-42 ○
- 629 Proposal for multiple new lesions as complement of hyperprogressive disease in NSCLC patients treated with PD-1/PD-L1 immunotherapy. **2022**, 173, 28-34 ○
- 628 Discrepancies Between the Cost of Advanced Lung Cancer Treatment and How Much Is Reimbursed by the Brazilian Public Healthcare System. **2023**, 33, 1-6 ○
- 627 Chemotherapy for Lung Cancer. **2022**, ○
- 626 Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment. **2022**, 40, 101753 ○
- 625 The Research Progress of Immune Checkpoint Inhibitor and Chemoradiotherapy for Limited Stage Small Cell Lung Cancer. **2022**, 12, 8145-8150 ○
- 624 Nuclear Medicine in the Assessment of Adverse Effects of Cancer Therapy in the Lung, Kidney, Gastrointestinal Tract, and Central Nervous System. **2022**, 1755-1774 ○
- 623 Diagnostic Applications of Nuclear Medicine: Lung and Mediastinal Tumors. **2022**, 743-809 ○
- 622 Checkpoint Inhibitors in Non-small Cell Lung Cancer: Potentials and Challenges. **2022**, ○

- 621 Immunotherapy in Early Stage Non-Small Cell Lung Cancer. **2022**, 11, 31-44 o
- 620 Long-term follow-up of a patient with synchronous brain metastasis in squamous cell lung cancer. (A clinical case and a literature review). **2022**, 11, 51 o
- 619 Translational Research in Lung Cancer. **2022**, o
- 618 Recognition of immune-related tumor antigens and immune subtypes for mRNA vaccine development in lung adenocarcinoma. **2022**, 20, 5001-5013 o
- 617 Optimal Treatments for NSCLC Patients Harboring Primary or Acquired MET Amplification. **2022**, 21, 153303382211284 o
- 616 Real-world observational study of current treatment patterns and outcomes in recurrent or locally advanced/metastatic non-small cell lung cancer. **2022**, 33, 100637 o
- 615 High-resolution profiling of lung adenocarcinoma identifies expression subtypes with specific biomarkers and clinically relevant vulnerabilities. o
- 614 High dose androgen suppresses natural killer cytotoxicity of castration-resistant prostate cancer cells via altering AR/circFKBP5/miRNA-513a-5p/PD-L1 signals. **2022**, 13, 1
- 613 Combination Intravenous Immune Globulin (IVIG) and High Dose Steroids for Treatment of Immune-Related Myelitis in a Non-Small Cell Lung Cancer Patient Treated With Pembrolizumab and Palliative Radiation Treatment: A Case Report. **2022**, o
- 612 Cost-Effectiveness of Pembrolizumab for the treatment of Non-Small-Cell lung cancer: A systematic review. 12, o
- 611 New Biomarkers and Immunotherapy Decision. **2022**, 1-15 o
- 610 DEGRO practical guideline for central nervous system radiation necrosis part 2: treatment. o
- 609 Tobacco Use and Response to Immune Checkpoint Inhibitor Therapy in Non-Small Cell Lung Cancer. **2022**, 29, 6260-6276 o
- 608 Efficacy and safety of concomitant immunotherapy and denosumab in patients with advanced non-small cell lung cancer carrying bone metastases: A retrospective chart review. 13, 1
- 607 Multimodal integration of radiology, pathology and genomics for prediction of response to PD-(L)1 blockade in patients with non-small cell lung cancer. 2
- 606 Safety of First-line Nivolumab Plus Ipilimumab in Patients With Metastatic Non-Small Cell Lung Cancer: A Pooled Analysis of CheckMate 227, CheckMate 568, and CheckMate 817. **2022**, o
- 605 The necroptosis-related signature and tumor microenvironment immune characteristics associated with clinical prognosis and drug sensitivity analysis in stomach adenocarcinoma. o
- 604 Construction of a Humanized PBMC-PDX Model to Study the Efficacy of a Bacterial Marker in Lung Cancer Immunotherapy. **2022**, 2022, 1-12 o

603	Efficacy and Safety of Combined Brain Stereotactic Radiotherapy and Immune Checkpoint Inhibitors in Non-Small-Cell Lung Cancer with Brain Metastases. 2022 , 10, 2249	0
602	Non-small-cell lung cancer patients harboring TP53/KRAS co-mutation could benefit from a PD-L1 inhibitor. 2022 , 18, 3031-3041	0
601	Combating pancreatic cancer with ovarian cancer cells.	0
600	Editorial: Beyond chemotherapy and immunotherapy in thoracic malignancies: Overcoming resistance by tackling new molecular pathways. 12,	0
599	Metabolic tumor volume as significant predictor for chemotherapy containing PD-L1 blocker in extensive stage small cell lung cancer.	0
598	Sarcomatoid malignant pleural mesothelioma treated with nivolumab: A case series. 2022 , 24,	0
597	First-line Immune Checkpoint Inhibitor Versus Immune Checkpoint Inhibitor With Chemotherapy for Cisplatin-ineligible Metastatic Urothelial Carcinoma: Evidence From a Real-world, Multicenter Analysis. 2022 , 45, 407-414	0
596	Pathological Digital Biomarkers: Validation and Application. 2022 , 12, 9823	0
595	Association of Oncologist Participation in Medicare's Oncology Care Model With Patient Receipt of Novel Cancer Therapies. 2022 , 5, e2234161	0
594	Establishment of a Novel Signature to Predict Prognosis and Immune Characteristics of Pancreatic Cancer Based on Necroptosis-Related Long Non-Coding RNA.	0
593	MET-induced CD73 restrains STING-mediated immunogenicity of EGFR-mutant lung cancer.	1
592	Benefits from Adjuvant Chemotherapy in Patients with Resected Non-Small Cell Lung Cancer: Possibility of Stratification by Gene Amplification of ACTN4 According to Evaluation of Metastatic Ability. 2022 , 14, 4363	0
591	Characteristics of the immune microenvironment and their clinical significance in non-small cell lung cancer patients with ALK-rearranged mutation. 13,	0
590	Current Landscape of Therapeutic Resistance in Lung Cancer and Promising Strategies to Overcome Resistance. 2022 , 14, 4562	1
589	Measuring the indirect cost associated with advanced non-small cell lung cancer: a nationwide cross-sectional study in China.	0
588	Exosomes and cancer - Diagnostic and prognostic biomarkers and therapeutic vehicle. 2022 , 11,	4
587	Biomarkers of related driver genes predict anti-tumor efficacy of immune checkpoint inhibitors. 13,	0
586	Clinical relevance and therapeutic aspects of professional antigen-presenting cells in lung cancer. 2022 , 39,	1

585	Clinical predictive value of naïve and memory T cells in advanced NSCLC. 13,	o
584	Pembrolizumab monotherapy for untreated PD-L1-Positive non-small cell lung cancer in the elderly or those with poor performance status: A prospective observational study. 12,	o
583	Phase 1 trial of CV301 in combination with anti-PD -1 therapy in nonsquamous non-small cell lung cancer.	o
582	Combination Antiemetic Therapy for Chemotherapy-Induced Nausea and Vomiting in Patients with NSCLC Receiving Carboplatin-Based Chemotherapy. Volume 14, 2673-2680	o
581	Case Report: Durable response to immuno-chemotherapy in a case of ROS1 fusion-positive advanced lung adenocarcinoma: A case report. 13,	o
580	PTEN Expression Was Significantly Associated with PD-L1 Score but Not with EBV Infection in Gastric Cancer. Volume 15, 1011-1020	o
579	Radiation Recall Pneumonitis: A Rare Syndrome That Should Be Recognized. 2022 , 14, 4642	1
578	Immune-related interstitial lung disease adverse event following immune checkpoint inhibitors and immune checkpoint inhibitors plus anti-VEGF antibody/chemotherapy: A real-world study from 2014 to 2022 based on FAERS databases.	o
577	The Use of Palliative Radiotherapy in the Treatment of Lung Cancer. 2022 ,	o
576	Real-world data analysis of pembrolizumab monotherapy for non-small cell lung cancer utilizing Japanese post-marketing all-case surveillance data. 2022 , 100404	o
575	FGFR1 RNA-Based Gene Alteration and Expression Analysis in Squamous Non-Small Cell Lung Cancer. 2022 , 23, 10506	o
574	Comparative combinatorial implications and Theranostics of immunotherapy in the impediment of Alveolar Soft part Sarcoma. 2022 , 28,	o
573	Immune-related 3-lncRNA signature with prognostic connotation in a multi-cancer setting. 2022 , 20,	1
572	Signature based on RNA-binding protein-related genes for predicting prognosis and guiding therapy in non-small cell lung cancer. 13,	o
571	Real-World Outcomes and Treatments Patterns Prior and after the Introduction of First-Line Immunotherapy for the Treatment of Metastatic Non-Small Cell Lung Cancer. 2022 , 14, 4481	o
570	Beyond PD-L1 : Assessment of LAG -3 and other predictive biomarkers in non-small cell lung carcinoma.	o
569	A comprehensively prognostic and immunological analysis of actin-related protein 2/3 complex subunit 5 in pan-cancer and identification in hepatocellular carcinoma. 13,	o
568	The Interaction of the IFN/JAK/STAT1 and JAK/STAT3 Signalling Pathways in EGFR-Mutated Lung Adenocarcinoma Cells. 2022 , 2022, 1-16	o

567	Development of Inhibitors Targeting the V-Domain Ig Suppressor of T Cell Activation Signal Pathway. 2022 , 65, 11900-11912	0
566	EPHA5 mutation was associated with adverse outcome of atezolizumab treatment in late-stage non-small cell lung cancers. 2022 , 22,	0
565	Thyroid Dysfunction in Nonâ€Small Cell Lung Cancer With Immune Checkpoint Inhibitors: A Meta-Analysis.	0
564	The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers. 13,	5
563	Current perspectives of the Japanese Esophageal Oncology Group on the development of immunotherapy for esophageal cancer.	0
562	High levels of AXL expression in untreated EGFR -mutated NSCLC negatively impacts the use of osimertinib.	0
561	Molecular analysis and favorable clinical outcomes in real-world patients with metastatic renal cell carcinoma. 1-10	0
560	The predictive value of total-body PET/CT in non-small cell lung cancer for the PD-L1 high expression. 12,	0
559	Immunosuppressive tumor microenvironment modulation by chemotherapies and targeted therapies to enhance immunotherapy effectiveness. 2022 , 11,	4
558	Novel lymphocyte-independent antitumor activity by PD-1 blocking antibody against PD-1+ chemoresistant lung cancer cells..	0
557	TNFR2 antagonist and agonist: a potential therapeutics in cancer immunotherapy. 2022 , 39,	0
556	CT-based radiomics signature to predict CD8+ tumor infiltrating lymphocytes in non-small-cell lung cancer. 028418512211265	0
555	Results from the IMpower132 China cohort: Atezolizumab plus platinum-based chemotherapy in advanced non-small cell lung cancer.	0
554	Definition of a new blood cell count score for early survival prediction for non-small cell lung cancer patients treated with atezolizumab: Integrated analysis of four multicenter clinical trials. 13,	0
553	Treatment of Brain Metastases: The Synergy of Radiotherapy and Immune Checkpoint Inhibitors. 2022 , 10, 2211	1
552	Harnessing the immune system by targeting immune checkpoints: Providing new hope for Oncotherapy. 13,	0
551	DSTYK inhibition increases the sensitivity of lung cancer cells to T cellâ€mediated cytotoxicity. 2022 , 219,	1
550	Identification of Immuno-Targeted Combination Therapies Using Explanatory Subgroup Discovery for Cancer Patients with EGFR Wild-Type Gene. 2022 , 14, 4759	0

549	Validating ORR and PFS as surrogate endpoints in phase II and III clinical trials for NSCLC patients: difference exists in the strength of surrogacy in various trial settings. 2022 , 22,	0
548	In vivo CRISPR screens reveal the landscape of immune evasion pathways across cancer.	0
547	The Management of Oligometastases in Non-small Cell Lung Cancer â Stereotactic Ablative Radiotherapy now Standard of Care?. 2022 ,	0
546	Commentary: Another win for immunotherapy. 2022 ,	1
545	Biomarkers and immunotherapy: where are we?. 2022 , 34, 579-586	1
544	TLR3 agonist nanoscale coordination polymer synergizes with immune checkpoint blockade for immunotherapy of cancer. 2022 , 121831	1
543	Probability of Study Success (PrSS) Evaluation Based on Multiple Endpoints in Late Phase Oncology Drug Development. 1-34	0
542	Modeling strategies to analyse longitudinal biomarker data: An illustration on predicting immunotherapy non-response in non-small cell lung cancer. 2022 , e10932	1
541	Signaling pathways and targeted therapies in lung squamous cell carcinoma: mechanisms and clinical trials. 2022 , 7,	0
540	Emerging immune checkpoint inhibitors for the treatment of non-small cell lung cancer. 1-12	0
539	Non-Small Cell Lung Cancer Patients Treated with Anti-PD1 Immunotherapy Show Distinct Microbial Signatures and Metabolic Pathways According to Clinical Outcomes.	0
538	The Ring Study: an international comparison of PD-L1 diagnostic assays and their interpretation in non-small cell lung cancer, head and neck squamous cell cancer and urothelial cancer. 2022 ,	0
537	Delta radiomics model for the prediction of progression-free survival time in advanced non-small-cell lung cancer patients after immunotherapy. 12,	1
536	There Is No Unmet Need for Another Programmed Cell Death Protein-1 or Programmed Death-Ligand 1 Inhibitor for Metastatic NSCLC. 2022 , 17, 1171-1174	0
535	Novel NRF2 -activated cancer treatments utilizing synthetic lethality.	1
534	Immune-checkpoint inhibitor use in patients with cancer and pre-existing autoimmune diseases.	2
533	Pulsed radiotherapy to mitigate high tumor burden and generate immune memory. 13,	1
532	Surgical Results of the Lung Cancer Mutation Consortium 3 (LCMC 3) Trial:. 2022 ,	1

531	Genomic analysis of 5-methylcytosine-related molecular subtypes reveals the characterisation of prognosis and immunotherapy in lung squamous cell carcinoma.	0
530	Prognostic value of cuproptosis-related genes signature and its impact on the reshaped immune microenvironment of glioma. 13,	0
529	Risk of developing hypothyroidism with the use of tyrosine kinase inhibitors and immune checkpoint inhibitors. 2022 , 81, 102265	1
528	The role of metformin in the treatment of non-small cell lung cancer. 2022 , 51, 32-53	0
527	Cancer Immunotherapy Clinical Trials. 2022 , 1-24	0
526	Molecular Pathology of Gastric Cancer. 2022 , 22, 264	0
525	A case of pembrolizumab-induced hypopituitarism subsequent to hypothyroidism. 2022 , 48, 295-300	0
524	Emerging genetic biomarkers in lung adenocarcinoma. 2022 , 10, 205031212211323	0
523	Pembrolizumab-induced esophagitis dissecans superficialis in a patient with squamous cell lung carcinoma. 2022 , 30, 121-124	0
522	Intestinal Microbiota: The Driving Force behind Advances in Cancer Immunotherapy. 2022 , 14, 4796	1
521	Advances in sex disparities for cancer immunotherapy: unveiling the dilemma of Yin and Yang. 2022 , 13,	0
520	Research Trends and Emerging Hotspots of Lung Cancer Surgery during 2012-2021: A 10-Year Bibliometric and Network Analysis. 2022 , 2022, 1-10	0
519	Improving Time-to-Treatment for Advanced Non-Small Cell Lung Cancer Patients through Faster Single Gene EGFR Testing Using the Idylla®EGFR Testing Platform. 2022 , 29, 7900-7911	0
518	Nivolumab-induced radiation recall pneumonitis in non-small cell lung cancer patients with thoracic radiation therapy.	0
517	From Cold to Hot: Changing Perceptions and Future Opportunities for Quantitative Systems Pharmacology (QSP) Modeling in Cancer Immunotherapy.	1
516	State of the Art: nicht onkogen alteriertes nichtkleinzelliges Lungenkarzinom im Stadium IV.	0
515	EGFR mutations and high PD-L1 expression of lung squamous cell carcinoma patients achieving pCR following neoadjuvant immuno-chemotherapy: Case report. 12,	0
514	History and Evidence of Immune Checkpoint Inhibitors in the Respiratory Field. 2022 , 73, 325-331	0

- 513 Mechanisms of primary and acquired resistance to immune checkpoint inhibitors in advanced non-small cell lung cancer: a multiplex immunohistochemistry-based single-cell analysis. **2022**, 0
- 512 Patient-reported outcomes with cemiplimab monotherapy for first-line treatment of advanced non-small cell lung cancer with PD-L1 of $\geq 50\%$: The EMPOWER-Lung 1 study. 0
- 511 Immune checkpoint inhibitors in patients aged 80 or older with advanced non-small cell lung cancer or melanoma: a real-life multicentre study. 1-8 0
- 510 Immune Checkpoint Inhibitors in Urothelial Carcinoma (Literature Review). **2022**, 12, 205-216 0
- 509 Outcomes of EGFR tyrosine kinase inhibitors and immune checkpoint inhibitors for advanced EGFR-mutated non-small cell lung cancer. 0
- 508 Vidutolimod in Combination With Atezolizumab With and Without Radiation Therapy in Patients With PD-1/PD-L1 Blockade-Resistant Advanced Non-small Cell Lung Cancer. **2022**, 100423 0
- 507 Translational Research in Cancer Immunotherapies. **2022**, 62, 363-370 0
- 506 The Prognostic and Therapeutic Potential of DNA Damage Repair Pathway Alterations and Homologous Recombination Deficiency in Lung Cancer. **2022**, 14, 5305 2
- 505 Cancer Genomics and Evolution. 1-30 0
- 504 Natural killer cell-mimicking nanomaterial for overcoming the multidrug resistance of tumor via cascade catalysis. 0
- 503 The Association of Immunotherapy With the Overall Survival of Inoperable Stage III Non-small Cell Lung Cancer Patients Who Do not Receive Chemoradiation. Publish Ahead of Print, 0
- 502 Concurrent Administration of Immune Checkpoint Inhibitors and Stereotactic Radiosurgery Is Well-Tolerated in Patients With Melanoma Brain Metastases: An International Multicenter Study of 203 Patients. **2022**, Publish Ahead of Print, 1
- 501 Risk factors for immune-mediated hepatotoxicity in patients with cancer treated with immune checkpoint inhibitors: a systematic review and meta-analysis. **2022**, 21, 1275-1287 0
- 500 Successful control of intestinal bleeding from metastasis of pulmonary pleomorphic carcinoma with pembrolizumab: A case report. **2022**, 101, e31220 0
- 499 Les nouveautés en immunothérapie : nouvelles cibles, rationnel et données précoces dans les cancers broncho-pulmonaires non à petites cellules. **2022**, 14, 2S219-2S224 0
- 498 Traitements systémiques du cancer bronchique non à petites cellules chez les sujets âgés. **2022**, 14, 2S327-2S337 0
- 497 Combining single-cell sequencing data to construct a prognostic signature to predict survival, immune microenvironment, and immunotherapy response in gastric cancer patients. 13, 0
- 496 Predicting Immunotherapy Outcomes in Older Patients with Solid Tumors Using the LIPI Score. **2022**, 14, 5078 1

- 495 Peripheral blood markers predict immunotherapeutic efficacy in patients with advanced non-small cell lung cancer: A multicenter study. 13, o
- 494 Immune-Mediated Pneumonitis: A Clinical Conundrum in a Patient with Stage IV Lung Adenocarcinoma with a Dramatic and Durable Response to Checkpoint Inhibitor Case Report. **2022**, 100195 o
- 493 Meeting an un-MET need: Targeting MET in non-small cell lung cancer. 12, o
- 492 Current updates of CRISPR/Cas9-mediated genome editing and targeting within tumor cells: an innovative strategy of cancer management. 1
- 491 Precision Medicine in Oncology Drug Development. 1-15 o
- 490 Development of the Novel Bifunctional Fusion Protein BR102 That Simultaneously Targets PD-L1 and TGF- β for Anticancer Immunotherapy. **2022**, 14, 4964 o
- 489 R animation en oncologie   l  ure de l  immunoth  apie. **2022**, 14, 2S287-2S292 o
- 488 Current Status of Immune Checkpoint Inhibitors. **2022**, 73, 303-307 o
- 487 Risk factors for severe immune-related adverse events after first-line pembrolizumab monotherapy or combination chemotherapy for non-small-cell lung cancer. o
- 486 Pseudohypoxia in paraganglioma and pheochromocytoma is associated with an immunosuppressive phenotype. o
- 485 The Lung Microbiota and Lung Cancer: A Growing Relationship. **2022**, 14, 4813 o
- 484 The Role of Genomics and Proteomics in Lung Cancer Early Detection and Treatment. **2022**, 14, 5144 o
- 483 2D Catalytic, Chemodynamic, and Ferroptotic Vermiculite Nanomedicine. 2208220 o
- 482 Pharmacotherapy for Advanced Non-Small Cell Lung Cancer with Performance Status 2 without Druggable Gene Alterations: Could Immune Checkpoint Inhibitors Be a Game Changer?. **2022**, 14, 4861 o
- 481 Cancer of the Lung. 1-29 o
- 480 Squamous cell lung cancer: Current landscape and future therapeutic options. **2022**, o
- 479 Preoperative stereotactic radiosurgery in the management of brain metastases and gliomas. 9, o
- 478 Predictive Factors for the Efficacy of Immune Checkpoint Inhibitors Against Lung Cancer. **2022**, 62, 355-362 o

- 477 Du rep age syst matique au sevrage tabagique : un nouveau paradigme. **2022**, 14, 2S10-2S15 o
- 476 Circ_0084043-miR-134-5p axis regulates PCDH9 to suppress melanoma. 12, o
- 475 PD-1-mAb Plus Regimen in the First and Second Lines of Advanced and Unresectable Biliary Tract Carcinoma: A Real-World, Multicenter Retrospective Analysis. Volume 15, 6031-6046 o
- 474 Tumor microenvironment shows an immunological abscopal effect in patients with NSCLC treated with pembrolizumab-radiotherapy combination. **2022**, 10, e005248 o
- 473 Peripheral T cell cytotoxicity predicts the efficacy of anti-PD-1 therapy for advanced non-small cell lung cancer patients. **2022**, 12, o
- 472 Exploring histopathological and serum biomarkers in lung adenocarcinoma: Clinical applications and translational opportunities (Review). **2022**, 61, 1
- 471 Immune-Checkpoint Inhibitors (ICIs) in Metastatic Colorectal Cancer (mCRC) Patients beyond Microsatellite Instability. **2022**, 14, 4974 2
- 470 Pan-cancer analyses of classical protein tyrosine phosphatases and phosphatase-targeted therapy in cancer. 13, 1
- 469 Methylome Profiling of PD-L1-Expressing Glioblastomas Shows Enrichment of Post-Transcriptional and RNA-Associated Gene Regulation. **2022**, 14, 5375 o
- 468 Exploring Gut Microbiome in Predicting the Efficacy of Immunotherapy in Non-Small Cell Lung Cancer. **2022**, 14, 5401 1
- 467 Immunoterapia en pacientes con c ncer de pulm n y met stasis cerebrales de inicio. **2022**, 25, o
- 466 Liquid Biopsy and Immuno-Oncology for Advanced Nonsmall Cell Lung Cancer. o
- 465 High tumor hexokinase-2 expression promotes a pro-tumorigenic immune microenvironment by modulating CD8+/regulatory T-cell infiltration. **2022**, 22, o
- 464 Cost of illness of stage IV non-small cell lung cancer (NSCLC) positive for programmed cell death ligand 1 (PD-L1) in the US. 1-7 o
- 463 Prognosis prediction and tumor immune microenvironment characterization based on tryptophan metabolism-related genes signature in brain glioma. 13, o
- 462 Imaging of Immune Checkpoint Inhibitor Immunotherapy for Non Small Cell Lung Cancer. **2022**, 42, 1956-1974 2
- 461 Predictors of Survival to Immunotherapy and Chemoimmunotherapy in Non-Small Cell Lung Cancer: A Meta-Analysis. o
- 460 The product of the PD-L1 expression and neutrophil-to-lymphocyte ratio as a predictor of postoperative recurrence in non-small-cell lung cancer. o

- 459 The treatment in patients with unresectable locally advanced non-small cell lung cancer: Explorations on hot issues. **2022**, 551, 215947 ○
- 458 Advances in immunotherapy for MMR proficient colorectal cancer. **2022**, 111, 102480 1
- 457 Cardiovascular risks of chemo-immunotherapy for lung cancer: A population-based cohort study. **2022**, 174, 67-70 ○
- 456 Immune checkpoint inhibitors plus chemotherapy versus chemotherapy alone as first-line therapy for advanced gastric and esophageal cancers: A systematic review and meta-analysis. **2022**, 113, 109317 ○
- 455 Impact of KRAS G12C mutation in patients with advanced non-squamous non-small cell lung cancer treated with first-line pembrolizumab monotherapy. **2022**, 174, 45-49 ○
- 454 RAS: Circuitry and therapeutic targeting. **2023**, 101, 110505 ○
- 453 Development of models for predicting the objective response of immune checkpoint inhibitor therapy in patients with nonsmall-cell lung cancer. **2022**, 8, 27 ○
- 452 Immune checkpoint inhibitor (ICI)-induced hepatitis diagnosed by liver biopsy followed by ICI-free chemotherapy leading to therapeutic effect: A case of lung cancer treatment. **2022**, 40, 101773 ○
- 451 Drug Resistance in Lung Cancer. **2022**, ○
- 450 The Latest Information on Chemotherapy for Patients with Advanced Lung Cancer. **2021**, 110, 2441-2448 ○
- 449 NKp44-Derived Peptide Used in Combination Stimulates Antineoplastic Efficacy of Targeted Therapeutic Drugs. **2022**, 23, 14054 ○
- 448 Behandelingen bij longkanker. **2022**, 28, 47-53 ○
- 447 Clinical significance of interstitial lung abnormalities and immune checkpoint inhibitor-induced interstitial lung disease in patients with non-small cell lung cancer. ○
- 446 Prognostic value of 18F-FDG PET/CT in patients with advanced or metastatic non-small-cell lung cancer treated with immune checkpoint inhibitors: A systematic review and meta-analysis. 13, ○
- 445 Alternate Pembrolizumab Dosing Interval in Advanced NSCLC with PD-L1 TPS ≥50%: 3 Weekly Compared to 6 Weekly Dosing. **2022**, 29, 8686-8692 ○
- 444 Analysis of the efficacy and safety of immunotherapy in advanced thymoma patients. ○
- 443 Single-cell RNA sequencing reveals cellular and molecular reprogramming landscape of gliomas and lung cancer brain metastases. **2022**, 12, ○
- 442 Quantitative Radiological Features and Deep Learning for the Non-Invasive Evaluation of Programmed Death Ligand 1 Expression Levels in Gastric Cancer Patients: A Digital Bopsy Study. **2022**, ○

- 441 Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes With Pembrolizumab Plus Chemotherapy Versus Chemotherapy For Metastatic NSCLC. **2022**, 100431 ○
- 440 Real-World Outcomes and Prognostic Factors Among Patients with Advanced Non-Small Cell Lung Cancer and High PD-L1 Expression Treated with Immune Checkpoint Inhibitors as First-Line Therapy. Volume 14, 3191-3202 ○
- 439 Tailored modulation of stemness and drug resistance marker characteristics in K-Ras mutant lung cancer cells via PD-L1 gene suppression. **2022**, 121171 ○
- 438 Cost-effectiveness of first-line pembrolizumab monotherapy versus chemotherapy in high PD-L1 advanced non-small cell lung cancer in the Irish healthcare setting. **2022**, ○
- 437 Management of cancer-related fatigue in Taiwan: an evidence-based consensus for screening, assessment and treatment. ○
- 436 A single center analysis of first-line treatment in advanced KRAS mutant non-small cell lung cancer: real-world practice. **2022**, 22, ○
- 435 PD-L1 expression as predictor of immunotherapy eligibility in penile squamous cell carcinoma patients. 11, 1281 ○
- 434 CD8+ T cell/cancer-associated fibroblast ratio stratifies prognostic and predictive responses to immunotherapy across multiple cancer types. 13, ○
- 433 Translating the evolving molecular landscape of tumors to biomarkers of response for cancer immunotherapy. **2022**, 14, ○
- 432 Loss of SATB2 expression correlates with cytokeratin 7 and PD-L1 tumor cell positivity and aggressiveness in colorectal cancer. **2022**, 12, 1
- 431 Molecular subtypes identified by pyroptosis-related genes are associated with tumor microenvironment cell infiltration in colon cancer. ○
- 430 Sintilimab versus docetaxel as second-line treatment in advanced or metastatic squamous non-small-cell lung cancer: an open-label, randomized controlled phase 3 trial (ORIENT-3). ○
- 429 Predictive performance of PD-L1 tumor proportion score for nivolumab response evaluated using archived specimens in patients with non-small cell lung cancer experiencing a postoperative recurrence. ○
- 428 Serine and glycine metabolism-related gene expression signature stratifies immune profiles of brain gliomas, and predicts prognosis and responses to immunotherapy. 13, ○
- 427 The effect of organ-specific tumor microenvironments on response patterns to immunotherapy. 13, ○
- 426 Cardiac arrhythmias associated with immune checkpoint inhibitors: A comprehensive disproportionality analysis of the FDA adverse event reporting system. 13, ○
- 425 Spatial Immunophenotypes of Distant Metastases but not Matched Primary Urothelial Carcinomas Predict Response to Immune Checkpoint Inhibition. **2022**, ○
- 424 Clinical Implications and Molecular Characterization of Drebrin-Positive, Tumor-Infiltrating Exhausted T Cells in Lung Cancer. **2022**, 23, 13723 ○

- 423 Necitumumab plus gemcitabine and cisplatin in previously treated lung squamous cell carcinoma. o
- 422 Immune checkpoint inhibitors in lung tumors with rare histologies and other thoracic malignancies. o
- 421 Pembrolizumab and Chemotherapy Combination Prolonged Progression-Free Survival in Patients with NSCLC with High PD-L1 Expression and Low Neutrophil-to-Lymphocyte Ratio. **2022**, 15, 1407 o
- 420 Protein kinase C η mediates immunosuppression in lung adenocarcinoma. **2022**, 14, o
- 419 Nanotheranostic Strategies for Cancer Immunotherapy. 2200718 o
- 418 Comprehensive 18F-FDG PET-based radiomics in elevating the pathological response to neoadjuvant immunochemotherapy for resectable stage III non-small-cell lung cancer: A pilot study. 13, o
- 417 Biomarkers in the management of lung cancer: changing the practice of thoracic oncology. **2022**, o
- 416 Clinical impact of venous thromboembolism in non-small cell lung cancer patients receiving immunotherapy. **2022**, 1 o
- 415 MicroRNA-326 Negatively Regulates CD155 Expression in Lung Adenocarcinoma. o
- 414 Comparison of 22C3-PD-L1 Expression Between Paired Tumor Paraffin Blocks of Surgical Resection Specimens of Nonsmall Cell Lung Cancer. Publish Ahead of Print, o
- 413 Effect of histology on the efficacy of immune checkpoint inhibitors in advanced non-small cell lung cancer: A systematic review and meta-analysis. 12, o
- 412 Editorial: Impact of immunotherapy in lung cancer. 12, o
- 411 Purine metabolism-related gene expression signature predicts survival outcome and indicates immune microenvironment profile of gliomas. 13, o
- 410 Distribution and concordance of PD-L1 expression by routine 22C3 assays in East-Asian patients with non-small cell lung cancer. **2022**, 23, o
- 409 Comparison between immunotherapy efficacy in early non-small cell lung cancer and advanced non-small cell lung cancer: a systematic review. **2022**, 20, o
- 408 Durable Response and Improved CD8 T Cell Plasticity in Lung Cancer Patients After PD1 Blockade and JAK Inhibition. o
- 407 The impact of tertiary lymphoid structures on clinicopathological, genetic and gene expression characteristics in lung adenocarcinoma. **2022**, 174, 125-132 o
- 406 Hemophagocytic Lymphohistiocytosis as a complication of immune checkpoint inhibitor therapy for sarcoma. **2022**, 8, 100202 o

- 405 Combined immunotherapy for metastatic triple-negative breast cancer based on PD-1/PD-L1 immune checkpoint blocking. **2022**, 113, 109444 1
- 404 Immune checkpoint therapy and response biomarkers in non-small-cell lung cancer: Serum NY-ESO-1 and XAGE1 antibody as predictive and monitoring markers. **2022**, 0
- 403 Tumor Immune Microenvironment and Immunotherapy in Non-Small Cell Lung Cancer: Update and New Challenges. **2022**, 13, 1615 0
- 402 Long-term survival with first-line nivolumab plus ipilimumab in patients with advanced non-small cell lung cancer: a pooled analysis. **2022**, 0
- 401 Longitudinal Modulation of Loco-Regional Immunity in Ovarian Cancer Patients Receiving Intraperitoneal Chemotherapy. **2022**, 14, 5647 0
- 400 A case of immune checkpoint inhibitor-related myocarditis induced by pembrolizumab for tongue cancer. **2022**, 68, 385-391 0
- 399 REFINE (REduced Frequency ImmuNE checkpoint inhibition in cancers): A multi-arm phase II basket trial testing reduced intensity immunotherapy across different cancers. **2023**, 124, 107030 0
- 398 Plasma tumor mutation burden is associated with clinical benefit in patients with non-small cell lung cancer treated with anti-programmed death-1 monotherapy. **2022**, 14, 175883592211417 0
- 397 Research Progress of Intestinal Flora in the Treatment of Lung CancerâIntestinal Flora and Lung Cancer. **2022**, 12, 10933-10941 0
- 396 Delayed-onset immune-related adverse events involving the thyroid gland by immune checkpoint inhibitors in combination with chemotherapy: a case report and retrospective cohort study. **2022**, 0
- 395 Patient-Reported Distress and Clinical Outcomes with Immuno-Oncology Agents in Metastatic Non-Small Cell Lung Cancer (mNSCLC): A Real-World Retrospective Cohort Study. **2023**, 175, 17-26 0
- 394 Effect of chemotherapy, immunotherapy, and targeted therapies on removal of indwelling pleural catheters in non-small cell lung cancer patients with malignant pleural effusions. **2023**, 206, 107093 0
- 393 Clinical Outcomes of Patients With Metastatic NSCLC After Discontinuation of Immunotherapy Because of Immune-Related Adverse Effects. **2023**, 4, 100441 0
- 392 Multi-Scale Temporal Imaging: From Micro- and Meso- to Macro-scale-time Nuclear Medicine. **2023**, 18, 135-148 0
- 391 The use of medical cannabis concomitantly with immune checkpoint inhibitors in non-small cell lung cancer: A sigh of relief?. **2023**, 180, 52-61 0
- 390 Durable complete leptomeningeal and intracerebral responses to first-line Pembrolizumab in highly-selected Non-small cell lung cancer patients. **2023**, 9, 100209 0
- 389 The Use of Immunotherapy in Cancer Patients with Autoimmune Diseases. **2022**, 0
- 388 A Random Forest Genomic Classifier for Tumor Agnostic Prediction of Response to Anti-PD1 Immunotherapy. **2022**, 21, 117693512211360 0

387	Tumor glycolytic profiling through 18F-FDG PET/CT predicts immune checkpoint inhibitor efficacy in advanced NSCLC. 2022 , 14, 175883592211383	0
386	Management of Non-Small Cell Lung Cancer: The Era of Immunotherapy. 100-107	0
385	Immunotherapy for Cancer: Common Gastrointestinal, Liver, and Pancreatic Side Effects and Their Management. 2022 , 117, 1917-1932	0
384	Immune biology of NSCLC revealed by single-cell technologies: implications for the development of biomarkers in patients treated with immunotherapy.	0
383	Lack of SIRP -alpha reduces lung cancer growth in mice by promoting anti-tumour ability of macrophages and neutrophils.	0
382	Design and reporting of phase III oncology trials with prospective biomarker validation.	0
381	A Study on the Availability of Survival Analysis of Lung Cancer Patients Using Synthetic Data. 2022 , 47, 279-289	0
380	Development of Radiomic-Based Model to Predict Clinical Outcomes in Non-Small Cell Lung Cancer Patients Treated with Immunotherapy. 2022 , 14, 5931	0
379	An EGFR L858R mutation identified in 1862 Chinese NSCLC patients can be a promising neoantigen vaccine therapeutic strategy. 13,	1
378	Increased tumor glycolysis is associated with decreased immune infiltration across human solid tumors. 13,	0
377	Rechallenge of immune checkpoint inhibitors in a case with adverse events inducing myasthenia gravis. 2022 , 10, e005970	0
376	Complete response to pembrolizumab as a single agent in a patient with stage III NSCLC with high PD-L1 expression: a case report.	0
375	Predictive value of serum high-mobility group box 1 levels for checkpoint inhibitor pneumonitis.	0
374	A phase 2 trial of chemotherapy plus pembrolizumab in patients with advanced non-small cell lung cancer previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029. 2023 , 129, 264-271	1
373	The Prognostic Value of Plasma Programmed Death Protein-1 (PD-1) and Programmed Death-Ligand 1 (PD-L1) in Patients with Gastrointestinal Stromal Tumor. 2022 , 14, 5753	0
372	A tumor vasculature-based imaging biomarker for predicting response and survival in patients with lung cancer treated with checkpoint inhibitors. 2022 , 8,	0
371	Malignant neoplasm of the bronchi and lung: Russian clinical guidelines. 2022 , 24, 269-304	0
370	Development of therapeutic antibodies for the treatment of diseases. 2022 , 3,	1

- 369 Histology-Agnostic Drugs: A Paradigm ShiftâA Narrative Review. o
- 368 Assessing the efficacy of immunotherapy in lung squamous carcinoma using artificial intelligence neural network. 13, o
- 367 Prognostic and predictive value of YTHDF1 and YTHDF2 and their correlation with tumor-infiltrating immune cells in non-small cell carcinoma. 12, o
- 366 Hyperprogressive disease in non-small cell lung cancer treated with immune checkpoint inhibitor therapy, fact or myth?. 12, o
- 365 Advances in CAR T cell immunotherapy for paediatric brain tumours. 12, o
- 364 Integrated modeling to implicate evolving neoantigen-T cell interplays and immunotherapy efficacy in tumors. o
- 363 The Safety and Efficacy of Preoperative Immunotherapy Combined with Chemotherapy in Patients with Stage IIIA-IIIB Lung Squamous Cell Carcinoma. o
- 362 Hub Genes in Non-Small Cell Lung Cancer Regulatory Networks. **2022**, 12, 1782 o
- 361 miRNome profiling of lung cancer metastases revealed a key role for miRNA-PD-L1 axis in the modulation of chemotherapy response. o
- 360 Multicentre, randomised, open-label, parallel-group, clinical phase II study to evaluate immunonutrition in improving efficacy of immunotherapy in patients with metastatic non-small cell lung cancer, undergoing systematic nutritional counseling. **2022**, 22, o
- 359 Management of Lung Cancer in the Patient with Interstitial Lung Disease. o
- 358 The bleeding risk and safety of repeated bronchoscopies with tissue sampling in patients with pulmonary lesions. 1-6 o
- 357 Proceedings From the ASCO/College of American Pathologists Immune Checkpoint Inhibitor Predictive Biomarker Summit. **2022**, o
- 356 Smoking Cessation after Cancer Diagnosis and Enhanced Therapy Response: Mechanisms and Significance. **2022**, 29, 9956-9969 1
- 355 Immunotherapy and Biomarker Testing in Recurrent and Metastatic Head and Neck Cancers: ASCO Guideline. 1
- 354 Integrated investigation of the prognostic role of HLA LOH in advanced lung cancer patients with immunotherapy. 13, o
- 353 Transcriptional upregulation of CXCL13 is correlated with a favorable response to immune checkpoint inhibitors in lung adenocarcinoma. o
- 352 The immune checkpoint expression in the tumor immune microenvironment of DLBCL: Clinicopathologic features and prognosis. 12, o

351	Interleukin-10 induces expression of CD39 on CD8+T cells to potentiate anti-PD1 efficacy in EGFR-mutated non-small cell lung cancer. 2022 , 10, e005436	o
350	Establishing a whole blood CD4+ T cell immunity measurement to predict response to anti-PD-1. 2022 , 22,	o
349	Current status and novel insights into the role of metastasectomy in the era of immunotherapy. 1-10	o
348	Whole-Blood Gene Expression Profiles Correlate with Response to Immune Checkpoint Inhibitors in Patients with Metastatic Renal Cell Carcinoma. 2022 , 14, 6207	o
347	Virtual clinical trials: A tool for predicting patients who may benefit from treatment beyond progression with pembrolizumab in non-small cell lung cancer.	o
346	A study of Non Small Cell Lung Cancer (NSCLC) patients with brain metastasis: a single centre experience. 2022 , 100673	o
345	PEOPLE (NCT03447678), a first-line phase II pembrolizumab trial, in negative and low PD-L1 advanced NSCLC: clinical outcomes and association with circulating immune biomarkers. 2022 , 7, 100645	o
344	Pneumologie meets Onkologie.	o
343	Potential Role of Tumor-Derived Exosomes in Non-Small-Cell Lung Cancer in the Era of Immunotherapy. 2022 , 12, 2104	1
342	Expanding Indication of Immune Checkpoint Inhibitor and Future Challenges in the Treatment of Lung Cancer. 2022 , 62, 918-921	o
341	A novel plasma proteomic computational model for predicting therapeutic benefit from immune checkpoint inhibitors in non-small cell lung cancer.	o
340	Clinical Potential of Circulating Cell-Free DNA (cfDNA) for Longitudinally Monitoring Clinical Outcomes in the First-Line Setting of Non-Small-Cell Lung Cancer (NSCLC): A Real-World Prospective Study. 2022 , 14, 6013	1
339	Analysis of prognostic model based on immunotherapy related genes in lung adenocarcinoma. 2022 , 12,	o
338	Bintrafusp Alfa, a Bifunctional Fusion Protein Targeting TGF- β and PD-L1, in Patients With Non-Small Cell Lung Cancer Resistant or Refractory to Immune Checkpoint Inhibitors.	o
337	Clinical characteristics of adrenal insufficiency induced by pembrolizumab in non-small-cell lung cancer.	o
336	Clonal KEAP1 mutations with loss of heterozygosity share reduced immunotherapy efficacy and low immune cell infiltration in lung adenocarcinoma.. 2022 ,	o
335	A Complete Sustained Response of Advanced Non-Small-Cell Lung Cancer After Immune Checkpoint Inhibitor, Radiotherapy, and Chemotherapy. 2022 ,	o
334	Selection Criteria and Treatment Outcome for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Unfit for Platinum-Based First-Line Therapy: Results of the MOON-OSS Observational Trial. 2022 , 14, 6074	o

- 333 Clinical outcomes and risk factor of immune checkpoint inhibitors-related pneumonitis in non-small cell lung cancer patients with chronic obstructive pulmonary disease. **2022**, 22, 0
- 332 Assessing the risk of cardiovascular events in patients receiving immune checkpoint inhibitors. 9, 0
- 331 Next-generation sequencing of homologous recombination genes could predict efficacy of platinum-based chemotherapy in non-small cell lung cancer. 12, 0
- 330 Prognostic pyroptosis-related lncRNA signature predicts the efficacy of immunotherapy in hepatocellular carcinoma. **2022**, 32, 101389 0
- 329 Small Molecule PTPN2 Inhibitors Sensitize Resistant Melanoma to Anti-PD-1 Immunotherapy. 0
- 328 Inferencing Bulk Tumor and Single-Cell Multi-Omics Regulatory Networks for Discovery of Biomarkers and Therapeutic Targets. **2023**, 12, 101 0
- 327 Prognostic value of inflammatory and nutritional indexes among advanced NSCLC patients receiving PD -1 inhibitor therapy. 1
- 326 Short-term dynamics of circulating tumor DNA predicting efficacy of sintilimab plus docetaxel in second-line treatment of advanced NSCLC: biomarker analysis from a single-arm, phase 2 trial. **2022**, 10, e004952 0
- 325 Towards the characterization of the tumor microenvironment through dictionary learning-based interpretable classification of multiplexed immunofluorescence images. **2023**, 68, 014002 0
- 324 Multivalent state transitions shape the intratumoral composition of small cell lung carcinoma. **2022**, 8, 0
- 323 The ectonucleotidase CD39 identifies tumor-reactive CD8+ T cells predictive of immune checkpoint blockade efficacy in human lung cancer. **2022**, 0
- 322 Predicting response to immune checkpoint blockade in NSCLC with tumour-only RNA-seq. 0
- 321 Identifying Patients at Risk of Acute Kidney Injury among Patients Receiving Immune Checkpoint Inhibitors: A Machine Learning Approach. **2022**, 12, 3157 0
- 320 Consolidative high-dose thoracic radiotherapy for limited metastatic nonsmall cell lung cancer: Focusing on oligo-progressive disease. 0
- 319 Monitoring PD-L1 Expression on Circulating Tumor-Associated Cells in Recurrent Metastatic Non-Small-Cell Lung Carcinoma Predicts Response to Immunotherapy With Radiation Therapy. **2022**, 1
- 318 Lung Cancer Immunotherapy: Beyond Common Immune Checkpoints Inhibitors. **2022**, 14, 6145 0
- 317 Identification of prognostic factors and nomogram model for patients with advanced lung cancer receiving immune checkpoint inhibitors. 10, e14566 0
- 316 Cutaneous adverse events in lung cancer patients on the therapy based on PD-1/PD-L1 inhibitors: A prospective observational cohort study. **2022**, 100934 0

315	An Efficient Combination Immunotherapy for Antitumor Immunity without Accelerating Cardiac Allograft Rejection.	0
314	Therapeutic strategies for EGFR-mutated non-small cell lung cancer patients with osimertinib resistance. 2022 , 15,	1
313	Evolving landscape of PD-L2: bring new light to checkpoint immunotherapy.	0
312	Image-guided thermal ablation for patients with epidermal growth factor receptor-mutant nonsmall cell lung cancer.	0
311	Nanoparticle accumulation in liver may induce resistance to immune checkpoint blockade therapy.	0
310	Analysis of scRNA-seq and bulk RNA-seq demonstrates the effects of EVI2B or CD361 on CD8+ T cells in osteosarcoma. 153537022211426	0
309	MYCBP2 expression correlated with inflammatory cell infiltration and prognosis immunotherapy in thyroid cancer patients. 13,	0
308	Global research landscape and trends of lung cancer immunotherapy: A bibliometric analysis. 13,	0
307	Immunotherapeutics in lung cancers: from mechanistic insight to clinical implications and synergistic perspectives.	0
306	CLINICAL AND TECHNICAL INSIGHTS OF TUMOUR MUTATIONAL BURDEN IN NON-SMALL CELL LUNG CANCER.. 2022 , 103891	0
305	Prognostic factors of toxicity of immune checkpoint inhibitors in nonsmall cell lung cancer and small cell lung cancer patients: The ToxImmune study.	0
304	Combination bezafibrate and nivolumab treatment of patients with advanced nonâ€small cell lung cancer. 2022 , 14,	1
303	A Community Challenge to Predict Clinical Outcomes After Immune Checkpoint Blockade in Non-Small Cell Lung Cancer.	0
302	A case of thoracic SMARCA4 -Deficient undifferentiated tumor successfully treated with combination Ipilimumabâ€nivolumab. 2022 , 10,	0
301	Cancer of unknown primary: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up. 2022 ,	0
300	Biomarkers and Outcomes in Diverse Cancers: Meta-Analysis of Early Phase Immuno-Oncology Trials.	0
299	spaCI: deciphering spatial cellular communications through adaptive graph model.	2
298	Investigating the Quality of Life for Cancer Patients and Estimating the Cost of Immunotherapy in Selected Cases. 2022 ,	0

- 297 Model-based meta-analysis of non-small cell lung cancer with standard-of-care PD -1 inhibitors and chemotherapy for early development decision making. ○
- 296 Mechanistic modeling of brain metastases in NSCLC provides computational markers for personalized prediction of outcome. ○
- 295 Application of individualized multimodal radiotherapy combined with immunotherapy in metastatic tumors. 13, ○
- 294 Evolution of treatment patterns and survival outcomes in patients with advanced non-small cell lung cancer treated at Frankfurt University Hospital in 2012–2018. **2023**, 23, ○
- 293 Immunotherapy Assessment: A New Paradigm for Radiologists. **2023**, 13, 302 1
- 292 Camrelizumab Plus Carboplatin and Pemetrexed as First-line Treatment for Advanced Non-squamous NSCLC: Extended Follow-up of CameL Phase 3 Trial. **2023**, ○
- 291 Open Pocket and Tighten Holes: Inhalable Lung Cancer-Targeted Nanocomposite for Enhanced Ferroptosis-Apoptosis Synergetic Therapy. **2023**, 141487 1
- 290 Clinical best practices in optimal monitoring, early diagnosis, and effective management of antibody–drug conjugate-induced interstitial lung disease or pneumonitis: a multidisciplinary team approach in Singapore. 1-11 ○
- 289 Long-term comparative efficacy and safety of nivolumab plus ipilimumab relative to other first-line therapies for advanced non-small-cell lung cancer: a systematic literature review and network meta-analysis. **2023**, ○
- 288 Who Should Receive the Chemotherapy-Free Combination of Nivolumab Plus Ipilimumab as the First-Line Treatment of Advanced Non–Small-Cell Lung Cancer?. ○
- 287 Configuring Therapeutic Aspects of Immune Checkpoints in Lung Cancer. **2023**, 15, 543 ○
- 286 Genomic and immunogenomic analysis of three prognostic signature genes in LUAD. **2023**, 24, ○
- 285 Thoracic imaging. **2023**, 179-198 ○
- 284 The promise of targeting heme and mitochondrial respiration in normalizing tumor microenvironment and potentiating immunotherapy. 12, ○
- 283 Editorial: Impact of tumor microenvironment on lung cancer. 13, ○
- 282 Individual patient data to allow a more elaborated comparison of trial results with real-world outcomes from first-line immunotherapy in NSCLC. **2023**, 23, ○
- 281 Development of a Novel Predictive-Prognostic Scoring Index for Immune Checkpoint Inhibitors in Advanced Non-small Cell Lung Cancer. **2023**, ○
- 280 A Subset of PD-1-Expressing CD56bright NK Cells Identifies Patients with Good Response to Immune Checkpoint Inhibitors in Lung Cancer. **2023**, 15, 329 ○

279	Pembrolizumab for first-line treatment of advanced unresectable or metastatic esophageal or gastroesophageal junction cancer. 2023 , 16, 175628482211482	o
278	EGFR-Directed Therapy in Lung Cancer. 2023 ,	o
277	Pan-cancer analysis identifies proteasome 26S subunit, ATPase (PSMC) family genes, and related signatures associated with prognosis, immune profile, and therapeutic response in lung adenocarcinoma. 13,	o
276	Increasing cure rates of solid tumors by immune checkpoint inhibitors. 2023 , 12,	o
275	Nintedanib in an elderly non-small-cell lung cancer patient with severe steroid-refractory checkpoint inhibitor-related pneumonitis: A case report and literature review. 13,	o
274	Real-World Treatment Patterns and Effectiveness of Targeted and Immune Checkpoint Inhibitor Based Systemic Therapy in BRAF-Mutation Positive Non-Small Cell Lung Cancer. 2023 , 100460	o
273	Circulating tumor cells PD-L1 expression detection and correlation of therapeutic efficacy of immune checkpoint inhibition in advanced non-small-cell lung cancer.	o
272	Programmed Cell Death Ligand 1 (PD-L1) Expression in Non-Small Cell Lung Cancer: Findings from a tertiary care institute in western part of India. 2023 ,	o
271	The mutation in splicing factor genes correlates with unfavorable prognosis, genomic instability, anti-tumor immunosuppression and increased immunotherapy response in pan-cancer. 10,	o
270	KLRG1 marks tumor-infiltrating CD4 T cell subsets associated with tumor progression and immunotherapy response.	o
269	Therapeutic strategies for non-small cell lung cancer: Experimental models and emerging biomarkers to monitor drug efficacies. 2023 , 108347	o
268	Association between pre-treatment chest imaging and pulmonary function abnormalities and immune checkpoint inhibitor pneumonitis.	o
267	Updated Views in Targeted Therapy in the Patient with Non-Small Cell Lung Cancer. 2023 , 13, 167	1
266	A case of late and lethal Trousseau's syndrome induced by pembrolizumab in lung adenocarcinoma.	o
265	C-PLAN index as a prognostic factor for patients with previously untreated advanced non-small cell lung cancer who received combination immunotherapy: A multicenter retrospective study.	o
264	Non-oncogene addicted metastatic non-small-cell lung cancer: ESMO Clinical Practice Guideline for diagnosis, treatment and follow-up 2023,	o
263	Paclitaxel Has a Reduced Toxicity Profile in Healthy Rats After Polymeric Micellar Nanoparticle Delivery. Volume 18, 263-276	o
262	Strahlentherapie und Immuntherapie. 2023 , 1-20	o

- 261 A network meta-analysis of immunotherapy-based treatments for advanced nonsquamous non-small cell lung cancer. ○
- 260 Combination of chemotherapeutic agents and biological response modifiers (immunotherapy) in triple-negative/Her2(+) breast cancer, multiple myeloma, and non-small-cell lung cancer. **2022**, 34, 1
- 259 Wnt/ β -Catenin Signaling and Resistance to Immune Checkpoint Inhibitors: From Non-Small-Cell Lung Cancer to Other Cancers. **2023**, 11, 190 ○
- 258 The Effects of Clonal Heterogeneity on Cancer Immunosurveillance. **2023**, 7, ○
- 257 The impact of combined PD-L1 positive score on clinical response to nivolumab in patients with advanced esophageal squamous cell carcinoma. ○
- 256 Genetic, DNA methylation, and immune profile discrepancies between early-stage single primary lung cancer and synchronous multiple primary lung cancer. **2023**, 15, ○
- 255 Canine oral squamous cell carcinoma as a spontaneous, translational model for radiation and immunology research. 12, ○
- 254 Microbiota in Cancer Immunotherapy: The Next Milestone of Immuno-oncology?. **2023**, 269-287 ○
- 253 Targeting regulatory T cells in gastric cancer: Pathogenesis, immunotherapy, and prognosis. **2023**, 158, 114180 ○
- 252 Serum-derived exosomal miR-125a-3p predicts the response to anti-programmed cell death-1/programmed cell death-ligand 1 monotherapy in patients with non-small cell lung cancer. **2023**, 857, 147177 ○
- 251 Anti-Programmed Death Receptor 1 Signalling Immunotherapy as a Part of Curative Intent Strategies for Stages I-III Non-Small Cell Lung Cancer. 109-116 ○
- 250 Emerging Biomarkers in Immune Oncology to Guide Lung Cancer Management. ○
- 249 Targeting Notch-Driven Cytokine Secretion: Novel Therapies for Triple Negative Breast Cancer. 1
- 248 Impact of Results of TTF-1 Immunostaining on Efficacy of Platinum-Doublet Chemotherapy in Japanese Patients with Nonsquamous Non-Small-Cell Lung Cancer. **2023**, 12, 137 ○
- 247 The Role of Immune Checkpoint Inhibitors in Cancer Therapy. **2023**, 13, 22-40 2
- 246 miRNome profiling of lung cancer metastases revealed a key role for miRNA-PD-L1 axis in the modulation of chemotherapy response. **2022**, 15, ○
- 245 PD-1 Inhibitor for Disseminated Mycobacterium avium Infection in a Person With HIV. **2023**, 10, ○
- 244 Pretraining Transformers for TCR-pMHC Binding Prediction. **2022**, ○

- 243 Exploring the Dynamic Crosstalk between the Immune System and Genetics in Gastrointestinal Stromal Tumors. **2023**, 15, 216 o
- 242 Trends in real-world biomarker testing and overall survival in US patients with advanced non-small-cell lung cancer. o
- 241 Preventive effect of tertiary lymphoid structures on lymph node metastasis of lung adenocarcinoma. o
- 240 Microsatellite instability assessment is instrumental for Predictive, Preventive and Personalised Medicine: status quo and outlook. 1
- 239 Immune checkpoint inhibitors efficacy across solid cancers and the utility of PD-L1 as a biomarker of response: a systematic review and meta-analysis. o
- 238 Comprehensive Genomic Profiling in Lung Cancer in the Era of Immunotherapy Approaches: The Role of Molecular Tumour Boards. **2023**, o
- 237 Treatment of Advanced Non-Small Cell Lung Cancer with RET Fusions: Reality and Hopes. **2023**, 24, 2433 o
- 236 Tumor immunology. **2023**, 245-452 o
- 235 Atezolizumab versus Pembrolizumab for First-line Treatment in Non-small-cell Lung Cancer with High PD-L1 Expression: A Network Meta-analysis and Cost-effectiveness Analysis from Chinese Perspectives. o
- 234 Association of immune-related adverse events and efficacy in advanced non-small-cell lung cancer: a systematic review and meta-analysis. o
- 233 [18F]FDG PET/CT Imaging in Cancer Treatment with Checkpoint Inhibitors. **2023**, 1-40 o
- 232 Duration of Immunotherapy in Non-Small Cell Lung Cancer Survivors: A Lifelong Commitment?. **2023**, 15, 689 o
- 231 The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy. o
- 230 Cost-effectiveness of first-line immunotherapies for advanced non-small cell lung cancer. o
- 229 Comparison of ASCL1 , NEUROD1 , and POU2F3 expression in surgically resected specimens, paired tissue microarrays, and lymph node metastases in small cell lung carcinoma. o
- 228 A signature-based classification of lung adenocarcinoma that stratifies tumor immunity. 12, o
- 227 Predicting PD-L1 expression status in patients with non-small cell lung cancer using [18F]FDG PET/CT radiomics. **2023**, 13, o
- 226 Impact of Frailty on Outcomes of First-Line Pembrolizumab Monotherapy in a Real-World Population with Advanced Non-Small Cell Lung Cancer. **2023**, 12, 191 o

- 225 Lung Immunotherapy in the Elderly with NSCLC â€”The Who, the What, and the When. **2023**, o
- 224 A Novel Humanized PD-1/PD-L1 Mouse Model Permits Direct Comparison of Antitumor Immunity Generated by Food and Drug Administrationâ€”Approved PD-1 and PD-L1 Inhibitors. **2023**, 7, 125-139 o
- 223 Role of antiangiogenic agents in first-line treatment for advanced NSCLC in the era of immunotherapy. **2023**, 23, o
- 222 Microenvironment and the progress of immunotherapy in clinical practice of NSCLC brain metastasis. 12, o
- 221 Immune and genomic biomarkers of immunotherapy response in cancer of unknown primary. **2023**, 11, e005809 o
- 220 Real-world multicentre cohort of first-line pembrolizumab alone or in combination with platinum-based chemotherapy in non-small cell lung cancer PD-L1 â‰¥50%. o
- 219 Immune checkpoint inhibitors as first-line therapy for non-small cell lung cancer: A systematic evaluation and meta-analysis. o
- 218 Concurrent administration of immune checkpoint inhibitors and single fraction stereotactic radiosurgery in patients with non-small cell lung cancer, melanoma, and renal cell carcinoma brain metastases is not associated with an increased risk of radiation necrosis over non-concurrent treatment: An international multicenter study of 657 patients. **2023**, o
- 217 Associations of Tissue Tumor Mutational Burden and Mutational Status With Clinical Outcomes in KEYNOTE-042: Pembrolizumab Versus Chemotherapy For Advanced PD-L1 Positive NSCLC. **2023**, o
- 216 Multiple immunosuppressants for immune-related acholia in a patient with metastatic colorectal cancer. **2023**, 10, 38 o
- 215 Treatment strategies based on different oligoprogressive patterns after immunotherapy failure in metastatic NSCLC. **2023**, 15, 175883592311563 o
- 214 Gastrointestinal perforation associated with novel antineoplastic agents: A real-world study based on the FDA Adverse Event Reporting System. 26, o
- 213 Cytological Samples: An Asset for the Diagnosis and Therapeutic Management of Patients with Lung Cancer. **2023**, 12, 754 o
- 212 FDG-PET metrics in advanced non-small cell lung cancer (NSCLC): a review and meta-analysis. o
- 211 A text-mining approach to study the real-world effectiveness and potentially fatal immune-related adverse events of PD-1 and PD-L1 inhibitors in older patients with stage III/IV non-small cell lung cancer. **2023**, 23, o
- 210 Efficacy of Immune Checkpoint Inhibitor Plus Chemotherapy in Patients With ROS1-Rearranged Advanced Lung Adenocarcinoma: A Multicenter, Retrospective Cohort Study. **2023**, o
- 209 Multiple cardiotoxicities during osimertinib therapy. 107815522311643 o
- 208 New Therapies on the Horizon. **2023**, o

- 207 Management of patients with recurrent/metastatic endometrial cancer: Consensus recommendations from an expert panel from Brazil. 13, o
- 206 Combating pancreatic cancer with ovarian cancer cells. **2023**, 15, 2189-2207 o
- 205 Programmed Death-Ligand 1 Copy Number Alteration as an Adjunct Biomarker of Response to Immunotherapy in Advanced Non-small Cell Lung Cancer. **2023**, o
- 204 Soluble interleukin-2 receptor as a predictive biomarker for poor efficacy of combination treatment with anti-PD-1/PD-L1 antibodies and chemotherapy in non-small cell lung cancer patients. o
- 203 Statistical Approaches for Establishing Appropriate Immunogenicity Assay Cut Points: Impact of Sample Distribution, Sample Size, and Outlier Removal. **2023**, 25, o
- 202 The Evolving Role for Systemic Therapy in Resectable Non-small Cell Lung Cancer. **2023**, o
- 201 Efficacy of immunotherapy as second-line or later-line therapy and prognostic significance of KRAS and/or TP53 mutations in advanced non-small cell lung cancer patients. Publish Ahead of Print, o
- 200 Multicentre real-world data of ramucirumab plus docetaxel after combined platinum-based chemotherapy with programmed death-1 blockade in advanced non-small cell lung cancer: NEJ051 (REACTIVE study). **2023**, 184, 62-72 o
- 199 Biomarkers of response to immunotherapy in early stage non-small cell lung cancer. **2023**, 184, 179-196 o
- 198 Anti-angiogenic agents for NSCLC following first-line immunotherapy: Rationale, recent updates, and future perspectives. **2023**, 179, 107173 o
- 197 Immune-related interstitial lung disease induced by different immune checkpoint inhibitors regimens: A real-world study from 2014 to 2022 based on FAERS databases. **2023**, 946, 175561 o
- 196 Combined radiation- and immune checkpoint-inhibitor-induced pneumonitis â The challenge to predict and detect overlapping immune-related adverse effects from evolving laboratory biomarkers and clinical imaging. **2023**, 39, 100892 o
- 195 Secondary prevention and treatment innovation of early stage non-small cell lung cancer: Impact on diagnostic-therapeutic pathway from a multidisciplinary perspective. **2023**, 116, 102544 o
- 194 Forskolin affects proliferation, migration and Paclitaxel-mediated cytotoxicity in non-small-cell lung cancer cell lines via adenylyl cyclase/cAMP axis. **2023**, 102, 151292 1
- 193 Physical Function and Physical Activity in Patients with Advanced Lung Cancer. **2022**, 275-291 o
- 192 Implications of Tumor Immune Microenvironment and Molecular Markers for Cancer Immunotherapy. **2022**, 1-34 o
- 191 Lung Immune Therapy Evaluation (LITE) Risk, a Novel Prognostic Model for Patients With Advanced Non-Small Cell Lung Cancer Treated With Immune Checkpoint Blockade. **2023**, 1
- 190 Immune signatures predict development of autoimmune toxicity in patients with cancer treated with immune checkpoint inhibitors. **2023**, 4, 113-129.e7 o

- 189 The Influence of the microbiome on the innate immune microenvironment of solid tumors. **2023**, 37, 100878 ○
- 188 Analysis on methylation and expression of PSMB8 and its correlation with immunity and immunotherapy in lung adenocarcinoma. **2022**, 14, 1427-1448 ○
- 187 Monitoring and Modulating Diet and Gut Microbes to Enhance Response and Reduce Toxicity to Cancer Treatment. **2023**, 15, 777 ○
- 186 Atezolizumab with or without bevacizumab and platinum-pemetrexed in patients with stage IIIB/IV non-squamous non-small cell lung cancer with EGFR mutation, ALK rearrangement or ROS1 fusion progressing after targeted therapies: A multicentre phase II open-label non-randomised study *GFPC 06-2018*. **2023**, 183, 38-48 ○
- 185 First-line nivolumab plus ipilimumab for metastatic non-small cell lung cancer, including patients with ECOG performance status 2 and other special populations: CheckMate 817. **2023**, 11, e006127 ○
- 184 Tensor Radiomics: Paradigm for Systematic Incorporation of Multi-Flavoured Radiomics Features. ○
- 183 Efficacy, Safety, and Health-Related Quality of Life With Camrelizumab Plus Pemetrexed and Carboplatin as First-Line Treatment for Advanced Nonsquamous NSCLC With Brain Metastases (CAP-BRAIN): A Multicenter, Open-Label, Single-Arm, Phase 2 Study. **2023**, ○
- 182 Liquid biopsy-based decision support algorithms for diagnosis and subtyping of lung cancer. **2023**, 178, 28-36 ○
- 181 Study protocol of KeyPemls -004: A phase 2 study of pembrolizumab in combination with plinabulin and docetaxel in previously treated patients with metastatic non-small cell lung cancer and progressive disease (PD) after immunotherapy (PD -1/ PD-L1 inhibitor) alone or in combination with platinum-doublet chemotherapy. **2023**, 14, 773-778 ○
- 180 Clinical Utility and Application of Liquid Biopsy Genotyping in Lung Cancer: A Comprehensive Review. Volume 14, 11-25 ○
- 179 Sleeve Lobectomy After Neoadjuvant Chemoimmunotherapy Versus Chemotherapy for Squamous Cell Lung Cancer: A Multicenter, Retrospective Study. **2023**, 4, 100472 ○
- 178 Second-line treatment outcomes after progression from first-line chemotherapy plus immunotherapy in patients with advanced non-small cell lung cancer. **2023**, 178, 116-122 ○
- 177 Re-Irradiation by Stereotactic Radiotherapy of Brain Metastases in the Case of Local Recurrence. **2023**, 15, 996 ○
- 176 Differential treatment responses to immune checkpoint inhibitor (ICI) therapy in a case of multiple primary malignancies: the programmed death ligand-1 (PD-L1) negative ureteral and lung metastasis from a clear cell renal cell carcinoma appearing after robotic-assisted partial nephrectomy progressed after ICI therapy, while synchronous PD-L1 positive primary lung cancer resected after ICI therapy. **2023**, 17, 100922 ○
- 175 Lung Cancer Resection after Immunochemotherapy Versus Chemotherapy in Oligometastatic Nonsmall Cell Lung Cancer. 1
- 174 Efficacy and safety of pembrolizumab monotherapy in patients with advanced thyroid cancer in the phase 2 KEYNOTE-158 study. **2023**, 129, 1195-1204 ○
- 173 Proto-Oncogene FAM50A Can Regulate the Immune Microenvironment and Development of Hepatocellular Carcinoma In Vitro and In Vivo. **2023**, 24, 3217 ○
- 172 Effectiveness and safety of pembrolizumab for patients with advanced non-small cell lung cancer in real-world studies and randomized controlled trials: A systematic review and meta-analysis. 13, ○

- 171 Efficacy and clinicogenomic correlates of response to immune checkpoint inhibitors alone or with chemotherapy in non-small cell lung cancer. **2023**, 14, ○
- 170 Intratumoral microbiome is driven by metastatic site and associated with immune histopathological parameters: An ancillary study of the SHIVA clinical trial. **2023**, 183, 152-161 ○
- 169 Neoadjuvant immune-checkpoint inhibitors in lung cancer - a primer for radiologists. **2023**, 161, 110732 ○
- 168 Overall survival and role of programmed death ligand 1 expression in patients with metastatic non-small-cell lung cancer and immunotherapy: an observational study from central Switzerland. **2023**, 153, 40039 ○
- 167 Upfront Advanced Radiotherapy and New Drugs for NSCLC Patients with Synchronous Brain Metastases: Is the Juice Worth the Squeeze? A Real-World Analysis from Lombardy, Italy. **2023**, 15, 1103 ○
- 166 First-line nab -paclitaxel plus carboplatin for patients with advanced non-small cell lung cancer: Final results of the NEPTUN study. ○
- 165 Effect of Cancer-Related Cachexia and Associated Changes in Nutritional Status, Inflammatory Status, and Muscle Mass on Immunotherapy Efficacy and Survival in Patients with Advanced Non-Small Cell Lung Cancer. **2023**, 15, 1076 ○
- 164 Development and validation of a decision model for the evaluation of novel lung cancer treatments in the Netherlands. **2023**, 13, ○
- 163 A Novel Radiogenomics Biomarker for Predicting Treatment Response and Pneumotoxicity From Programmed Cell Death Protein or Ligand-1 Inhibition Immunotherapy in NSCLC. **2023**, ○
- 162 Circulating Biomarkers for Prediction of Immunotherapy Response in NSCLC. **2023**, 11, 508 ○
- 161 Clinical Characteristics and Pharmacokinetics Change of Long-Term Responders to Antiprogrammed Cell Death Protein 1 Inhibitor Among Patients With Advanced NSCLC. **2023**, 4, 100474 ○
- 160 EHBP1L1 Drives Immune Evasion in Renal Cell Carcinoma through Binding and Stabilizing JAK1. **2023**, 10, ○
- 159 Efficacy and safety of immune checkpoint inhibitors combined with recombinant human endostatin and chemotherapy as the first-line treatment of advanced non-small-cell lung cancer. **2023**, 19, 147-158 ○
- 158 Predicting survival of NSCLC patients treated with immune checkpoint inhibitors: Impact and timing of immune-related adverse events and prior tyrosine kinase inhibitor therapy. 13, ○
- 157 Prognostic Associations of Concomitant Antibiotic Use in Patients with Advanced NSCLC Treated with Atezolizumab: Sensitivity Analysis of a Pooled Investigation of Five Randomised Control Trials. **2023**, 11, 528 ○
- 156 Systemic Inflammation/Nutritional Status Scores Are Prognostic but Not Predictive in Metastatic Non-Small-Cell Lung Cancer Treated with First-Line Immune Checkpoint Inhibitors. **2023**, 24, 3618 ○
- 155 Neoadjuvant PD-1 Blockade in Non-Small Cell Lung Cancer: Current perspectives and Moving Forward. Volume 16, 99-108 ○
- 154 Immunotherapy for Head and Neck Cancers. **2023**, 1-28 ○

- 153 Clinical efficacy and safety of individualized pembrolizumab administration based on pharmacokinetic in advanced non-small cell lung cancer: A prospective exploratory clinical trial. **2023**, 178, 183-190 ○
- 152 Immunotherapy for Metastatic Non-Small Cell Lung Cancer: Therapeutic Advances and Biomarkers. **2023**, 30, 2366-2387 ○
- 151 Mean platelet volume, thrombocytosis, and survival in non-small cell lung cancer patients treated with first-line pembrolizumab alone or with chemotherapy. ○
- 150 Monocyte chemoattractant protein 1 as a potential biomarker for immune checkpoint inhibitor-associated neurotoxicity. ○
- 149 Development and validation of a radiomics-based nomogram for predicting a major pathological response to neoadjuvant immunochemotherapy for patients with potentially resectable non-small cell lung cancer. 14, ○
- 148 Prospects and feasibility of synergistic therapy with radiotherapy, immunotherapy, and DNA methyltransferase inhibitors in non-small cell lung cancer. 14, ○
- 147 The predictive value of plasma exosomal lncRNAs/mRNAs in NSCLC patients receiving immunotherapy. **2023**, 68, 86-93 ○
- 146 New Approaches in Early-Stage NSCL Management: Potential Use of PARP Inhibitors and Immunotherapy Combination. **2023**, 24, 4044 ○
- 145 Efficacy and Prognostic Factors of Immune Checkpoint Inhibitors in the Treatment of Advanced Non-small Cell Lung Cancer. **2023**, 46, 161-166 ○
- 144 Adjuvant and neo-adjuvant immunotherapy in resectable non-small cell lung cancer (NSCLC): Current status and perspectives. **2023**, 2, 65-78 ○
- 143 Prognostic significance of epidermal growth factor receptor and programmed cell death-ligand 1 co-expression in esophageal squamous cell carcinoma. ○
- 142 Impact of COVID-19 Pandemic on Frontline Pembrolizumab-Based Treatment for Advanced Lung Cancer. **2023**, 12, 1611 ○
- 141 Response to Abemaciclib and Immunotherapy Rechallenge with Nivolumab and Ipilimumab in a Heavily Pretreated TMB-H Metastatic Squamous Cell Lung Cancer with CDKN2A Mutation, PIK3CA Amplification and TPS 80%: A Case Report. **2023**, 24, 4209 ○
- 140 Understanding the landscape of immunotherapy in thymic epithelial tumors. **2023**, 129, 1162-1172 ○
- 139 Standard versus low-dose nab-paclitaxel in previously treated patients with advanced non-small cell lung cancer: A randomized phase II trial (JMTO LC14 -01). ○
- 138 Cell adhesion molecules and immunotherapy in advanced non-small cell lung cancer: Current process and potential application. 13, ○
- 137 Gender Differences in Symptom Burden, Functional Performance and Global Quality of Life of Lung Cancer Patients Receiving Inpatient versus Outpatient Treatment. Volume 15, 175-183 ○
- 136 Lung cancer immunotherapy: progress, pitfalls, and promises. **2023**, 22, ○

- 135 Combinatorial biomarker for predicting outcomes to anti-PD-1 therapy in patients with metastatic clear cell renal cell carcinoma. **2023**, 4, 100947 o
- 134 Emerging roles of the gut microbiota in cancer immunotherapy. 14, o
- 133 Impact of Antibiotic Exposure Before Immune Checkpoint Inhibitor Treatment on Overall Survival in Older Adults With Cancer: A Population-Based Study. o
- 132 Liquid Biopsies in Lung Cancer. **2023**, 15, 1430 o
- 131 Pulmonary Surfactant-Based Paclitaxel-Loaded Nanovesicles for Inhalation Therapy of Lung Adenocarcinoma. **2023**, 6, 3693-3703 1
- 130 Chorioallantoic membrane assay revealed the role of TIPARP (2,3,7,8-tetrachlorodibenzo-p-dioxin-inducible poly (ADP-ribose) polymerase) in lung adenocarcinoma-induced angiogenesis. **2023**, 23, o
- 129 Targeting tumor microenvironment for non-small cell lung cancer immunotherapy. **2023**, o
- 128 MRTX-500 Phase 2 Trial: Sitravatinib With Nivolumab in Patients With Nonsquamous NSCLC Progressing On or After Checkpoint Inhibitor Therapy or Chemotherapy. **2023**, o
- 127 Bronchiolitis obliterans syndrome associated with an immune checkpoint inhibitor in a patient with non-small cell lung cancer. **2023**, 42, 101824 o
- 126 CD169 + sinus macrophages in regional lymph nodes do not predict mismatch-repair status of patients with colorectal cancer. o
- 125 PD-L1 gene amplification and focality: relationship with protein expression. **2023**, 11, e006311 1
- 124 Immunotherapy in Elderly Patients Affected by Non-Small Cell Lung Cancer: A Narrative Review. **2023**, 12, 1833 o
- 123 Chemoimmunotherapy vs. Immunotherapy for First Line Treatment of Advanced Non-Small Cell Lung Cancer With a PD-L1 Expression $\geq 50\%$ or $\geq 90\%$. **2023**, o
- 122 Radiomics-guided checkpoint inhibitor immunotherapy for precision medicine in cancer: A review for clinicians. 14, o
- 121 Overcoming Acquired Drug Resistance to Cancer Therapies through Targeted STAT3 Inhibition. **2023**, 24, 4722 o
- 120 Immunotherapy in Non-Small-Cell Lung Cancer (NSCLC). **2023**, 112, 143-147 1
- 119 Acral Melanoma Is Infiltrated with cDC1s and Functional Exhausted CD8 T Cells Similar to the Cutaneous Melanoma of Sun-Exposed Skin. **2023**, 24, 4786 o
- 118 Immune-related toxicity and soluble profile in patients affected by solid tumors: a network approach. o

- 117 Precision Surgery in NSCLC. **2023**, 15, 1571 ○
- 116 Comparison of clinicopathological and genomic profiles in anal squamous cell carcinoma between Japanese and Caucasian cohorts. **2023**, 13, ○
- 115 CDK4/6 inhibition triggers ICAM1-driven immune response and sensitizes LKB1 mutant lung cancer to immunotherapy. **2023**, 14, ○
- 114 Dynamic changes in circulating tumor DNA assessed by shallow whole-genome sequencing associate with clinical efficacy of checkpoint inhibitors in NSCLC. ○
- 113 Nomogram prediction for the risk of venous thromboembolism in patients with lung cancer. **2023**, 23, ○
- 112 Immune checkpoint inhibitors related respiratory disorders in patients with lung cancer: A meta-analysis of randomized controlled trials. 14, ○
- 111 Programmed Cell Death-1 (PD-1) anchoring to the GPI-linked co-receptor CD48 reveals a novel mechanism to modulate PD-1-dependent inhibition of human T cells. **2023**, 156, 31-38 ○
- 110 Eosinophil and IFN- γ associated with immune-related adverse events as prognostic markers in patients with non-small cell lung cancer treated with immunotherapy. 14, ○
- 109 Prognostic Significance of Circulating Basophil Counts in Patients Who Underwent Esophagectomy for Esophageal Cancer. ○
- 108 Pneumonitis associated with pembrolizumab plus chemotherapy for non-squamous non-small cell lung cancer. **2023**, 13, ○
- 107 TTF-1 Expression and Clinical Outcomes of Combined Chemoimmunotherapy in Patients With Advanced Lung Adenocarcinoma: A Prospective Observational Study. **2023**, 4, 100494 ○
- 106 The DNA damage response pathway regulates the expression of the immune checkpoint CD47. **2023**, 6, ○
- 105 Clinical implications and molecular features of tertiary lymphoid structures in stage I lung adenocarcinoma. ○
- 104 Prognostic Role of Soluble and Extracellular Vesicle-Associated PD-L1, B7-H3 and B7-H4 in Non-Small Cell Lung Cancer Patients Treated with Immune Checkpoint Inhibitors. **2023**, 12, 832 ○
- 103 Pexidartinib synergize PD-1 antibody through inhibiting treg infiltration by reducing TAM-derived CCL22 in lung adenocarcinoma. 14, ○
- 102 Effect of BIM expression on the prognostic value of PD-L1 in advanced non-small cell lung cancer patients treated with EGFR-TKIs. **2023**, 13, ○
- 101 Current Advances in Immune Checkpoint Therapy. ○
- 100 Comparative evaluation of PD-L1 expression in cytology imprints, circulating tumour cells and tumour tissue in non-small cell lung cancer patients. ○

- 99 Economic Evaluation of Nivolumab Versus Docetaxel for the Treatment of Advanced Squamous and Non-squamous Non-small Cell Lung Cancer After Prior Chemotherapy in China. **2023**, 7, 273-284 o
- 98 Socioeconomic and racial disparities in survival for patients with stage IV cancer. **2023**, o
- 97 Comparison of sequential and joint nonlinear mixed effects modeling of tumor kinetics and survival following Durvalumab treatment in patients with metastatic urothelial carcinoma. o
- 96 Post-progression survival in advanced non-small cell lung cancer treated with anti-PD-1/PDL-1 monotherapy: progression after durable clinical benefit versus primary resistance. o
- 95 Cost-effectiveness of first line nivolumab-ipilimumab combination therapy for advanced non-small cell lung cancer: A systematic review and methodological quality assessment. 3, o
- 94 Anti-PD-(L)1 therapy of non-small cell lung cancer—a summary of clinical trials and current progresses. **2023**, 9, e14566 o
- 93 Descriptive Analysis of First-Line Non-Small Cell Lung Cancer Treatment with Pembrolizumab in Tumors Expressing PD-L1 ≥50% in Patients Treated in Quebec—University Teaching Hospitals (DALP-First Study). **2023**, 30, 3251-3262 o
- 92 Immune checkpoint inhibitors in metastatic NSCLC: challenges and future directions. o
- 91 Tissue Age Affects Antigenicity and Scoring for the 22C3 Immunohistochemistry Companion Diagnostic Test. **2023**, 36, 100159 o
- 90 Trends in Survival Rates of Non-Small Cell Lung Cancer With Use of Molecular Testing and Targeted Therapy in Korea, 2010-2020. **2023**, 6, e232002 o
- 89 Expression and Clinical Significance of PD-L1 and PD-1 in Thymic Carcinoma. **2023**, 13, 3702-3708 o
- 88 What are the indications and survivorship of tumor endoprosthetic reconstructions for patients with extremity metastatic bone disease?. o
- 87 Anti-TIGIT therapies for solid tumors: a systematic review. **2023**, 8, 101184 o
- 86 NSCLC in the Era of Targeted and Immunotherapy: What Every Pulmonologist Must Know. **2023**, 13, 1117 o
- 85 Vascular Normalization Was Associated with Colorectal Tumor Regression upon Anti-PD-L1 Combinational Therapy. **2023**, 2023, 1-13 o
- 84 Efficacy of immunotherapy in oncogene-driven non-small-cell lung cancer. **2023**, 15, 175883592311614 o
- 83 Antitumor effect of neoantigen-reactive T cells combined with PD1 inhibitor therapy in mouse lung cancer. o
- 82 Organ-specific immune checkpoint inhibitor treatment in lung cancer: a systematic review and meta-analysis. **2023**, 13, e059457 o

- 81 Only EBUS-Guided Mediastinal Lymph Node Cryobiopsy Enabled Immunotherapy in a Patient with Non-Small Cell Lung Cancer. **2023**, 12, 2355 ○
- 80 Long-Lasting Therapeutic Response following Treatment with Pembrolizumab in Patients with Non-Small Cell Lung Cancer: A Real-World Experience. **2023**, 24, 5938 ○
- 79 Classification of Tumor Immune Microenvironment According to Programmed Death-Ligand 1 Expression and Immune Infiltration Predicts Response to Immunotherapy Plus Chemotherapy in Advanced Patients With NSCLC. **2023**, ○
- 78 Aging microenvironment and antitumor immunity for geriatric oncology: the landscape and future implications. **2023**, 16, ○
- 77 Examination of the Functional Relationship between PD-L1 DNA Methylation and mRNA Expression in Non-Small-Cell Lung Cancer. **2023**, 15, 1909 ○
- 76 Tumour microenvironment in pheochromocytoma and paraganglioma. 14, ○
- 75 Global trends in the health economics field of PD-1/PD-L1 inhibitors: A bibliometric and visualized study. 14, ○
- 74 Immune checkpoint inhibitor-induced autoimmune encephalitis in metastatic squamous cell lung cancer. **2023**, 15, 409-416 ○
- 73 Letter: be careful of gastrointestinal CMV infection in adverse events from ICIs therapy in solid tumours. **2023**, 57, 916-917 1
- 72 Immunotherapy in the first-line treatment of elderly patients with advanced non-small-cell lung cancer: results of an International Experts Panel Meeting by the Italian Association of Thoracic Oncology (AIOT). **2023**, 8, 101192 ○
- 71 Positron Emission Tomography-Based Immunoimaging for Cancer Patient Stratification: Toward a More Holistic Approach. ○
- 70 Editorial: Unravelling the sarcoma microenvironment: Impact of the genomic landscape on molecular signaling, immunosuppression, and treatment resistance. 13, ○
- 69 Immune-mediated Gastritis in a Patient with metastatic Lung Cancer due to Therapy with the immune Checkpoint Inhibitor Pembrolizumab âDifferences and Similarities in Comparison to âEndogenousâAutoimmune Type A Gastritis and a review of literature. ○
- 68 Identification of novel prognostic model based on homologous recombination deficiency associated lncRNAs in lung adenocarcinoma. **2023**, 9, e14811 ○
- 67 Quantification of follow-up time in oncology clinical trials with a time-to-event endpoint: Asking the right questions. ○
- 66 Infectious Complications of Targeted Therapies for Solid Cancers or Leukemias/Lymphomas. **2023**, 15, 1989 ○
- 65 Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Strategies and Biomarkers Predicting Response and/or Resistance. **2023**, 11, 1020 ○
- 64 Neoadjuvant immunotherapy in resectable non-small-cell lung cancer. **2023**, 15, 175883592311637 ○

- 63 Immune checkpoint inhibitors and Carbon iON radiotherapy In solid Cancers with stable disease (ICONIC). **2023**, 19, 193-203 o
- 62 Immunotherapy efficacy predictive tool for lung adenocarcinoma based on neural network. 14, o
- 61 PD-1/PD-L1 Inhibitor Plus Chemotherapy Versus PD-1/PD-L1 Inhibitor in Microsatellite Instability Gastrointestinal Cancers: A Multicenter Retrospective Study. **2023**, o
- 60 Real-world data on the efficacy and safety of immune-checkpoint inhibitors in elderly patients with non-small cell lung cancer. o
- 59 Liquid biopsy on the horizon in immunotherapy of non-small cell lung cancer: current status, challenges, and perspectives. **2023**, 14, o
- 58 All-round counterattack to conquer lung cancer. **2023**, 66, 154-158 o
- 57 Hyperprogressive disease during atezolizumab plus bevacizumab treatment in patients with advanced hepatocellular carcinoma from Japanese real-world practice. **2023**, 23, o
- 56 Feasibility and safety of shortened hypofractionated high-dose palliative lung radiotherapy â retrospective planning study. **2023**, 108, 102559 o
- 55 New Progress of Immunotherapy in Gastric Cancer. **2023**, 13, 4904-4911 o
- 54 Nasopharyngeal Carcinoma Subtype Discovery via Immune Cell Scores from Tumor Microenvironment. **2023**, 2023, 1-13 o
- 53 Impact of the treatment crossover design on comparative efficacy in EMPOWER-Lung 1: Cemiplimab monotherapy as first-line treatment of advanced non-small cell lung cancer. 12, o
- 52 Randomized Clinical Trials: Pitfalls in Design, Analysis, Presentation, and Interpretation. **2023**, o
- 51 Lysine-Specific Demethylase 1 Promises to Be a Novel Target in Cancer Drug Resistance: Therapeutic Implications. **2023**, 66, 4275-4293 o
- 50 The potential clinical utility of cell-free DNA for gastric cancer patients treated with nivolumab monotherapy. **2023**, 13, o
- 49 Anlotinib succeeded in rescue therapy for hyperprogression induced by immune checkpoint inhibitors: a case report. o
- 48 Spatial analysis of human lung cancer reveals organized immune hubs enriched for stem-like CD8 T cells and associated with immunotherapy response. o
- 47 Vimentin expression correlates with immune-checkpoint inhibitor efficacy in nonâsmall cell lung cancer. o
- 46 Genomic and transcriptomic analysis of checkpoint blockade response in advanced non-small cell lung cancer. o

- 45 ??????????????????. **2023**, 74, 103-105 ○
- 44 Actual role of immunotherapy in a treatment of lung cancer. **2023**, 17, 8-11 ○
- 43 Immunohistochemical analysis of B7-H3 expression in patients with lung cancer following various anti-cancer treatments. ○
- 42 Administration of immune checkpoint inhibitors at rural towns using the Teleoncology model of careâ North Queensland perspective. ○
- 41 Promising Therapeutic Impact of Immune Checkpoint Inhibitors in Type II Endometrial Cancer Patients with Deficient Mismatch Repair Status. **2023**, 11, 1073 ○
- 40 MYC activation impairs cell-intrinsic IFNÎ³signaling and confers resistance to anti-PD1/PD-L1 therapy in lung cancer. **2023**, 4, 101006 ○
- 39 Role of Surgical Pathologist for the Detection of Immuno-oncologic Predictive Factors in Non-small Cell Lung Cancers. **2023**, 30, 174-194 ○
- 38 Cuprotosis Clusters Predicts Prognosis and Immunotherapy Response in Low-grade glioma. ○
- 37 Research Progress of Immunotherapy for Gastric Cancer. **2023**, 22, 153303382211505 ○
- 36 Monoclonal antibodies for the treatment of squamous cell carcinoma: A literature review. ○
- 35 The Significance of SPP1 in Lung Cancers and Its Impact as a Marker for Protumor Tumor-Associated Macrophages. **2023**, 15, 2250 ○
- 34 Interaction between Radiation Therapy and Targeted Therapies in HER2-Positive Breast Cancer: Literature Review, Levels of Evidence for Safety and Recommendations for Optimal Treatment Sequence. **2023**, 15, 2278 ○
- 33 Radiomics of Tumor Heterogeneity in 18F-FDG-PET-CT for Predicting Response to Immune Checkpoint Inhibition in Therapy-Naïve Patients with Advanced Non-Small-Cell Lung Cancer. **2023**, 15, 2297 ○
- 32 Clinical Relevance of Targeted Therapy and Immune-Checkpoint Inhibition in Lung Cancer. **2023**, 15, 1252 ○
- 31 Tumor PD-L1 expression and molecular profiling are not associated with immune checkpoint inhibitor-induced thyroid dysfunction in advanced NSCLC patients. 29, ○
- 30 In vivoCRISPR screen identifies KRAS-induced COX-2 as a driver of immune evasion and immunotherapy resistance in lung cancer. ○
- 29 PD-1/PD-L1 inhibitors-associated cardiac adverse events: a retrospective and real-world study based on the FDA Adverse Event Reporting System (FAERS). 1-11 ○
- 28 Potential for companion diagnostic use and inter-rater agreement of programmed death ligand-1 (PD-L1) clone 22C3 expression scores in colorectal cancer. ○

- 27 Pyroptosis: A promising target for lung cancer therapy. **2023**, ○
- 26 Immunotherapy in Lung Cancer: Current Landscape and Analysis of Biomarkers. **2023**, 13, 37-43 ○
- 25 Identifying optimal first-line immune checkpoint inhibitors based regiments for advanced non-small cell lung cancer without oncogenic driver mutations: A systematic review and network meta-analysis. **2023**, 18, e0283719 ○
- 24 Prognostic Biomarker SLCO4A1 Is Correlated with Tumor Immune Infiltration in Colon Adenocarcinoma. **2023**, 2023, 1-13 ○
- 23 PD-L1 and PD-L2 Immune Checkpoint Protein Induction by Type III Interferon in Non-Small Cell Lung Cancer Cells. **2023**, 152389 ○
- 22 Methods for assessment of the tumour microenvironment and immune interactions in non-small cell lung cancer. A narrative review. 13, ○
- 21 Prognostic influence of PD-1/PD-L1 suppressors in combination with chemotherapeutic agents for non-small cell pulmonary carcinoma: system review and meta-analysis. 13, ○
- 20 Value of 18F-FDG PET/CT Based on PD-L1 to Predict Outcomes of Immunotherapy in NSCLC. **2023**, 14, 151-161 ○
- 19 Effects of Auricular Acupressure on Symptom Burden and Quality of Life in Patients With Advanced Lung Cancer Treated With Immunotherapy Based on the Midnight-noon Ebb-flow Theory: A Randomized Controlled Trial. **2023**, 3, e040 ○
- 18 Clinical benefit of platinum doublet combination therapy in older adults with advanced non-small cell lung cancer: A prospective multicenter study by the National Hospital Organization in Japan. ○
- 17 The Value of Peripheral Blood Index in the Evaluation of Curative Effect of Advanced Non-Small Cell Lung Cancer. **2023**, 13, 5979-5988 ○
- 16 SAA1 Has Potential as a Prognostic Biomarker Correlated with Cell Proliferation, Migration, and an Indicator for Immune Infiltration of Tumor Microenvironment in Clear Cell Renal Cell Carcinoma. **2023**, 24, 7505 ○
- 15 Anti-PD-1 therapy achieves favorable outcomes in HBV-positive non-liver cancer. **2023**, 12, ○
- 14 Novel predictors of immune checkpoint inhibitor response and prognosis in advanced non-small-cell lung cancer with bone metastasis. ○
- 13 Chemotherapy. **2023**, 7-159 ○
- 12 A multispecies framework for modeling adaptive immunity and immunotherapy in cancer. **2023**, 19, e1010976 ○
- 11 bITH, a blood-based metric of intratumor heterogeneity, is associated with clinical response to immune checkpoint blockade in non-small cell lung cancer. **2023**, 91, 104564 ○
- 10 Continuous Treatment of Non-small-cell Lung Cancer with an Immune Checkpoint Inhibitor Followed by Resection of Recurrent Mediastinal Lymph Node Metastasis. **2023**, 63, 95-100 ○

- 9 Cytokine profiling identifies circulating IL-6 and IL-15 as prognostic stratifiers in patients with non-small cell lung cancer receiving anti-PD-1/PD-L1 blockade therapy. ○
- 8 Performance of Endobronchial Ultrasound Transbronchial Needle Aspiration as the First Nodal Staging Procedure for the Determination of Programmed Death Ligand-1 Expression in Non-Small Cell Lung Cancer Patients. ○
- 7 Advanced non-small-cell lung cancer treated with first-line pembrolizumab plus chemotherapy: tumor response dynamics as a marker for survival. ○
- 6 Predictive factors and prognosis of immune checkpoint inhibitor-related pneumonitis in non-small cell lung cancer patients. 13, ○
- 5 A novel integrated approach to predicting cancer immunotherapy efficacy. ○
- 4 Research Hotspot and Application Status of Immune Evasion Mechanism in Ovarian Cancer. **2023**, 11, 443-455 ○
- 3 A systematic review and meta-analysis on the optimal treatment duration of checkpoint inhibitors in solid tumors: The OTHERS study. **2023**, 187, 104016 ○
- 2 Incidence and Risk Factors for Pneumonitis Associated With Checkpoint Inhibitors in Advanced Non-Small Cell Lung Cancer: A Single Center Experience. ○
- 1 PDE4D/cAMP/IL-23 axis determines the immunotherapy efficacy of lung adenocarcinoma via activating the IL-9 autocrine loop of cytotoxic T lymphocytes. **2023**, 565, 216224 ○